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This thesis “Targeting heme using single domain antibodies” aimed to develop 
methodologies that would overcome the current limitations in the detection and 
quantification of “free heme”, i.e. redox active heme that is loosely bound to 
proteins or to other biological molecules. Here, we described the generation of 
single domain antibodies specific against heme using phage display technology and 
characterized them by different techniques such as affinity determination, antigen 
binding specificity, structural analysis (spectroscopy techniques), in vitro and ex-
vivo actions. These sdAbs were further used to develop methodologies for the 
quantitative and qualitative analysis of “free heme” and its cellular detection as well 
as to modulate heme reactivity.  
This research work was performed mainly in Instituto Gulbenkian de Ciência 
under the scientific supervision of Dr. Miguel P. Soares. While, the development of 
the sdAbs was performed in collaboration and under the supervision of Dr. João 
Gonçalves in Faculdade de Farmácia da Universidade de Lisboa and Dr. Frederico 
Aires-da-Silva in Technophage from Instituto de Medicina Molecular da 
Universidade de Lisboa. Spectroscopy work was performed in the Instituto 
tecnologia Química e Biológica. These include Resonance Raman spectroscopy 
under the scientific supervision of the co-supervisor Dr. Smilja Todorovic and CD 
and FTIR spectroscopy in collaboration and under the scientific supervision of Dr. 
Claúdio Soares. The sdAb affinity measurements were also performed in Instituto 
tecnologia Química e Biológica with the supervision of Dr. Frederico Aires-da-Silva. 
The flow cytometry and immunofluorescence assay was performed by Ana Rita 
Carlos, IGC and ascorbate oxidation designed Roland Stocker, University of New 
South Wales, Australia. 
The thesis is organized in three chapters, preceded by a Portuguese abstract 
translated in English. In the chapter 1, general introductory review on the subject is 
provided. In the chapter 2 the general and most significant results obtained during 




integrating all work and future perspectives are presented. In the appendix is 
presented and discussed supplementary information about a preliminary work to 
generate constructs, namely dimers of sdAbs and sdAbs containing an additional 
region of heme recognition (CDR), based on the sdAbs developed in chapter 2, 
namely sdAbs 1A6 and 2H7. 
During my PhD project was able to participate in the elaboration of a review 
manuscript entitled “Heme Cytotoxicity And The Pathogenesis of Immune Mediated 
Inflammatory Diseases.” (DOI:10.3389/fphar.2012.00077) from Rasmus Larsen, 
Zélia Gouveia, Miguel P. Soares and Raffaella Gozzelino, published in the Journal 








Hemo, i.e. ferro (Fe) contido na porfirina IX, funciona como grupo prostético numa 
variedade de hemoproteins que exercem funções biológicas vitais e portanto, 
essenciais para sustentar a vida. Hemo é uma molecula extremamente reactiva, 
podendo participar em reacções redox e presumivelmente por esse motivo deve 
ser sequestrado no interior de um bolso hémico nas hemoproteínas, para controlo 
da sua reactividade. Contudo, sob condições de stress biológico, as hemoproteínas 
podem libertar o seu grupo prostético formando “hemo livre” que liga-se fracamente 
às proteínas, ou outras moléculas adquirindo presumivelmente actividade redox 
descontrolada.  Para além disso, um crescente número de evidências suporta a 
noção de que o “hemo livre” pode comportar-se como um agente vasoativo, pro -
inflamatório e citotóxico quando libertado de um subconjunto de hemoproteínas 
como por exemplo, a extracelular hemoglobina gerada durante condições 
hemolíticas. Assim sendo, eventualmente o “hemo livre” contribui para a 
patogénese de  doenças inflamatórias imuno-mediadas associadas com hemólise.  
As actuais limitações das abordagens metodológicas que possibilitem a análise 
quantitativa e qualitativa do “hemo livre” impedem a determinação inequívoca dos 
seus efeitos patológicos, tal como o seu eventual tratamento terapêutico. Para 
superar estas limitações, usamos a technologia de exibição de fagos para gerar um 
painel de anticorpos de domínio único (‘single domain antibodies’, sdAbs), 
nomeadamente cadeia variável leve (VL), que reconhecem específicamente “hemo 
livre” após libertação das respectivas hemoproteínas.   
O sdAb 2H10 foi selecionado, uma vez que é o mais específico para o “hemo 
livre” e a sua ligação ao hemo foi caracterizada usando as várias técnicas 
espectroscopicas (absorção no UV-visível, Raman ressonante, Dicroísmo circular). 
Estas técnicas demonstraram a presença de um hemo férrico seis coordenado de 
baixo ‘spin’, com uma cisteína como quinto ligando e, possívelmente uma lisina ou  
tirosina como o sexto ligado. Para além disso, a estructura secondária do sdAb, 




conformacionais para acomodar o hemo.  Foi também demonstrado que estes 
sdAbs podem ser usados para detectar “hemo livre” em células humanas atravês 
de técnicas de imunofluorescência ou citometria de fluxo, tal como no plasma 
utilizando um ensaio ‘enzyme linked immunoabsorbant assay’ (ELISA), 
desenvolvido a partir dos sdAbs.   
Para verificar a existência do “hemo livre” no plasma, utilizámos um modelo 
experimental previamente estabelecido usando a fenilhidrazina (PHZ) para induzir 
hemólise aguda em murganhos. Neste ensaio o “hemo livre” não é detectado no 
plasma, mesmo quando os níveis de hemo total e de absorção celular do hemo 
aumentam, enquanto que a capacidade do plasma para ligar o hemo diminui 
transitoriamente. Eventualmente, a elevada capacidade de tampão do plasma é 
assegurada por proteínas, ou outras moléculas biológicas, proporcionando um 
mecanismo preciso e regulador para a manutenção da homeostase sistémica do 
hemo. Demonstrámos ainda que a ligação de sdAb 2H10 ao hemo reduz a sua 
actividade redox, ainda mais eficientemente do que o seu eliminador plasmático, 
albumina, uma acção que possivelmente possibilitará a inhibição dos efeitos 
patológicos do hemo.  
Em resumo, nós demonstramos que estes sdAbs podem ser usados para 
ultrapassar as actuais limitações relativas à análise quantitativa e qualitativa do 
“heme livre” em  condições hemolíticas, ou noutras condições biológicas 
associadas presumivelmente com a libertação do hemo das hemoproteinas. 
Propõe-se a utilização dos sdAbs para fins terapêuticos, nomeadamente do sdAb 
2H10, na captação do “hemo livre”, tal como na modulação da sua actividade redox 






Heme, i.e. iron (Fe) protoporphyrin IX, functions as a prosthetic group in a variety of 
hemoproteins that participate in vital biologic functions essential to sustain life. 
Heme is a highly reactive molecule, participating in redox reactions, and 
presumably for this reason it must be sequestered within the heme pockets of 
hemoproteins, controlling its reactivity. However, under biological stress conditions, 
hemoproteins can release their prosthetic groups, generating “free heme”, which 
binds loosely to proteins or to other molecules and presumably acquires unfettered 
redox activity.  Moreover, a growing body of evidence supports the notion that “free 
heme” can act in a vasoactive, pro-inflammatory and cytotoxic manner when 
released from a subset of these hemoproteins, such as extracellular hemoglobin, 
generated during hemolytic conditions. Presumably, “free heme” contributes to the 
pathogenesis of immune mediated inflammatory diseases associated with 
hemolysis. Current limitations in methodological approaches allowing a qualitative 
and quantitative analyzes of “free heme”, hinder the capability of determining 
unequivocally its pathologic effects as well as its eventual therapeutic targeting. To 
overcome this, we use phage display technology to generate a panel of single 
domain antibodies (sdAbs), namely variable light (VL), recognizing specifically “free 
heme”. We selected the sdAb 2H10, as being the most specific for “free heme”, 
characterized heme binding to this sdAb using spectroscopic techniques (UV-
Visible absorption, Resonance Raman and Circular Dichroism). This revealed the 
presence of a 6 coordinate low spin ferric heme probably, with a cysteine as the 
fifth ligand and possibly a lysine or tyrosine as the sixth axial ligand. Furthermore, 
the secondary structure of the sdAb, composed predominantly by anti-parallel β-
sheets, undergoes conformational changes to accommodate heme. We also 
demonstrate that these sdAb can be used to detect “free heme” in human cells 
using immunofluorescent techniques or flow cytometry as well as in plasma using 




To verify the existence of “free heme” in plasma, we used a well-established 
experimental model of phenylhydrazine induced acute hemolysis in mice. This 
assay revealed that no “free heme” is detected in plasma even though total heme 
levels and cellular heme uptake increased while the heme binding capacity of 
plasma decreased transiently. Presumably, the high buffer capacity of plasma 
provided by proteins or other biological molecules provides a tight regulatory 
mechanism for the maintenance of systemic heme homeostasis. We also 
demonstrated that the binding of sdAb 2H10 inhibits the heme redox activity, 
presumably contributing for the prevention of the deleterious effect of heme.  
In summary, we demonstrate that sdAbs can be used to overcome the current 
limitation in the quantitative and qualitative analysis of “free heme” under hemolytic 
conditions or other biological conditions presumably associated with the release of 
heme from hemoproteins. We propose the usage of the sdAbs, namely sdAb 2H10 
for therapeutically targeting of “free heme” as well as to modulate its redox activity 














General Introduction 1 
1. The Biology of Heme 2 
1.1. Discovery of Heme Molecule 2 
1.2. Structure and Biochemistry of Heme 3 
1.2.1. Heme Interaction with Proteins 5 
1.2.1.1 Heme Pocket 6 
1.2.1.2 Heme Binding Motifs 10 
1.2.1.3 Non-planar Heme Structure 11 
2. Heme Biosynthesis 12 
3. Heme Transporters 15 
3.1. Heme Importers 15 
3.2. Heme Exporters 18 
4. Heme Binding Proteins/Chaperones 21 
4.1. Intracellular Heme Binding Proteins 23 
4.2. Extracellular Heme Binding Proteins 25 
5. Heme Catabolism 30 
5.1. Enzymatic Mechanism of Heme Catabolism – Heme oxygenase 31 
5.2. Non-Enzymatic Mechanism of heme Catabolism 33 
5.2.1 Hydrogen Peroxide 33 
5.2.2 Hydrochlorous 33 
6. Heme as a Pathophysiological Molecule 34 
Index 
6.1. Pro-Oxidant Activity of Heme 35 
6.2. Pro-Inflammatory Properties of Heme 38 
7. Heme in the Pathogenesis of Immune Mediated Inflammatory 
Diseases 42 
7.1. Heme and Malaria 43 
7.2. Heme and Sepsis 44 
7.3. Heme and Sickle Cell Disease 46 
8. Targeting Heme in the Treatment of Immune Mediated Inflammatory 
Diseases 48 
8.1. Pharmacologic Administration of Gasotransmitters 49 
8.2. Induction of HO-1 51 
8.3. Hemoglobin and Heme Scavengers 53 
8.4. Heme Transporters 54 
8.5. Therapeutic Application of Antibodies, Abs 54 
8.5.1. Abs Structure and Function 56 
8.5.1.1. Ab Fragments 58 
8.5.1.2. Single Domain Abs 60 
8.5.2. Ab Production using Phage Display 61 
8.5.2.1. Selection and Screening of Abs using Phage Display 
Technology 63 
8.5.2.2. Libraries used in Phage display Technology 65 
9. Aims of the Thesis 67 
10. References 68 
  
Chapter 2: 
Targeting Heme with Single Domain Antibodies 87 
1. Abstract 91 
2. Introduction 92 
3. Results 94 
3.1. Development and selection of sdAbs against “free heme” 94 
3.2. Heme sdAb specificity 96 
3.3. Structural characterization of sdAbs/heme complexes 100 
3.4. Detection of cellular heme 104 
3.5. Quantitative analysis of circulating heme after acute hemolysis in 
vivo 107 
3.6. Modulation of heme biologic activity by sdAb 109 
4. Discussion 112 
5. Experimental Procedures 117 
6. Acknowledgements 130 
7. References 131 
8. Supplementary figure 134 
  
Chapter 3: 
General Discussion 137 
References 161 
  
Appendix: Supplementary Information 
Engineering of sdAbs: Dimerization of sdAbs against heme and 
generation of sdAbs containing CDR3 167 
1. Abstract 170 
2. Introduction 170 
3. Results 172 
3.1. Generation of different constructs of based on previously described 
sdAbs 172 
3.2. Constructs expression in different bacteria strains and their 
purification 173 
3.3. Heme Binding 175 
3.4. Specificity of the sdAbs constructs 177 
4. Discussion 180 
5. Experimental Procedures 182 
6. Acknowledgements 187 







General Introduction  
Figure 1. Hemoproteins containing the most common heme types 4 
Figure 2. Structure of the different heme groups existent in hemoproteins 
from a variety of species 5 
Figure 3. Hemoproteins with their respective heme pockets 7 
Table 1. Selected representatives of mammalian hemoproteins and 
heme transient binding proteins. 8 
Figure 4. Non-planar distortions in the porphyrin macrocycle in different 
hemoproteins 11 
Figure 5. Heme biosynthesis 13 
Figure 6. Extracellular and intracellular heme transport 16 
Table 2: Putative heme and/or porphyrin transporters 17 
Table 3. Described heme scavengers 22 
Figure 7. Heme scavengers 28 
Figure 8. Predicted heme distribution in plasma 29 
Figure 9. Heme catabolism. 30 
Figure 10. Pathophysiologic effect of heme. 34 
Figure 11. Pro-oxidant effect of heme. 37 
Figure 12. Pro-inflammatory effect of heme. 41 
Figure 13. Targeting “free heme” 49 
Figure 14. Hybridoma and Phage display technology for the 
development of Abs. 55 
Figure 15. Schematic representation of the five different classes of Abs 
(IgA, IgD, IgE, IgG and IgM) and their general properties. 56 
Figure 16. Structure of IgG and its schematic representation. 58 
Figure 17. Schematic representation of different types of Abs 59 
  
List of Figures and Tables 
Figure 18. Schematic representation of a filamentous phage expressing 
sdAb on their surface fused with pIII protein and the structure and 
aminoacid sequence of sdAbs. 62 
Figure 19. Schematic representation of a phage display cycle, also 
named phage display panning, applied in the selection of Abs. 64 
  
Chapter 2: 
Targeting Heme with Single Domain Antibodies   
Figure 1. Selection of heme binding sdAbs 95 
Figure 2. SdAbs heme binding specificity 97 
Figure 3. SdAbs heme binding specificity to other heme analogs and 
hemoproteins 99 
Table 1. Summary of the sdAbs binding specificity against different 
tetrapyrroles 100 
Figure 4. Characterization of sdAb binding to heme 103 
Figure 5. Detection of intracellular heme by sdAbs 105 
Figure 6. Detection of heme in different cellular organelles 106 
Figure 7. Heme accumulation in plasma during acute hemolysis in mice 109 
Figure 8. Targeting heme biologic activity with sdAbs 111 
Suppl. Figure 1. MALDI-TOF/TOF zoom analysis of biotinylated heme 134 
Suppl. Figure 2. Sensogram of heme binding to sdAb 2H10 135 
Suppl. Figure 3. Characterization of heme binding to sdAb 1A6 and 2H7 
by UV-Visible spectrophotometry        135 
Suppl. Figure 4. Sandwich ELISA for heme detection 136 
  
Chapter 3: 
General Discussion  
Figure 1. 3D model structure of 2H10 sdAbs 150 
Figure 2. Model of heme distribution upon hemolysis according to the 
results obtained in this work 159 
  
Appendix: Supplementary Information 
Engineering of sdAbs: Dimerization of sdAbs against heme and 
generation of sdAbs containing CDR3  
Figure 1. Generation of sdAbs constructs 172 
Figure 2. Protein expression in different bacteria strains and their 
purification 174 
Figure 3. Binding to heme 176 
Figure 4. Structure of the different heme analogs 178 
Figure 5. CDR1CDR3 2H7-2H7  heme binding specificity to heme, its 












General Introduction 1 
1. The Biology of Heme 2 
1.1. Discovery of Heme Molecule 2 
1.2. Structure and Biochemistry of Heme 3 
1.2.1. Heme Interaction with Proteins 5 
1.2.1.1 Heme Pocket 6 
1.2.1.2 Heme Binding Motifs 10 
1.2.1.3 Non-planar Heme Structure 11 
2. Heme Biosynthesis 12 
3. Heme Transporters 15 
3.1. Heme Importers 15 
3.2. Heme Exporters 18 
4. Heme Binding Proteins/Chaperones 21 
4.1. Intracellular Heme Binding Proteins 23 
4.2. Extracellular Heme Binding Proteins 25 
5. Heme Catabolism 30 
5.1. Enzymatic Mechanism of Heme Catabolism – Heme oxygenase 31 
5.2. Non-Enzymatic Mechanism of heme Catabolism 33 
5.2.1 Hydrogen Peroxide 33 
5.2.2 Hydrochlorous 33 
6. Heme as a Pathophysiological Molecule 34 
Index 
6.1. Pro-Oxidant Activity of Heme 35 
6.2. Pro-Inflammatory Properties of Heme 38 
7. Heme in the Pathogenesis of Immune Mediated Inflammatory 
Diseases 42 
7.1. Heme and Malaria 43 
7.2. Heme and Sepsis 44 
7.3. Heme and Sickle Cell Disease 46 
8. Targeting Heme in the Treatment of Immune Mediated Inflammatory 
Diseases 48 
8.1. Pharmacologic Administration of Gasotransmitters 49 
8.2. Induction of HO-1 51 
8.3. Hemoglobin and Heme Scavengers 53 
8.4. Heme Transporters 54 
8.5. Therapeutic Application of Antibodies, Abs 54 
8.5.1. Abs Structure and Function 56 
8.5.1.1. Ab Fragments 58 
8.5.1.2. Single Domain Abs 60 
8.5.2. Ab Production using Phage Display 61 
8.5.2.1. Selection and Screening of Abs using Phage Display 
Technology 63 
8.5.2.2. Libraries used in Phage display Technology 65 
9. Aims of the Thesis 67 
10. References 68 
  
Chapter 2: 
Targeting Heme with Single Domain Antibodies 87 
1. Abstract 91 
2. Introduction 92 
3. Results 94 
3.1. Development and selection of sdAbs against “free heme” 94 
3.2. Heme sdAb specificity 96 
3.3. Structural characterization of sdAbs/heme complexes 100 
3.4. Detection of cellular heme 104 
3.5. Quantitative analysis of circulating heme after acute hemolysis in 
vivo 107 
3.6. Modulation of heme biologic activity by sdAb 109 
4. Discussion 112 
5. Experimental Procedures 117 
6. Acknowledgements 130 
7. References 131 
8. Supplementary figure 134 
  
Chapter 3: 
General Discussion 137 
References 161 
  
Appendix: Supplementary Information 
Engineering of sdAbs: Dimerization of sdAbs against heme and 
generation of sdAbs containing CDR3 167 
1. Abstract 170 
2. Introduction 170 
3. Results 172 
3.1. Generation of different constructs of based on previously described 
sdAbs 172 
3.2. Constructs expression in different bacteria strains and their 
purification 173 
3.3. Heme Binding 175 
3.4. Specificity of the sdAbs constructs 177 
4. Discussion 180 
5. Experimental Procedures 182 
6. Acknowledgements 187 







General Introduction  
Figure 1. Hemoproteins containing the most common heme types 4 
Figure 2. Structure of the different heme groups existent in hemoproteins 
from a variety of species 5 
Figure 3. Hemoproteins with their respective heme pockets 7 
Table 1. Selected representatives of mammalian hemoproteins and 
heme transient binding proteins. 8 
Figure 4. Non-planar distortions in the porphyrin macrocycle in different 
hemoproteins 11 
Figure 5. Heme biosynthesis 13 
Figure 6. Extracellular and intracellular heme transport 16 
Table 2: Putative heme and/or porphyrin transporters 17 
Table 3. Described heme scavengers 22 
Figure 7. Heme scavengers 28 
Figure 8. Predicted heme distribution in plasma 29 
Figure 9. Heme catabolism. 30 
Figure 10. Pathophysiologic effect of heme. 34 
Figure 11. Pro-oxidant effect of heme. 37 
Figure 12. Pro-inflammatory effect of heme. 41 
Figure 13. Targeting “free heme” 49 
Figure 14. Hybridoma and Phage display technology for the 
development of Abs. 55 
Figure 15. Schematic representation of the five different classes of Abs 
(IgA, IgD, IgE, IgG and IgM) and their general properties. 56 
Figure 16. Structure of IgG and its schematic representation. 58 
Figure 17. Schematic representation of different types of Abs 59 
  
List of Figures and Tables 
Figure 18. Schematic representation of a filamentous phage expressing 
sdAb on their surface fused with pIII protein and the structure and 
aminoacid sequence of sdAbs. 62 
Figure 19. Schematic representation of a phage display cycle, also 
named phage display panning, applied in the selection of Abs. 64 
  
Chapter 2: 
Targeting Heme with Single Domain Antibodies   
Figure 1. Selection of heme binding sdAbs 95 
Figure 2. SdAbs heme binding specificity 97 
Figure 3. SdAbs heme binding specificity to other heme analogs and 
hemoproteins 99 
Table 1. Summary of the sdAbs binding specificity against different 
tetrapyrroles 100 
Figure 4. Characterization of sdAb binding to heme 103 
Figure 5. Detection of intracellular heme by sdAbs 105 
Figure 6. Detection of heme in different cellular organelles 106 
Figure 7. Heme accumulation in plasma during acute hemolysis in mice 109 
Figure 8. Targeting heme biologic activity with sdAbs 111 
Suppl. Figure 1. MALDI-TOF/TOF zoom analysis of biotinylated heme 134 
Suppl. Figure 2. Sensogram of heme binding to sdAb 2H10 135 
Suppl. Figure 3. Characterization of heme binding to sdAb 1A6 and 2H7 
by UV-Visible spectrophotometry        135 
Suppl. Figure 4. Sandwich ELISA for heme detection 136 
  
Chapter 3: 
General Discussion  
Figure 1. 3D model structure of 2H10 sdAbs 150 
Figure 2. Model of heme distribution upon hemolysis according to the 
results obtained in this work 159 
  
Appendix: Supplementary Information 
Engineering of sdAbs: Dimerization of sdAbs against heme and 
generation of sdAbs containing CDR3  
Figure 1. Generation of sdAbs constructs 172 
Figure 2. Protein expression in different bacteria strains and their 
purification 174 
Figure 3. Binding to heme 176 
Figure 4. Structure of the different heme analogs 178 
Figure 5. CDR1CDR3 2H7-2H7  heme binding specificity to heme, its 












1 THE BIOLOGY OF HEME  
 
Heme is an iron (Fe)-containing protoporphyrin IX molecule involved in vital 
biological processes in numerous organisms, including mammals. It is incorporated 
as prosthetic group of hemoproteins that have crucial roles in biological processes, 
such as gas storage and transport, enzymatic catalysis and regulation of gene 
expression, among others (Chapman et al., 1997;Poulos, 2007b).  
The distribution of heme varies among different organisms, tissues and cells. In 
humans around 80% of heme remains in red blood cells (RBC) while 15% is found 
in the liver and the remaining 5% in other tissues (Zhang, 2011). Nevertheless, all 
mammalian cells require basal levels of heme used for the synthesis and correct 
function of crucial hemoproteins. 
 
1.1 Discovery of The Heme Molecule 
The circulatory system sustains blood transit through the organism and as such, is 
critical to maintain homeostasis. For instance, it transports nutrients (such as amino 
acids; aa and electrolytes), oxygen (O2), carbon dioxide (CO2), hormones, proteins 
as well as RBC and immune cells. RBCs are the most common cell type in blood, 
accounting for around 35-40% of the total blood volume (5x106 RBC/µm3 of blood). 
The remaining volume corresponds to plasma, composed by water containing 
around 70 g/L proteins (e.g. albumin, globulins) and electrolytes (e.g. sodium, 
calcium, magnesium), glucose, hormones and other compounds as well as other 
cell types (Edsall, 1972b).  
In the early 1840s, a pigment conferring the intense red color to the RBC was 
crystallized from mammals, birds and fishes (Edsall, 1972b). At around 1864, this 
pigment was further studied using spectrophotometry and named hemoglobin by 
Hoppe-Seyer (Garcia-Sanchez et al., 2013). The discovery of co-factor of 
hemoglobin started in 1853 by Teichmann, with the first description of the 
separation of the blood pigment into a crystal with a reddish-brown color and a 
colorless protein (Fischer and Zeile, 1929). The reddish-brown crystal substance 
was named heme, a molecule containing Fe, and the colorless protein was named 
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globin, the two assembling to form hemoglobin (Edsall, 1972a). It was only in 1929 
however, that the chemical structure of heme was revealed by Fischer, who 
synthesized hemin, i.e. chloride (Cl) Fe-protoporphyrin (PP) IX molecule, and 
confirmed its structure, as previously proposed by Piloty and Küster (Fischer and 
Zeile, 1929). This discovery was awarded with the Nobel Prize in Chemistry in 1930 
in recognition of “researches into the constitution of haemin and chlorophyll and 
especially for his synthesis of haemin” (Fischer and Zeile, 1929;Garcia-Sanchez et 
al., 2013). 
 
1.2 Structure and Biochemistry of Heme 
Heme is a hydrophobic metallo-compound composed by four methane-bridged 
pyrroles (tetrapyrrole ring) bound to a central Fe atom through their nitrogen atoms 
(Fig. 1) (Kumar and Bandyopadhyay, 2005;Tsiftsoglou et al., 2006;Poulos, 2007b). 
The Fe atom can acquire different oxidative states, most commonly ferrous (Fe2+) 
with a neutral chemical charge or ferric (Fe3+), positively charged and optimized for 
anion binding (Kumar and Bandyopadhyay, 2005). Although ferrous and ferric are 
the most common, other oxidation heme states from Fe2+ to Fe5+ can occur, as 
observed in cytochrome c oxidase or peroxidases (Ogura et al., 1996). Additionally, 
the planar conformation of heme can suffer small distortions within proteins, which 
are very common and functionally relevant (Shelnutt et al., 1998).  
Heme displays a variety of subtle chemical conformational modifications, giving 
rise to different heme a, b and c variants (Fig. 1) (Chapman et al., 1997;Tsiftsoglou 
et al., 2006;Smith et al., 2010). The most common and abundant heme type in 
mammals is heme b, present in hemoglobin and myoglobin, among others (Evans 
and Brayer, 1990;Kakar et al., 2010a). While heme b displays the standard 
structure of Fe protoporphyrin IX, heme a, found in cytochrome c oxidase, has the 
vinyl group replaced by a 17-hydroxyethylfarnesyl group and one methyl group 
replaced by a formyl group (Caughey et al., 1975) (Fig. 2). In heme c, the vinyl 
groups are replaced by sulfhydryl groups (Bowman and Bren, 2008) (Fig. 2), as 
found in cytochrome c (Cytc) (Tsukihara et al., 1995). Whereas heme c can bind 
covalently to proteins, via two thioether bonds, heme b and a cannot, allowing their 
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release from hemoproteins (Allen et al., 2003). Other heme variants can be found in 
a variety of organisms such as bacteria, namely heme d (Murshudov et al., 1996), 
heme d1 (Sjogren and Hajdu, 2001), heme o (Abramson et al., 2000), heme P460 





Figure 1: Hemoproteins containing the most common heme types. Crystalographic structure 
of bovine heart cytochrome C oxidase (PDB ID: 1OCC), human hemoglobin (PDB ID: 2W6V) and 
horse heart cytochrome c (PDB ID: 1HRC) (upper) and their prosthetic group, heme type a 





1.2.1  Heme Interaction with Proteins  
Heme is essential for the proper folding and function of hemoproteins (Chapman et 
al., 1997;Poulos, 2007b) that perform a wide range of biological functions, including 
transport (e.g hemoglobin) and storage (e.g. myoglobin) of diatomic gaseous 
molecules such as oxygen (O2), nitric oxide (NO) and CO (Evans and Brayer, 
 
Figure 2: Structure of the different heme groups existent in hemoproteins from a variety of 
species. Heme types: a (ChEBI: 83281), b (ChEBI: 55376), c (ChEBI: 60562), d (ChEBI: 62802), 
d1(ChEBI: 61147), P460(ChEBI: modified 60562), o (ChEBI: 36301), siroheme (ChEBI: 28599) and 
myeloperoxidase (also known as heme m, ChEBI: 55376) are found in hemoproteins, such as 
cytochrome c oxidase, hemoglobin, cytochrome c, catalase hydroperoxidase II, cytochrome cd1 
nitrite reductase, hydroxylamine oxidoreductase, ubiquinol oxidase, sulfite reductase and 
myeloperoxidase, respectively. These structures were manipulated according to their ChEBI 
(Chemical Entities of Biological Interest; http://www.ebi.ac.uk/chebi/), using the software Acceryls 
Draw. Table shows the relative abundance of the heme type amongst all hemoproteins described in 
the database; http://www.hemeprotein.info/detailquery.php, i.e. for a total of 112 different 
hemoproteins among several species, respectively. 
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1990;Aono, 2008;Kakar et al., 2010b). Some hemoproteins are endowed with 
enzymatic activity (e.g. peroxidases, catalase and synthases) (Reid et al., 
1981;Crane et al., 1997;Zederbauer et al., 2007b;Capitanio et al., 2011) and are 
involved in key metabolic processes (e.g. cytochromes P-450, peroxidases) 
(Bushnell et al., 1990;Guengerich, 2001). These include the respiratory electron 
transport chain in the mitochondria (e.g. cytochromes c, cytochrome c oxidase) 
(Gray and Winkler, 1996;Capitanio et al., 2011), gene transcription (e.g. heme 
binding to the transcription regulatory protein basic leucine zipper transcription 
factor 1, BACH1) (Youn et al., 2006;Hira et al., 2007), micro-RNA processing (e.g 
RNA-binding protein DiGeorge critical region-8, DGCR8) (Weitz et al., 2014), 
regulation of circadian rhythms (e.g. Neuronal PAS domain-containing protein 2, 
NPAS2)(Kaasik and Lee, 2004) and signal transduction pathways (e.g.BACH1) 
(Zenke-Kawasaki et al., 2007) or ion-channel functions (e.g. sodium channel) 
(Horrigan et al., 2005;Wang et al., 2009).  
 
1.2.1.1  Heme Pocket 
The “heme pockets” of hemoproteins (Fig. 1 and 3; Table 1) are characterized by a 
high abundance of aromatic amino acids (aa), i.e. as phenylalanine (Phe, F), 
tyrosine (Tyr, Y) or tryptophan (Trp, W) and by few non-charged aa (Li et al., 2011), 
conferring the hydrophobicity required to stabilize heme and its binding to protein 
matrix. Furthermore, hemoproteins contain frequently five highly conserved aa in 
their heme pockets, including histidine (His, H), methionine (Met, M), cysteine (Cys, 
C), Tyr and lysine (Lys, K) that can act as axial Fe-heme ligands (Li et al., 2011). 
Beside these, other aa can bind to Fe-heme, including proline (Pro, P) through its 
N-terminus amino group (Lanzilotta et al., 2000;Clark et al., 2004) or asparagine 
(Asp, N) via the -amine group (Leys et al., 2000). More recently, it has been 
proposed that threonine (Thr, T) can also support heme binding to proteins (Torda 
et al., 2013). Of these aa residues, His is the one found most frequently in the heme 
pocket of hemoproteins containing heme c or b, while Cys usually promotes binding 
to heme b, and Met to heme c (Table 1) (Fufezan et al., 2008;Li et al., 2011). Other 
hydrophobic aa such as leucine (Leu, L), isoleucine (Ile, I) and valine (Val, V) can 
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also establish interactions with the heme porphyrin, whereas arginine (Arg, R) and 
other positively charged aa can interact with the negatively charged heme 





Figure 3: Hemoproteins with their respective heme pockets.  Structure of human sperm whale 
oxymyoglobin (PDB ID: 1MBN), methemalbumin (PDB ID: 1N5U), rabbit heme scavenger 
hemopexin bound to heme (PDB ID: 1QJS) and horse heart cytochrome c (PDB ID: 1HRC) (upper) 
with their heme group highlighted. Detail view of heme group of the corresponding hemoproteins 
(lower). The heme-Fe in oxymyoglobin is a six coordinate (6c) low spin (LS) with a histidine (H93) 
and a molecule of oxygen (O2) axial ligands. Upon oxygen dissociation, myoglobin acquires a five 
coordinate (5c) high spin (HS) heme state. Heme in albumin is a 5cHS with a tyrosine (Y161) amino 
acid bound to Fe. In hemopexin, heme has two histidine (H213 and H266) coordinated to its Fe 
atom and therefore a 6cLS state. Unlike in heme b type hemoproteins, heme in cytochrome c is 
covalently attached to the protein through two cysteines (C14 and C17), as thus defined as heme c; 
its Fe is coordinated with a proximal Histidine (H18) and a distal methionine (M80), forming a 6c LS 
state.    
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Table 1: Selected representatives of mammalian hemoproteins and heme transient binding 
proteins. Proteins were classified according to their function and the number and type of heme 












Cytochrome c 1/ c-type His/Met (Mirkin et al., 2008) 
Cytochrome b5 1/ b-type His/ His (Wirtz et al., 2000) 
Cytochrome c oxidase 
(complex IV) 
2/ a-type His 
His/His 













Hemoglobin 4 / b-type His (Park et al., 2006) 
Myoglobin 1 / b-type His (Evans and Brayer, 
1988;Vojtechovsky et al., 
1999) 
Catalytic 
activity  - 
enzyme 
Catalase I 1/ b-type Tyr (Putnam et al., 2000) 
Cytochrome P450 (2D6) 1/ b-type Cys (Rowland et al., 2006) 
Indoleamine 2,3-
dioxygenase 
1/ b-type His/ligand (Sugimoto et al., 2006) 
NO synthase 2/ b-type Cys (Crane et al., 1997) 
Cystathione β-synthase 1/ b-type Cys/His (Meier et al., 2001) 
Tryptophan 2,3 
dioxygenase 
4/ b-type His (Zhang et al., 2007) 
Heme 
degradation 
Heme Oxygenase 1/ b-type His/ H2O (Lad et al., 2003) 
Heme binding  
and transport 
Hemopexin 1/ b-type His/His (Paoli et al., 1999) 
Albumin 1/ b-type Tyr (Wardell et al., 2002) 
α1-microglobulin 1/b-type His/Cys (Allhorn et al., 2003;Larsson 






NPAS2 2/b-type His/Cys or 
His/His 
His/? 
(Dioum et al., 2002a;Uchida 
et al., 2005) 
Bach 1 5/b-type 4x Cys 
1xCys/His 
(Hira et al., 2007) 
Iron regulatory protein 2 2/b-type Cys/? 
His/His 
(Jeong et al., 2004a;Jeong et 
al., 2004b;Ishikawa et al., 
2011) 
Soluble guanylyl cyclase 1/ b-type His (Pellicena et al., 2004;Martin 
et al., 2005;Ma et al., 2007) 
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The axial coordination of Fe in heme is directly correlated with protein function. Fe 
establishes primarily four bonds with the pyrrole nitrogens of protoporphyrin IX and 
one or two additional bounds with aa of the heme pocket (i.e. the axial ligands) 
constituting the five (5c) or six coordinate (6c) heme, respectively (Fig. 3). Usually, 
in gas transporter proteins such as myoglobin and hemoglobin, heme is in a 5c 
state with His as the fifth axial ligand while the remaining binding site is vacant for 
the binding of small molecules such as oxygen (Vojtechovsky et al., 1999;Park et 
al., 2006). In other proteins, namely enzymes with a 5c, one of the axial ligands can 
be either His or Tyr while the sixth axial is ligand-free and available for substrate 
binding (Reid et al., 1981;Rowland et al., 2006). Cytochromes involved in electron 
transfer reactions typically display six coordinated heme, in which both axial ligands 
are usually occupied by a bi-His or by His-Met (Mirkin et al., 2008).  
In some hemoproteins, heme performs catalysis in which the Fe and the 
protoporphyrin IX ring can undergo chemical and/or electronic modifications, as 
demonstrated for peroxidases, as well as cytochrome P450 and cytochrome c 
oxidase (Zederbauer et al., 2007b). Hydrogen peroxide (H2O2) can be used as 
substrate in oxido-reductive reactions catalyzed by heme, undergoing 
conformational alterations at the level of the protoporphyrin IX ring as well as in the 
Fe oxidation state. This is followed by oxidation of the second substrate, such as 
indoles, phenols, aromatic amines, lignin, manganese (Mn2+) ions, halide ions or 
proteins (Badyal et al., 2006;Zederbauer et al., 2007a). In other hemoproteins 
however, heme does not perform catalysis and the Fe redox state or protoporphyrin 
conformation are not altered (Poulos, 2007a). This is the case for hemoproteins that 
bind, transport or store gaseous molecules, such as hemoglobin, myoglobin, 
guanylate cyclase and NPAS2 (Dioum et al., 2002b;Poulos, 2007b). Binding of NO 
or CO to these hemoproteins modulates their biological activity, as illustrated by the 
increased production of cyclic guanosine monophosphate (cGMP) when NO or CO 
bind to the heme group of guanylate cyclase (Ma et al., 2007), regulation of O2 and 
carbon dioxide (CO2) transport in the case of hemoglobin or regulation of gene 
transcription in the case of NPAS2 (Dioum et al., 2002b). Alternatively, heme may 
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also bind proteins to regulate their biologic function, as it is the case for heme 
driven inhibition of the transcriptional repressor BACH1 (Hira et al., 2007). 
 
1.2.1.2  Heme Binding Motifs 
Hemoproteins possess characteristic sequences of aa, contained inside heme 
pockets, referred as heme-binding motifs (HBM) or heme regulatory motifs (HRM). 
There are two HBM that bind heme heme c covalently, namely CXXCH and CXXCK 
in which ”X” refers to any aa (Hartshorne et al., 2007;Fufezan et al., 2008;Smith et 
al., 2010;Li et al., 2011). Other HBM, such as CXXXCH and CXXXXCH, present in 
multi-hemic cytochromes also bind heme c (Aragao et al., 2003). The AXXCH and 
FXXCH HBM bind heme c covalently through a single thioether bond (Ginger et al., 
2012). In myeloperoxidases, heme c is bound covalently by two thioether bonds as 
well as by a unique methionyl-sulfonium bond involving a Met (Kooter et al., 1999). 
In cytochrome P460, heme c is also bound covalently through a CXXCH motif by an 
additional ligation to other aa, namely a Lys in cytochrome P460 (Pearson et al., 
2007) or a His in hydroxylamine oxidoreductase (Igarashi et al., 1997). 
Heme a, b, d (Murshudov et al., 1996), d1 (Sjogren and Hajdu, 2001), o 
(Abramson et al., 2000) and siroheme (Oliveira et al., 2008) (Fig. 2) create non-
covalent hydrophobic and electrostatic interactions with hemoproteins. For 
instance, heme b is mainly associated to a HBM with the aa GX[H/R]XC[P/L/ A/V]G, 
i.e. Glycine (Gly, G); X; His or Arg; X; Cys; Pro or Leu or Alanine (Ala, A) or Val and 
Gly, where X can be any aa (Li et al., 2011). Another related FXXGXXCXG motif, 
i.e Phe; X; X; Gly; X; X; Cys; X and Gly, was described in the mammalian 
cytochrome P450 as well as in plant and bacterial hemoproteins that bind heme b 
(Li et al., 2011). There is yet another common HBM composed by two aa only, Cys 
and Pro (i.e. CP) that can accommodate heme b (Ishikawa et al., 2005;Yang et al., 
2008;Li et al., 2011). More recently, similar motifs for the binding of heme b were 
proposed, i.e. the Cys and aspartic acid (Asp, D) (i.e. CD) and the Cys and Serine 






1.2.1.3  Non-planar Heme Structure 
Heme is classically represented in its planar conformation, which is the most 
favorable thermodynamically (Fig. 1 and 2). However, in the heme pocket of 
proteins, heme is exposed to several forces exerted by the surrounding aa, which 
induce distortions in the porphyrin structure (Shelnutt et al., 1998). This has been 
observed in several proteins with similar biological functions and in different 
organisms (Fig. 4), suggesting that alterations to the nonplanar structures of heme 
 
 
Figure 4: Non-planar distortions in the porphyrin macrocycle in different hemoproteins. 
Although heme is usually represented as a planar structure; it acquires different non-planar 
distortions in proteins. A. There are six lowest frequency out-of-plane normal coordinate 
deformations of the porphyrin macrocycle used to decomposed the non planar distortions of heme 
in proteins. These are referred to as saddling (sad, B2u), ruffling (ruf, B1u), doming (dom, A2u), 
waving [wav(x), wav(y); Eg], and propellering (pro,A1u). B. Non-planar distortion of the heme 
porphyrin macrocycle are dependent of the heme pocket of the hemoproteins, as exemplified for 
heme in α- or β- of deoxyhemoglobin A subunits and for the yeast isoenzyme-1 of cytochrome c 
(Figures  obtained from (Shelnutt et al., 1998) ). 
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modulate hemoproteins function (Shelnutt et al., 1998). To understand this 
observation, Shelnutt and co-workers developed a computational procedure named 
“normal-coordinate structural decomposition method”, that allows determining and 
comparing non-planar distortions of heme, as assessed in crystal structures of 
hemoproteins. These include six lowest frequency out-of-plane normal coordinate 
deformations, namely: saddling (sad, B2u), ruffling (ruf, B1u), doming (dom, A2u), 
waving [wav(x), wav(y); Eg], and propellering (pro,A1u) (Fig. 4) (Jentzen et al., 
1998;Shelnutt et al., 1998). The biggest heme distortions were found in type-c 
cytochromes and peroxidases that present mainly saddled distortions, while in 
myoglobin (type-b), heme was predominantly found in a domed conformation 
(Jentzen et al., 1998;Shelnutt et al., 1998).  
 
2 HEME BIOSYNTHESIS 
 
Heme biosynthesis is an essential metabolic pathway in most eukaryotic and 
prokaryotic cells (Layer et al., 2010). The synthesis of both hemoproteins and heme 
are coordinated so that heme binding to hemoproteins provides the correct protein 
conformation and biological function. Biosynthesis of heme has been intensively 
studied in eukaryotes, comprising eight steps, each involving different enzymes, 
expressed in the mitochondria and in the cytoplasm (Fig. 5) (Layer et al., 
2010;Hamza and Dailey, 2012). The first step consists in the condensation of Gly 
and succinyl-CoA into δ-aminolevulinic acid (ALA) and CO2, which is catalyzed by 
the mitochondrial δ-aminolevulinate synthase (ALAS) (E.C. 2.3.1.37). This enzyme 
acts as the rate-limiting step of the pathway and exists in mammals in two isoforms: 
ALAS1 (or ALAS-N) and ALAS2 (or ALAS-E). ALAS1 is encoded by the house-
keeping gene ALAS1 (chromosome 3), which is expressed in all tissues, including 
cells of the erythroid lineage, and provides the basal levels of heme necessary for 
maintenance of cellular homeostasis. ALAS2 is encoded by the ALAS2 gene 
(chromosome X) and is expressed only during the differentiation of erythroid cells, 
when an increase in the amounts of heme is required to support hemoglobin 




Figure 5: Heme biosynthesis.  The first step of heme biosynthesis occurs in the mitochondrial 
matrix with the condensation of glycine and succinyl-CoA by the mitochondrial δ-aminolevulinate 
synthase (ALAS) to generate δ-aminolevulinic acid (ALA). ALA is then translocated to the cytosol by 
unknown mechanism where the next four steps of heme biosynthesis occur. In the cytosol, two 
molecules of ALA react with pyridoxal phosphate to form a porphobilinogen (PBG) through the 
catalyst porphobilinogen synthase (PGBS). Four molecules of PBG are condensed by 
hydroxylmethylbilane synthase (HMBS), generating a molecule of hydroxymethylbilane (HMB) that 
is converted into uroporphyrinogen III (URO III) by uroporphyrinogen III co-synthase or isomerase 
(UROS). The last step in the cytosol is the conversion of decarboxylation of URO III into 
coproporphyrinogen III (COPRO III) by uroporphyrinogen III decarboxylase (UROD). COPRO III is 
then translocated into the mitochondrial intermembranal space by a proposed transporter, ABCB6 
and then by oxidative decarboxylation it is converted into protoporphyrinogen IX (PPG IX) by the 
coproporphyrinogen oxidase (CPOX). This is followed by PPG IX oxidation by protoporphyrin 
oxidase (PPOX) into protoporphyrin IX (PPIX) that is translocated to the mitochondrial matrix, for 
ferrous iron cation (Fe
2+
) incorporation by the enzyme ferrochelatase (FECH) into the macrocycle of 
PPIX to form protoheme IX (heme).   
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Both ALAS proteins harbor two putative HBM in the mitochondrial targeting peptide 
at the N-termini, and a third HBM near the N-terminus of the mature protein (Dailey 
et al., 2005). Heme binding to the HBM of the immature protein presumably blocks 
mitochondrial import and consequently heme synthesis, thus avoiding the 
accumulation of intracellular heme that would be otherwise deleterious (Munakata 
et al., 2004). This level of regulation occurs only on the ALAS1 and not on the 
ALAS2 isoform (Munakata et al., 2004). ALAS1 gene expression is down-regulated 
by heme itself, while ALAS2 expression is controlled at the transcriptional level by 
different erythroid specific factors, such as GATA binding protein 1 (globin 
transcription factor 1; GATA1) (Surinya et al., 1997).  
The following four steps in heme biosynthesis occur after ALA translocates into 
the cytosol, by a still unknown mechanism. Two molecules of ALA react with 
pyridoxal phosphate to form a porphobilinogen through the activity of catalyst 
porphobilinogen synthase (E.C. 4.2.4.24) (Bollivar et al., 2004). Then, four 
porphobilinogen molecules are condensed by hydroxylmethylbilane synthase (E.C. 
2.5.1.61) to generate hydroxymethylbilane (Gill et al., 2009). In the absence of the 
next enzyme of the heme pathway, i.e. uroporphyrinogen III co-synthase or 
isomerase (E.C. 4.2.1.75), the chemically unstable hydroxymethylbilane can 
spontaneously react to generate uroporphyrinogen I, an end product that cannot 
lead to heme formation. The uroporphyrinogen III co-synthase catalyzes the 
enzymatic reaction in which four molecules of hydroxylmethylbilane are converted 
into uroporphyrinogen III (Schubert et al., 2008). The last reaction occurring in the 
cytosol consists in a decarboxylation of uroporphyrinogen III to form 
coproporphyrinogen III by uroporphyrinogen III decarboxylase (E.C. 4.1.1.37) 
(Phillips et al., 1997). Later, coproporphyrinogen III is transported to the 
mitochondrial intermembranal space, presumably by the ATP-binding cassette sub-
family B member 6 (ABCB6) (Krishnamurthy et al., 2006), where the 
coproporphyrinogen oxidase (E.C. 1.3.3.3) catalyzes the oxidative decarboxylation 
of coproporphyrinogen III into protoporphyrinogen IX, that is subsequently oxidized 
to protoporphyrin IX (PPIX) by protoporphyrin oxidase (E.C. 1.3.3.4), producing 
three moles of hydrogen peroxide (Sorianello and Mazzetti, 2000). The final step 
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consists at the incorporation of a ferrous Fe cation (Fe2+) into the macrocycle of 
PPIX to form protoheme IX (heme), by the enzyme ferrochelatase (FECH) (E.C. 
4.99.1.1) in the mitochondrial matrix (Wu et al., 2001). The de novo synthesized 
heme is finally transported to the cytosol where it can either be incorporated into 
apoproteins to form hemoproteins or be directly involved in other biological 
functions (e.g. transcription, translation, cellular differentiation).  
 
3 HEME TRANSPORTERS  
 
Heme transport is tightly regulated so that heme is delivered to different 
compartments where it is used in diverse biological processes. The hydrophobic 
nature of heme determines its insolubility in aqueous solutions, making it unlikely 
that heme could be transported as a free molecule and suggesting the existence of 
heme binding partners that assist its transport from one cell compartment to 
another. Additionally, its hydrophobic nature should allow heme diffusion through 
cellular membranes, although this was shown to occur rather slowly, partially due to 
the hydrophilicity conferred by the propionate groups of heme (Light and Olson, 
1990). This dual nature of heme and its limitations to diffuse freely through 
membranes imposes the need for heme transporters, and several have been 
described (Fig. 6; Table 2). Considering that “free heme” is cytotoxic (Gozzelino et 
al., 2010;Larsen et al., 2010;Gozzelino and Soares, 2011) “carriers” and/or 
chaperone proteins transport heme to specific apoproteins or to be degraded in 
different cell compartments and/or tissues.  
 
3.1 Heme Importers 
Cellular heme transporters include Heme-Responsive Gene-1 (HRG-1), heme 
carrier protein 1 (HCP-1) and Feline Leukemia Virus Subgroup C Receptor 2 
(FLVCR2). HRG-1 was discovered in the roundworm Caenorhabditis elegans, a 
heme auxotroph that acquires heme exclusively from the environment (Rajagopal et 
al., 2008). HRG-1 has orthologs in several organisms such as Leishmania, 
zebrafish and mammals (Rajagopal et al., 2008;White et al., 2013). 
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The mammalian HRG-1 ortholog is highly expressed in the brain, heart, kidney and 
muscle and to a lesser extent in liver, lung, placenta and intestine (Rajagopal et al., 
 
Figure 6: Extracellular and intracellular heme transport. As “free heme” is highly cytotoxic, 
intracellular heme is maintained bound to a heme carrier/chaperone, providing a support for heme 
transfer between the different compartments and transporters. Intracellular heme transport is 
mediated by at least three importers, i.e. Haem carrier protein 1 (HCP-1), feline leukemia virus 
subgroup C cellular receptor 2 (FLVCR2) and Heme-responsive gene 1 protein (HRG-1) and three 
cellular membranar exporters, i.e. ATP-binding cassette, sub-family B 6 (ABCB6), feline leukemia 
virus subgroup C cellular receptor 1a (FLVCR1a) and ATP-binding cassette sub-family G member 2 
(ABCG2). HCP-1 has been described to be responsible for heme uptake in the intestine and 
FLVCR2 from a wide range of mammalian cells. HRG-1 was initially described to export heme from 
the lysosome/endosome compartment; however, HRG-1 can travel to the plasma membrane and 
import heme (Rajagopal et al., 2008). ABCB6 is localized in the plasma membrane as well as in the 
lysosome/endosome compartment (Kiss et al., 2012). FLVCR1b is responsible for heme export from 
the mitochondria into the cytosol. ABCB10 forms a complex with MFRN1 and FECH, probably 




2008). HRG-1 is localized in the membranes of endosomes and lysosomes and 
mediates heme transport from these acidic compartments into the cytoplasm (Fig. 
6). More recently, HRG-1 was identified in the plasma membranes and lysosomes 
of non-polarized human epithelial type 2 (Hep2) cells as well as coupled to the 
vacuolar ATPase (adenylpyrophosphatase; EC 3.6.1.3) proton pump, which 




Table 2: Putative heme and/or porphyrin transporters. The transporters were classified 
according to their functions and then localization and expression.  
Transporters Protein Localization Expression Reference 
Importers HRG-1 PM of 
endosomes/  
lysosomes  
brain, heart, kidney, skeletal muscle, 
liver, lung, placenta,  intestine 
(Rajagopal et al., 
2008;White et al., 
2013) 
HCP-1 PM duodenal and jejunal enterocytes 
and liver 
(Shayeghi et al., 
2005;Qiu et al., 
2006) 
FLVCR2 PM Multiple tissues: liver, fetal liver, 
brain, lung, kidney ,placenta 
(Quigley et al., 
2004;Duffy et al., 
2010) 
Exporters FLVCR1a PM hematopoietic tissues (PBL, fetal 
liver, spleen, Lymph node), 
pancreas, kidney, placenta 
(Tailor et al., 
1999;Vinchi et al., 
2014) 




PM Multiple tissues and highly in stem 
cells 
(Zhou et al., 
2001;Krishnamurth
y and Schuetz, 
2005) 
ABCB6 PM of 
endosomal/ 
lysosomal  
erythrocyte membrane, fetal liver (Krishnamurthy et 
al., 2007;Kiss et al., 
2012) 
ABCB10 MIM Multiple tissues: fetal liver, kidney, 
BM and erythrocytes 
(Shirihai et al., 
2000;Chen et al., 
2010) 
Plasma membrane (PM); Mitochondrial outer membrane (MOM); mitochondrial inner membrane (MIM);  Bone 






HCP-1 is a low affinity and non-exclusive heme cellular importer (e.g. it can 
also translocate folate), expressed mainly in the liver and in duodenum enterocytes 
and, to a lesser extent in jejunum enterocytes (Fig. 6). HCP-1 is responsible for 
heme absorption from food (Shayeghi et al., 2005;Qiu et al., 2006;Le Blanc et al., 
2012).  
FLVCR2 is a heme cellular importer expressed in several mammalian non-
hematopoietic tissues including brain, placenta, lung, liver, and kidney as well as in 
hematopoietic tissues, including fetal liver, spleen, lymph nodes, thymus, 
leukocytes, and bone marrow (Duffy et al., 2010)(Fig. the FLVCR2 6). Mutations in 
gene were linked to Fowler syndrome, a vascular disorder of the brain, but the 
association of its cellular function as a heme cellular importer with the disease still 
remains to be elucidated (Duffy et al., 2010).  
 
3.2  Heme Exporters 
After the last step of de novo heme synthesis, newly generated heme must be 
exported from the mitochondria so that it can be incorporated into apoproteins, 
generating a variety of hemoproteins. Two heme mitochondrial exporters have been 
described, namely, the Feline Leukemia Virus Subgroup C Receptor 1 (FLVCR1) 
(Quigley et al., 2004) and the ATP-binding cassette transporter G2 
(ABCG2)(Krishnamurthy and Schuetz, 2005).  
In mammals, FLVCR1 exists in two isoforms, FLVCR1a (full-length; ~60 kDa) 
(Quigley et al., 2000) and FLVCR1b (shorter protein; ~28 kDa) (Chiabrando et al., 
2012). FLVCR1a is responsible for heme cellular export, while FLVCR1b exports 
heme from the mitochondria (Fig. 6). FLVCR1a is expressed predominantly by 
hematopoietic cells, including peripheral blood lymphocytes, fetal liver, as well as 
leukocytes in the spleen and lymph nodes. It is also expressed in cells from non-
hematopoietic tissues, including in the pancreas, kidneys and placenta (Tailor et al., 
1999). FLVCR1b on the other hand, is mainly expressed in the brain, heart, skeletal 
muscle, bone marrow, and spleen. Interestingly, heme cellular export is increased 
in the presence of secreted heme binding proteins such as hemopexin and albumin, 
suggesting that these scavengers uptake heme delivered by FLVCR1, presumably 
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via a direct interaction between the transporter and the scavenger (Yang et al., 
2010b). The two FLVCR1 isoforms seem to have different functions. FLVCR1b is 
essential for erythroid differentiation, while FLVCR1a is required for intracellular 
heme homeostasis among different cells types, with an important impact on heme 
synthesis and consequently, on hemoprotein function (Chiabrando et al., 2012). 
The FLVCR1 transporter is required for erythroid maturation (Quigley et al., 
2004), a notion supported by the fact that FLVCR1-null mice lack mature 
erythrocytes, as they develop severe macrocytic anemia and proerythroblast 
apoptosis (Quigley et al., 2004). This is not observed in humans carrying point 
mutations in this transporter, which presumably lead to alterations in its 
transmembrane domains (Yanatori et al., 2012), but do not lead to overt defect in 
erythropoiesis (Yanatori et al., 2012). This questions whether FLVCR1 is essential 
for heme transport and erythropoiesis in humans.  
ABCG2 is another heme cellular exporter also known as breast cancer 
resistance protein (BCP), which was discovered based on its role in conferring drug 
resistance of tumor cells (Doyle et al., 1998;Miyake et al., 1999). ABCG2 is not 
specific for heme, as it can bind other protoporphyrins (PP) (e.g. Zinc PP, Cobalt 
PP, empty PP), preventing their accumulation within cells and contributing to PP 
homeostasis (Krishnamurthy et al., 2004;Desuzinges-Mandon et al., 2010). Even 
though ABCG2 binds to a wide range of PP, its highest binding affinity is for heme 
(Desuzinges-Mandon et al., 2010). Similarly to FLVCR1, it delivers heme to heme-
binding proteins such as albumin (Desuzinges-Mandon et al., 2010). ABCG2 is 
expressed in a wide variety of cells, including hematopoetic stem cells, being 
particularly expressed at high levels in the early stages of hematopoiesis (Zhou et 
al., 2001), contrarily to FLVCR1 that is mainly expressed during erythropoiesis 
(Quigley et al., 2004).  
Under certain pathologic conditions, heme can accumulate in cells to a level 
that becomes cytotoxic, causing cellular, tissue and eventually organ damage. 
When this occurs, heme must be exported from cells, as to avoid cytotoxicity. For 
instance, phagocytosis of senescent RBC by hemophagocytic macrophages (Møs) 
is followed by heme release from hemoglobin (Bratosin et al., 1998) and transit 
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from phagosomes into the cytoplasm where it is degraded by heme oxygenase 1 
(HO-1), a heme catabolizing enzyme anchored in endoplasmic reticulum (White et 
al., 2013;Yuan et al., 2013).  
Intracellular heme transport is controlled by the ATP-binding cassette sub-
family B member 6 (ABCB6), localized in the mitochondrial outer membrane, which 
was first described as an Fe transporter and only later as a heme transporter 
(Krishnamurthy et al., 2006) (Fig. 5). ABCB6 is also present in the 
endosomal/lysosomal compartments (Fig. 6) and in the plasma membrane of 
mature erythrocytes and hepatocellular carcinoma cells (Helias et al., 2012;Kiss et 
al., 2012). Absence of ABCB6 however does not interfere with heme biosynthesis 
nor does it affects erythropoiesis (Helias et al., 2012;Kiss et al., 2012).  
ATP-binding cassette sub-family B member 10 (ABCB10) (also known as ABC-
me) is a putative heme transporter localized in the inner mitochondrial membrane, 
presumably forming a stable complex with mitoferritin 1 (MFRN1) and 
ferrochelatase (Fig. 6) (Chen et al., 2010). This ABC transporter is expressed in 
several tissues, but is mainly found in fetal liver cells, kidney, adult bone marrow, 
and mature erythrocytes (Shirihai et al., 2000). ABCB10-null mice have impaired 
primitive erythropoiesis and lack of hemoglobinized cells, leading to embryonic 
lethality at midgestation (Hyde et al., 2012;Yamamoto et al., 2014). Moreover, these 
mice have defects in heme biosynthesis with concomitant accumulation of Fe and 
protoporphyrin IX in the mitochondria (Yamamoto et al., 2014). This suggests that 
the ABC transporter is essential for heme biosynthesis and erythropoiesis, 
presumably through heme transport from the mitochondria to cytosol (Hyde et al., 
2012;Yamamoto et al., 2014). More recently however, it has been argued that 
ABCB10 role in the early stages of heme biosynthesis relies on promoting not heme 
but ALA export from the mitochondria (Bayeva et al., 2013), at odds with a putative 
role of this ABC transporter as a heme transport (Hyde et al., 2012;Yamamoto et 
al., 2014). As such, further studies are required to assess whether ABCB10 is a 





4 HEME BINDING PROTEINS/CHAPERONES 
 
The cytotoxic nature of “free heme” imposes that its intra- and inter-cellular as well 
as inter-tissue transport are tightly regulated (Korolnek and Hamza, 2014). This is 
achieved not only by heme transporters (see section 3) but also by heme binding 
proteins and/or chaperones that assist heme transporters by delivering and/or 
acquiring heme. These proteins bind “free heme” transiently and deliver it to other 
proteins or cells for degradation. 
Several proteins have been identified as heme binding proteins/chaperones (Fig. 7; 
Table 3). Chaperone proteins play two major roles. On one hand they allow correct 
folding and assembly of nascent proteins into their functional active tertiary 
structure. On the other hand, they act upon stress allowing proteins to return to their 
initial conformation. In the early nineties, Robert Hausinger suggested that 
chaperones might also be responsible for the incorporation of metals, heme and 
heme analogs into metalloproteins (Hausinger, 1990). Nowadays, several 
chaperones have been described to have such function, e.g. the heme chaperone 
CcmE (cytochrome c maturation E) from the system I cytochrome c maturation 
(ccm) pathway found in bacteria, archaea and plants (Verissimo et al., 2013). In 
plants, these chaperones are expressed in the mitochondria and promote covalent 
heme binding to cytochrome c (Cytc). While the existence of such chaperones in 
mammals remains to be established, mammals have a variety of proteins that might 
act as heme binding proteins/chaperones, including intracellular proteins such as 
glutathione S-Transferase B (GST) (Caccuri et al., 1990), fatty acid binding protein 
(FABP) (Stewart et al., 1996), heme-binding protein 23 kDa (HBP23)/peroxiredoxin 
(Prx I) (Iwahara et al., 1995), heme-binding protein 22 (p22HBP) (Taketani et al., 
1998;Micaelo et al., 2010), SOUL from the same family (Sato et al., 2004), 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Chakravarti et al., 
2010;Hannibal et al., 2012) heat-shock protein 90 (HSP90)(Ghosh et al., 2011) and 




Table 3: Described heme scavengers.  The proteins were classified according to their localization 
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(Iwahara et al., 1995;Hirotsu 
et al., 1999) 
p22HBP 10
-6
  to 10
-7 
M 
Multiple tissues; higher in 
liver/hematopoietic tissues 
(Jacob Blackmon et al., 
2002;Dias et al., 2006) 
SOUL 10
-9
 M retina and pineal gland 
(Zylka and Reppert, 1999;Sato 













Multiple tissues; higher in 
liver,heart 
(Vincent and Muller-Eberhard, 
1985;Borchers and Spener, 
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Multiple tissues, higher in 
muscle, heart, brain 
(Chakravarti et al., 
2010;Tristan et al., 
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Mø / neutrophils… 
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1984a;b;Okuda et al., 
1992;Okazaki et al., 
1997;Kristiansen et al., 
2001;Thomsen et al., 




Primarily  hepatocytes; 
others nervous system, 
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(Paoli et al., 1999;Shipulina et 
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skeletal muscle, mammary 
gland 
(Adams and Berman, 
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Primarily  hepatocytes; 
others kidney 
(Tejler et al., 1978;Akerstrom 
et al., 2000;Larsson et al., 
2004;Meining and Skerra, 
2012) 
LDL and HDL 10
-11





(Camejo et al., 1998;Miller and 






Extracellular proteins such as haptoglobin (Hp; that binds to hemoglobin, avoiding 
heme release) (Okuda et al., 1992;Okazaki et al., 1997;Mollan et al., 2014), 
hemopexin (Paoli et al., 1999;Shipulina et al., 2000), albumin (Hanson et al., 2011), 
alpha-1-microglobin (α 1m) (Allhorn et al., 2002;Allhorn et al., 2003) and lipoproteins 
(Camejo et al., 1998) were also proposed to have such a function (Table 3).  
 
4.1 Intracellular Heme Binding Proteins 
In mammals, glutathione S-Transferase (GST; EC 2.5.1.18) is expressed in 
different tissues and cells and belongs to the family of the detoxification enzymes 
that catalyze phase II conjugation of reduced glutathione (GSH) with a variety of 
endogenous and exogenous electrophiles, playing a crucial role in the detoxification 
of xenobiotics (Caccuri et al., 1990;Board and Menon, 2013). This enzyme is also 
involved in the elimination of toxic by-products generated in oxidative reactions 
(Caccuri et al., 1990;Board and Menon, 2013), by binding to xenobiotics and 
porphyrins, including heme (Caccuri et al., 1990). Heme binding to GSTs can occur 
via two different binding sites, one with low affinity (KD=10
-6 M) and another with 
high (KD=10
-8M) affinity (Caccuri et al., 1990). Moreover, in the presence of 
glutathione the high affinity heme-binding site increases even further its affinity 
towards heme, presumably due to conformational changes upon glutathione 
binding. This supports the notion that GST is a heme binding protein and that 
glutathione acts as a modulator of heme binding to GST (Caccuri et al., 1990), 
regulating heme transport from the mitochondria to other cellular compartments 
through a still unknown mechanism (Kirschner-Zilber et al., 1989;Boyer and Olsen, 
1991). 
HBP23 is a stress-induced multifunctional antioxidant peroxiredoxin that binds 
heme with high affinity (KD≈10
-8M) (Iwahara et al., 1995;Hirotsu et al., 1999). 
Peroxiredoxins are expressed in a wide variety of tissues, including liver, kidney, 
spleen and heart (Iwahara et al., 1995;Immenschuh et al., 1997). Heme binding to 
HBP23 inhibits its antioxidant activity, suggesting an alternative mechanism of 
heme-induced cell damage, via inhibition of cellular antioxidants mechanisms (Ishii 
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et al., 1995). However, further studies are required to clarify the impact of heme 
binding to HBP23 on its antioxidant activity.  
The p22 heme binding protein (p22HBP) is a cytosolic protein particularly 
abundant in the liver, but also highly expressed in hematopoietic tissues (e.g. fetal 
liver, bone marrow), retina, pineal gland, erythrocytes and other tissues with 
presumably high heme metabolism. P22HBP binds to heme with moderate affinity 
(10-6 to 10-7 M) (Jacob Blackmon et al., 2002;Dias et al., 2006). Interestingly, this 
protein seems to have a crucial role in heme biosynthesis during erythroid 
differentiation. This notion is supported by the demonstration that knock-down of 
the p22HBP gene in murine erythroleukemia (MEL) cells leads to a decrease in 
heme biosynthesis and cellular heme levels, while its overexpression during 
erythroid differentiation leads to elevated heme biosynthesis and hemoglobin 
production (Taketani et al., 1998). Altogether, these data suggested that p22HBP 
promotes heme biosynthesis, increasing heme content during erythoid 
differentiation (Taketani et al., 1998). Moreover, the high levels of p22HBP 
messenger ribonucleic acid (mRNA) found in the liver suggest a role in hepatic 
heme metabolism, such as heme binding and/or transport (Taketani et al., 1998). 
Nevertheless, the precise biological function of p22HBP remains to be clarified. A 
protein sharing 40% sequence identity to p22HBP, named heme-binding protein 2 
(SOUL), has been suggested to bind heme as well (Sato et al., 2004), but this 
proposal has recently been challenged (Ambrosi et al., 2011). 
Fatty acid binding protein (FABP) interacts with and modulates fatty acid 
metabolism, thus preventing their cytotoxic effects (Listenberger et al., 2003;Martins 
de Lima et al., 2006). FABP also binds heme, with an affinity that varies according 
to the oxidative state of Fe (KD~ 10
-7 M to Fe3+ and 10-8 M to Fe2+) (Borchers and 
Spener, 1993). Once bound to heme, FABP is no longer able to bind fatty acids, 
suggesting that the same binding site might be shared between heme and fatty 
acids (Stewart et al., 1996;Thompson et al., 1999). While FABP is known to 
facilitate fatty acid transport, whether the same applies to heme remains unknown 
(Stewart et al., 1991).  
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Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; EC 1.2.1.12) is a heme 
binding protein with a heme affinity of around 10-8 M (Chakravarti et al., 
2010;Hannibal et al., 2012) highly expressed in tissues with high energy 
requirement (e.g. muscle, heart, and brain)(Tristan et al., 2011). This protein is 
involved in the insertion of heme into the inducible nitric oxide synthase (iNOS; EC 
1.14.13.39), promoting iNOS maturation and function (Chakravarti et al., 2010). 
This process is regulated by the product of iNOS, NO (Albakri and Stuehr, 
1996;Waheed et al., 2010), via S-nitrosylation of GAPDH and consequent inhibition 
of heme delivery to iNOS (Chakravarti et al., 2010), as a negative feed-back 
mechanism. A more recent study has shown that the heat-shock protein 90 
(HSP90) presents a similar function, acting in a nucleoside triphosphate (ATP) 
dependent manner (Ghosh et al., 2011). HSP90 is also needed for heme insertion 
into soluble guanylyl cyclase (sGC; EC 4.6.1.2), a step which is necessary to 
support sGC maturation and function (Ghosh and Stuehr, 2012).  
Biliverdin reductase (BVR; EC 1.3.1.24) catalyzes the conversion of biliverdin 
into the antioxidant bilirubin, but also has a wide range of other functions (Kapitulnik 
and Maines, 2009). More recently, BVR was shown to bind heme with an affinity of 
10-7 M, transporting heme to the nucleus for the induction of HO-1 protein in a 
heme-dependent manner (Tudor et al., 2008).  
 
4.2 Extracellular Heme Binding Proteins 
Extracellular heme binding proteins are present mainly in the plasma, where they 
bind heme released by oxidized hemoproteins, such as cell-free hemoglobin 
produced during hemolysis, ensuring its delivery to cells for recycling into 
hemoproteins or for degradation by the HO system (Fig. 7; Table 3). 
Haptoglobin is an acute phase glycoprotein that binds hemoglobin dimers, 
preventing the release of its heme groups during hemolysis (Tolosano et al., 
2002;Andersen et al., 2012a). Haptoglobin exists mainly in three different and 
highly stable haplotypes, namely Hp1-1 (dimers), Hp2-1 (oligomers) and Hp2-2 
(oligomers), with similar affinity for hemoglobin (KD≈10
-12M) (Okuda et al., 
1992;Kristiansen et al., 2001;Mollan et al., 2014). The hemoglobin-haptoglobin 
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complex is recognized by the cluster of differentiation (CD)163 (CD163), a 
scavenger receptor present at the surface of Mø and other cells such as 
hepatocytes. CD163 promotes endocytosis of the hemoglobin-haptoglobin complex, 
followed by lysosomal proteolysis of the globin protein and degradation of heme 
(see section 5) (Thomsen et al., 2013). Upon haptoglobin saturation, excess free 
hemoglobin undergoes auto-oxidation, leading to heme release and production of 
reactive oxygen species (ROS) (Ferreira et al., 2008;Silva et al., 2009;Gozzelino et 
al., 2010).  
Hemopexin is an acute phase β-1B-glycoprotein with high affinity for heme 
(KD<10
-12M) found at a concentration of 0.6 to 1.2 g/L in the plasma, under steady 
state conditions (Paoli et al., 1999;Shipulina et al., 2000). This protein is perceived 
as the first line of defense against “free heme” (Tolosano et al., 1999;Vinchi et al., 
2008). The hemopexin-heme complex binds to the low-density lipoprotein receptor-
related protein (LRP)/CD91 expressed at the surface of Mø, hepatocytes and 
neurons, resulting in its internalization by endocytosis (Hvidberg et al., 2005). Heme 
dissociates from hemopexin in lysosomes and is subsequently degraded by HO-1 
(Hvidberg et al., 2005).  
Albumin is the most abundant heme binding protein in the plasma (about 43 
g/L) and has an important role in the maintenance of plasma osmotic pressure as 
well as in the regulation of fluid distribution between body compartments. Albumin 
has also a high antioxidant capacity and (pseudo) enzymatic activity conferred by 
the transient binding to heme (Bourdon et al., 1999;Ascenzi et al., 2013). 
Additionally, human serum albumin has a high ligand-binding capacity for several 
endogenous and exogenous compounds such as fatty acids, bilirubin, metal ions, 
steroid hormones, several vitamins and drugs (Wardell et al., 2002;Fasano et al., 
2005). Human serum albumin binds heme with an affinity of 10-8 M (Adams and 
Berman, 1980). Its high concentration might compensate for the lower heme affinity 
making it a potent candidate for the major physiologic heme-binding protein in the 
serum acting as an important heme scavenger under conditions where hemopexin 
is saturated (Chow et al., 2008;Huang et al., 2014). Whether human serum albumin 
regulates heme delivery to cells remains to be established, even though the 
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presence of a human serum albumin receptor has been proposed, i.e. albumin 
binding protein and neonatal Fc receptor (FcRn). These can potentially mediate the 
intracellular import of albumin-heme, thus allowing its recycling (Gekle et al., 
1995;Tiruppathi et al., 1996;Chaudhury et al., 2006). The mechanism regulating 
albumin/FcRn binding is still not fully understood, however some studies have 
demonstrated that this binding is dependent on the pH and occurs in a non 
competitive manner to immunoglobulin G (IgG), another protein that binds to FcRn. 
This interaction would allow albumin-heme endocytosis and recycling (Chaudhury 
et al., 2006;Andersen et al., 2012b). Alternatively and most probably, albumin 
transfers heme directly to other heme scavengers such as hemopexin (Noyer et al., 
1998). 
α1-microglobin is another extracellular heme binding protein with the lowest 
known affinity for heme (KD of 10
-6 M), when compared to other plasma heme 
scavengers (Larsson et al., 2004;Olsson et al., 2011). This protein has a truncated 
form (t-α1microglobin) that lacks the C-terminal tetrapeptide (Leu-Ile-Pro-Arg; LIPR) 
and has a free Cys (C34) that is presumably removed by oxyhemoglobin cleavage. 
Nonetheless, this truncated form retains not only the heme binding properties of the 
full-length protein but in addition, acquires heme catabolism capacity (Allhorn et al., 
2002). Presumably therefore, the truncated form of α1microglobin is involved in the 
catabolism of “free heme”, providing an extracellular mechanism for heme 
detoxification, activated directly by the accumulation of oxidized cell-free 
hemoglobin in plasma (Allhorn et al., 2002). 
High (H) and low (L) density lipoproteins (DL) bind heme with high affinity 
(KD≈10
-11 to 10-12M)(Camejo et al., 1998), with faster kinetics than any other plasma 
heme scavenger. This suggests that, as it accumulates in the plasma, “free heme” 
would primarily bind to lipoproteins and then be transferred to hemopexin or 
albumin (Camejo et al., 1998). However, heme binding to lipoproteins can induce 
their oxidation, via heme-Fe or Fe release from heme, with the generation of toxic 
products. Lipoproteins can be highly cytotoxic upon oxidation, leading to cell death 
and promoting inflammation (Balla et al., 1991;Camejo et al., 1998;Jeney, 2002) a 
28 
 
deleterious effect that is prevented by their uptake by Mø via the CD36 receptor 
(Calvo et al., 1998;Camejo et al., 1998). 
 
 
Understanding the dynamics of heme transfer between different plasma heme 
scavengers is crucial to unravel the role of “free heme” under homeostatic and 
pathologic conditions. The kinetics of heme transfer between the main plasma 
 
Figure 7: Heme scavengers. There are several extracellular proteins that can bind heme 
transiently conferring protection against “free heme” released from cell free Hb during hemolysis. 
Cell free Hb is rapidly dissociated into dimers that can be scavenged by haptoglobin (Hp). The Hb-
Hp complex is then uptaken by CD163 pathway for endocytosis and degradation, preventing cell 
free Hb accumulation in plasma. When Hp is saturated, cell free Hb accumulates in plasma and 
upon oxidation releases heme, which is uptaken by hemopexin (HPX). The complex HPX-Heme is 
taken up by CD91 receptor, delivering heme for degradation by HO-1. There are other heme 
scavengers such as albumin, lipoproteins (LDL, HDL) and α1-microglobulin that presumably bind 
heme transiently. Whether heme bound to these scavengers can be directly uptaken by cells or 




heme scavengers, namely hemopexin, albumin and HDL or LDL suggests that 
about 80% of the heme released from cell-free hemoglobin is uptaken by the 
lipoproteins, while the remaining “free heme” binds to the other scavengers. 
However, under steady state conditions, heme distribution is estimated as 2.4%, 
18.6%, 44 % and 35% bound to LDL, HDL, human serum albumin and hemopexin, 
respectively, with a faster uptake of heme by hemopexin and human serum 
albumin, due to the high dissociation constants of Heme-HDL and –LDL complexes 
(Fig. 8) (Miller and Shaklai, 1999). This suggests that approximately 20% of heme 
still remains bound to lipoproteins, which can lead to lipid peroxidation (Miller and 







Figure 8: Predicted heme distribution in plasma. When released, 44%, 35%, 18,6% and 2,4% of 
the “free heme” is bound to hemopexin, albumin, HDL and LDL, respectively. Presumably, heme 
binds initially to lipoproteins, from which is rapidly uptaken by HPX and albumin. Nonetheless, about 
20% of heme remains bound to lipoproteins which might promote lipid peroxidation. 
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5 HEME CATABOLISM 
 
When delivered to cells, heme in hemoglobin-haptoglobin complexes, heme-
hemopexin, heme-albumin and/or “free heme” can be degraded via the HO system 
(Otterbein et al., 2003;Seixas et al., 2009;Gozzelino et al., 2010;Fraser et al., 2011) 
or presumably re-used in the de novo synthesis of hemoproteins. Heme can also be 
degraded by a non-enzymatic mechanism, mediated for instance by H2O2 and/or 
hypochlorous acid (HOCl) (Nagababu and Rifkind, 2000b;a;2004;Maitra et al., 
2011) as well as by glutathione (Atamna and Ginsburg, 1995) (Fig. 9).  
 
 
Figure 9: Heme catabolism. The majority of free heme is degraded by heme oxygenases, which 
catalyze heme catabolism into carbon monoxide (CO), Fe and biliverdin (BV), via a reaction 
assisted by adenine dinucleotide phosphate nicotinamide (NADPH) and oxygen (O2).  The released 
Fe is storaged in ferritin (Ft) while BV is converted into the antioxidant bilirubin (BR) by biliverdin 
reductase (BVR), via a reaction assisted by NADPH. Heme can also be degraded by hydrogen 
peroxide (H2O2) and/or hypochlorous acid (HOCl) with the concomitant formation of Fe and different 





5.1 Enzymatic Mechanism of Heme Catabolism – Heme Oxygenases 
Heme Oxygenases (HO, EC 1.14.99.3) are microsomal enzymes that convert heme 
into CO, Fe and biliverdin, as first described by Tenhunen and co-workers (Fig. 7 
and 9) (Tenhunen et al., 1968;Yoshida et al., 1974). Three isoforms of HO were 
identified so far: HO-1 encoded by HMOX1, HO-2 encoded by HMOX2 and HO-3 
encoded by HMOX-3a and HMOX-3b genes. The latter are processed 
pseudogenes that derive from HMOX-2 transcripts, comprising exons 2 through 5 
(no exon 1) of HMOX-2 and lacking introns, hence suggesting that there is no 
functional HO-3 protein (Scapagnini et al., 2002;Hayashi et al., 2004). Further 
studies are required to understand how the Hmox-3 pseudogenes were generated. 
Under homeostasis, most cells express HO-1 at low or undetectable levels, 
whereas HO-2 is constitutively expressed (Maines et al., 1986). Regarding HO-3, 
its expression in tissues is still unclear and further studies are required to 
characterize it.  
HO-2 activity seems to be more important to maintain heme levels under 
steady state conditions, while HO-1 is induced upon oxidative stress, heat shock, 
hypoxia and increased heme bioavailability (Applegate et al., 1991). Therefore, HO-
1 is classified as a stress response protein with an essential role in protecting cells 
against different forms of stress (Otterbein et al., 2003;Seixas et al., 2009;Soares 
and Bach, 2009;Gozzelino et al., 2010). The protective effects exerted by HO-1 act 
via different mechanisms that include inhibition of heme accumulation (Otterbein et 
al., 2003;Seixas et al., 2009;Dunn et al., 2014) and redox activity, by the 
biliverdin/bilirubin system (McDonagh, 2010) or upon CO binding (Soares et al., 
2002;Pamplona et al., 2007). CO has a high affinity for ferrous-heme, and once 
bound to the Fe in the heme group of hemoproteins, prevents its oxidation, thus 
inhibiting heme release (Pamplona et al., 2007;Ferreira et al., 2008;Ferreira et al., 
2011). This protective effect of CO is crucial to prevent the pathogenesis of several 
immune-mediated inflammatory diseases associated with hemolysis, as it inhibits 
heme release from hemoglobin (Pamplona et al., 2007;Ferreira et al., 2008;Ferreira 
et al., 2011;Jeney et al., 2014).  
32 
 
Heme degradation by HO generates two anti-oxidants, namely, biliverdin and 
bilirubin, produced via reduction of biliverdin in the presence of Nicotinamide 
adenine dinucleotide phosphate (NADPH) by BVR (Stocker et al., 1987). Bilirubin is 
a stronger antioxidant than biliverdin, preventing damage associated with lipid and 
protein oxidations (Neuzil and Stocker, 1994). In several immune-mediated 
inflammatory diseases, the biliverdin/bilirubin system was shown to have a 
cytoprotective effect, presumably by preventing oxidative damage (Ollinger et al., 
2007;Li et al., 2014b). Nevertheless, this protective mechanism still remains poorly 
understood.  
Another end product of heme degradation, Fe, is a potent pro-oxidant prone to 
generate harmful hydroxyl radicals through the Fenton reaction (Fenton, 1894) and 
more precisely through a process called “Haber-Weiss-cycle” (Kehrer, 2000). For 
that reason, cellular Fe content must be tightly regulated (Hentze et al., 2004), 
limiting its availability through storage into Fe storage proteins, such as ferritin 
(Arosio and Levi, 2002) or via extracellular Fe transport by ferroportin (Mitchell et 
al., 2014). 
Ferritin is a multimeric protein (24-subunits) composed by heavy/heart chains 
(FtH) and light/liver chains (FtL), with high capacity for Fe storage (about 4500 Fe 
ions per ferritin complex). The proportion of L-/H-chains depends on cell and tissue 
type, as well as their Fe content and varies among the different organisms. Ferritin 
with a higher proportion of FtH has higher ferroxidase activity due to the catalytic 
properties of FtH that converts Fe2+ into Fe3+, while ferritins with higher proportion of 
FtL promote Fe3+ nucleation and storage (Wang et al., 2006). Ferritin expression is 
coupled to that of HO-1, and while HO-1 is up-regulated by heme, Ft expression is 








5.2 Non-Enzymatic Mechanism of Heme Degradation 
 
5.2.1 Hydrogen Peroxide (H2O2) 
H2O2 is generated via dismutation of superoxide (O2
-) or catalyzed by the action of 
superoxide dismutase (SOD, EC 1.15.1.1), amine oxidase (EC 1.4.3.6) or glucose 
oxidase (EC 1.1.3.4) (Segura-Aguilar, 1993;Rypniewski et al., 1995;Salazar and 
Van Houten, 1997;Pietrangeli et al., 2000). In erythrocytes, H2O2 is produced 
mainly by the auto-oxidation of oxyhemoglobin (Misra and Fridovich, 1972) which 
leads to a cascade of reactions resulting in the production of fluorescent products 
belonging to the degradation of heme moiety, i.e. the protoporphyrin IX structure, 
amongst other product (Nagababu and Rifkind, 1998). Heme reaction with H2O2 
generates dipyrrolic propentdyopents, hematic acid and methylvinylmaleimide 
molecules, but further experiments are required to address the correct identity of 
other end products of this reaction (Nagababu and Rifkind, 2000b;a;2004) (Fig. 9). 
 
5.2.2 Hypochlorous (HOCl) 
Myeloperoxidase (MPO, EC 1.11.2.2), an enzyme predominantly expressed in 
neutrophils, catalyzes the conversion of H2O2 into HOCl in the presence of the 
chloride anion. HOCl is a powerful oxidant, which is important in the defense 
against microbial organisms (Albrich et al., 1981). HOCl has also been implicated in 
heme degradation by direct interaction with the tetrapyrrole ring of heme in 
hemoproteins (e.g. hemoglobin), leading to Fe release (Pullar et al., 2000). 
Presumably other molecules are generated from the tetrapyrrole ring destruction 










6 HEME AS A PATHOPHYSIOLOGICAL MOLECULE  
 
Several diseases are associated with disruption of the homeostatic parameters that 
compromise RBC integrity, causing hemolysis and release of hemoglobin into the 
plasma (Fig. 10, 11 and 12). Considering that in humans, one fourth of the total 
cells are RBC (2-3x1013 in adult) that have exceedingly high levels of hemoglobin 
(3x108 protein molecules/RBC) and heme (1.2x109 heme/RBC) contents, this 
results in rather small levels of hemolysis being associated with the generation of 
high levels of cell-free hemoglobin which presumably leads to “free heme” 
accumulation (Gozzelino and Soares, 2014). 
 
 
Figure 10: Pathophysiologic effect of heme. Under hemolytic conditions heme is released from 
oxidized hemoglobin (Hb) dimers and accumulates in plasma, acting in pro-oxidant and pro-
inflammatory manner. In presence of other cytotoxic agonists produced during inflammation, heme 





This non-hemoglobin bound heme, hereby referred to as “free heme”, can act in a 
pro-inflammatory (Graca-Souza et al., 2002;Figueiredo et al., 2007) and cytotoxic 
manner (Seixas et al., 2009;Gozzelino et al., 2010;Larsen et al., 2010), contributing 
to the pathogenesis of several immune-mediated inflammatory diseases. These 
include sickle cell disease (Vinchi et al., 2013), malaria (Pamplona et al., 
2007;Ferreira et al., 2011) and severe sepsis (Larsen et al., 2010), which probably 
comprise only a few among many others. Other sources of “free heme” cannot be 
excluded, as release upon oxidation of hemoproteins such as myoglobin from 
muscle cells, which contributes to the pathogenesis of rhabdomyolysis (Adornato et 
al., 1978;Nath et al., 1992).  
 
6.1  Pro-Oxidant Activity of Heme  
The pro-oxidant activity of heme is driven by the participation of its Fe in the Fenton 
reaction (Fenton, 1894)/“Haber-Weiss” (Kehrer, 2000) reaction (Fig. 11). Whether 
this is driven by heme-Fe itself, or by Fe when released from heme remains to be 
elucidated. In any case, heme-driven ROS generation can catalyze the oxidation of 
a variety of macromolecules, compromising their biological function, as 
demonstrated for proteins (Aft and Mueller, 1984), deoxyribonucleic acid (DNA) 
(Glei et al., 2006) and lipids (Gutteridge and Smith, 1988;Mashima et al., 2002). 
The latter are of particular importance, as the hydrophobic properties of heme favor 
its intercalation into phospholipid bilayers (Balla et al., 1991;Jeney et al., 2002), 
catalyzing lipid peroxidation and the concomitant generation of toxic compounds, 
enhancing membrane permeability and disrupting cell membrane components 
(Schmitt et al., 1993;Kumar and Bandyopadhyay, 2005). This is particularly relevant 
to RBC where heme can promote hemolysis (Chou and Fitch, 1981). This occurs 
via a peroxidation process targeting RBC membranes as well as the cytoskeleton, 
which cross-links and aggregates spectrin and protein 4.1 but not actin, thus 
compromising RBC integrity (Solar et al., 1990). Heme can also target DNA, 
namely mitochondrial DNA (mtDNA) (Suliman et al., 2002), leading to its deletion 
and eventually to programmed cell death (Suliman et al., 2002). Apart from RBC, 
the deleterious effect of “free heme” is also exerted in many other cell types, 
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including renal epithelial (Tracz et al., 2007), neuron-like (Goldstein et al., 2003) 
and cardiac cells (Bhoite-Solomon et al., 1993).  
Heme accumulation in plasma promotes the oxidation of lipoproteins, such as 
LDL and HDL (Camejo et al., 1998) and, in the presence of H2O2, generates 
conjugated dienes, thiobarbituric acid reacting substances, and F2-isoprostanes 
(Camejo et al., 1998). Oxidized LDLs are uptaken by Mø, leading to their 
conversion into foam cells, which are known to contribute to the development of 
pathologic conditions such as atherosclerosis (Miller and Shaklai, 1994;Kumar and 
Bandyopadhyay, 2005). Besides that, heme-driven LDL peroxidation leads as well 
to the generation of highly cytotoxic products that are deleterious to vascular 
endothelial cells (Balla et al., 1991;Jeney et al., 2002).  
The cytotoxic effects of heme are exacerbated by the concerted action of pro-
inflammatory agonists, such as tumor necrosis factor (TNF) and Fas, among others 
(Larsen et al., 2010;Gozzelino et al., 2012). This synergistic effect sensitizes cells 
(e.g. primary hepatocytes, pancreatic β cells, Human Embryonic Kidney 293 cells 
and oligodendrocytes) to undergo programmed cell death, presumably via a 
mechanism involving the unfettered production of free radicals (Gozzelino et al., 
2010;Larsen et al., 2010). This notion is supported by experiments in which heme 
sensitization of TNF-mediated programmed cell death is inhibited by the antioxidant 
N-acetylcysteine (NAC) (Seixas et al., 2009;Larsen et al., 2010;Gozzelino and 
Soares, 2011). Presumably, the cytotoxic effect of heme relies on sustained ROS-
driven activation of c-Jun N-terminal Kinase (JNK) signaling transduction pathway, 
most likely via inhibition of phosphatase enzymes that regulate JNK activation in 
response to TNF (Kamata et al., 2005;Gozzelino et al., 2012), as demonstrated in 
vitro and in vivo in Hepa 1-6 cells and mice, respectively (Gozzelino et al., 2012). 
Sustained JNK activation promotes the activation of effector caspases, namely 
caspase 3 (EC 3.4.22.56), that triggers programmed cell death via apoptosis 
(Gozzelino et al., 2012;Gozzelino and Soares, 2014). This cytotoxic effect can be 
prevented through the activation of NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells), a transcription factor involved in the inhibition of TNF 
induced programmed cell death (Kamata et al., 2005;Gozzelino et al., 2012). 
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The protective mechanism of NF-κB is mediated by the expression of anti-oxidant 
genes, such as manganese superoxide dismutase, FtH (Gozzelino and Soares, 
2014) and X-chromosome-linked inhibitor of apoptosis (XIAP) (Tang et al., 2001), 
among others. Recently, it has been demonstrated that Mø undergoes necroptosis 
when exposed to heme, through two independent but complementary mechanisms, 
 
 
Figure 11: Pro-oxidant effect of heme. “Free heme” is reactive, promoting oxidative stress, via a 
poorly understood mechanism, driven by the heme-Fe. Heme accumulation under hemolytic 
conditions leads to A. cellular damage via the generation of reactive oxygen species (ROS) and 
leading to DNA and protein damage as well as lipid peroxidation. B. Heme is cytotoxic for RBC, 
exacerbating hemolysis. C. Heme promotes the expression of pro-inflammatory genes in vascular 
endothelial cells as well as oxidation of lipoproteins (e.g.LDL), contributing to vasoconstrictions. D. 
Heme also sensitizes parenchyma cells to undergo tumor necrosis factor (TNF) mediated 






one involving Toll-like receptor 4 (TLR-4) signaling, leading to the production of 
TNF and another by ROS production induced by heme (Fortes et al., 2012). 
Furthermore, this cytotoxic effect is dependent on TNF mediated cell death by 
receptor-interacting protein (RIP)1 and RIP3 proteins as well as JNK activation 
(Fortes et al., 2012). 
 
6.2 Pro-Inflammatory Properties of Heme  
Heme can also act in a pro-inflammatory manner, promoting the activation of Mø 
and neutrophils as well as endothelial cells and possibly other cell types (Fig. 12) 
(Wagener et al., 2001;Graca-Souza et al., 2002;Belcher et al., 2014;Chen et al., 
2014;Dutra and Bozza, 2014). In endothelial cells, heme can activate the 
expression of P-selectin and von Willebrand factor (VWF) release from Weibel-
Palade bodies, i.e. endothelial cell storage granules, via a mechanism dependent of 
TLR4/Myd88 pathway (Belcher et al., 2014). Heme driven degranulation of Weibel-
Palade bodies is mediated via a mechanism that involves the activation of protein 
kinase C (PKC, EC 2.7.11.13), NADPH oxidase (NOX, EC 1.6.3.1) and ROS 
production (Belcher et al., 2014). Furthermore, heme promotes the expression of 
adhesion molecules, such as vascular cell adhesion molecule 1 (ICAM-1) and 
intercellular adhesion molecule 1 (ICAM-1) as well as leukocyte rolling and 
adhesion (Belcher et al., 2014). This mediates neutrophil adhesion to endothelium 
cell and its emigration from blood vessels.  
Heme is also able to active neutrophils via a mechanism involving the induction 
of PKC signal transduction pathway with ROS generation and actin polymerization 
as well as chemotaxis stimulation (Graca-Souza et al., 2002). Recent studies have 
shown that heme promotes neutrophil chemotaxis through the production of pro-
inflammatory mediator leukotriene B4 (LTB4) (Monteiro et al., 2011) or acting as a 
chemoattractant (Porto et al., 2007). Heme also stimulates the induction of 
superoxide anion production by neutrophils through an NOX dependent 
mechanism, leading to an oxidative burst (Graca-Souza et al., 2002). Additionally, 
heme can induce the production of chemokines, such as interleukine 8 (IL-8) by a 
process independent of PKC activation, promoting neutrophil chemotaxis and 
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priming neutrophils to undergo oxidative burst as well as adhesion to endothelial 
cells (Graca-Souza et al., 2002). IL-8 is also expressed in endothelial cells upon 
heme stimulation, presumably via the induction of oxidant-sensitive mechanisms, 
and inhibition of the transcription factor hypoxia inducible factor-1 (HIF-1) 
(Natarajan et al., 2007). This chemokine was shown to promote angiogenesis, 
encompassing endothelial cell proliferation, migration and increasing membrane 
permeability (Li et al., 2003). More recently, heme was shown to induce the 
formation of neutrophil extracellular traps (NETs), presumably via ROS production 
in neutrophils (Chen et al., 2014). NETs are extracellular fibers composed of 
decondensed chromatin and granular enzymes that confer host resistance to 
bacterial infection (Brinkmann et al., 2004). However, NETs can also be harmful to 
the organism, promoting inflammation and eventually trapping of self compounds, 
such as RBC (Fuchs et al., 2013). This was correlated with the pathogenesis of 
several non-infectious diseases, where the pathologic effect associated with NETs 
formation might be triggered by heme accumulation in plasma, as suggested for 
sickle cell disease (Chen et al., 2014). Yet another pro-inflammatory effect of heme 
relies on its ability to prolong neutrophil survival (Arruda et al., 2004), presumably 
via modulation of signaling pathways involved in cell survival, such as those 
involving the major mitogen-activated protein kinases (MAPKs), namely 
extracellular signal-regulated kinase (ERK)) and protein kinase B (Akt, EC 2.7.11-
12)/Phosphoinositide 3-kinase (PI3K, EC 2.7.1.137) pathways as well as the 
activation of NF-κB (Arruda et al., 2004;Arruda et al., 2006). This effect seems also 
to require the maintenance of mitochondrial integrity (Arruda et al., 2004;Arruda et 
al., 2006). In summary, accumulation of heme in plasma or tissues can lead to an 
uncontrolled activation of neutrophils and deleterious inflammation, compromising 
homeostasis through a variety of different mechanisms. 
The pro-inflammatory effect of heme was also shown to involve TLR4 
signaling, through activation of myeloid differentiation 88 (MyD88) pathway, 
involving MAPK and NF-κB and leading to the induction of pro-inflammatory gene 
expression including TNF and keratinocyte derived chemokine (KC) (Figueiredo et 
al., 2007;Belcher et al., 2014). TLR recognize pathogen-associated molecular 
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patterns (PAMPs), i.e bacterial lipopolysaccharide (LPS) and intracellular proteins 
such as high mobility group protein 1 (HMGB1), biglycan, oxidized LDL, fibrogen 
and monosodium urate crystals (Piccinini and Midwood, 2010). TNF production 
through TLR4 mediated heme activation is dependent of its Fe and the vinyl group 
(Figueiredo et al., 2007). Whether this occurs via direct interaction remains to be 
elucidated. Heme also synergizes with several cell surface (TLR2, TLR4, TLR5), 
endosome (TLR3, TLR9) and cytosolic (NOD1, NOD2) receptors to trigger the 
secretion TNF and IL-6 as well as IP-10 cytokines by MyD88 and TIR (Toll–IL-1 
receptor)-domain-containing adapter-inducing interferon (TRIF)- dependent 
mechanism (Fernandez et al., 2010).  
IL-1β is another cytokine induced by heme in LPS primed Mø, via a mechanism 
involving the activation of another pattern recognition receptor (PRR), namely the 
nucleotide binding domain and leucine rich repeat containing family pyrin domain 
containing 3 (NLRP3) inflammasome (Dutra et al., 2014). This effect was also 
shown to be dependent on mitochondrial ROS production, potassium efflux, 
NADPH oxidase-2 and activation of spleen tyrosine Kinase (Syk, EC 2.7.10.2). 
Contrarily to a previous work (Li et al., 2014a), heme activation of NLRP3 was 
unrelated with ATP release, lysossomal damage and purinergic receptor P2X7 
activation. These distinct results were correlated the experimental conditions used, 
namely with the presence/absence of serum in Mø cultures (Dutra et al., 2014;Li et 
al., 2014a). This suggests that heme activation of NLRP3 can occur by two different 
mechanisms that are dependent of serum. Alternatively, the results obtained by Li 
et al. (Li et al., 2014a) can be due to the observation that absence of serum leads to 
an increase in macrophage cell death with release of ATP and consequently 








Figure 12: Pro-inflammatory effect of heme. Accumulation of “free heme” in plasma acts in a pro-
inflammatory manner via A. activation of neutrophils and endothelial cells, where it is sensed via 
Toll-like receptor (TLR)4 leading to degranulation of Weibel Palade bodies with the release of P-
selectins and Von Willebrand factor (VWF). B. Heme sensed by TLR4 in Mø, induces the production 
of pro-inflammatory cytokines, i.e. keratinocyte-derived chemokine (KC) and tumor necrosis factor 
(TNF), via a mechanism involving MyD88 and Mitogen-activated protein kinases (MAPKs; ERK, p38 
and JNK) that activate NF-κB. C. Heme also promotes the phosphorilation of spleen tyrosine kinase 
(SyK) by an unknown mechanism. SyK activation triggers the activation of the protein kinase (PKC), 
inducing ROS production. Amplification of the immune response against microbial molecules is 
synergized by heme with cell surface (TLR2, TLR4, TLR5), endosome (TLR3, TLR9) and cytosolic 
(NOD1, NOD2) receptors, increasing the cytokine production (TNF, IL-6, IFNβ, IP-10). D. Heme 
activates the NLRP3 inflammasome with induction of IL-1β via a mechanism that involves Syk as 
well as activation of NADPH Oxidase (NOX) with mitochondrial ROS production. This requires the 
NF-κB driven NLRP3 expression and activation of caspase-1 via a mechanism dependent of K
+
 







Another important feature of heme is its ability to activate LPS stimulated B 
cells, promoting B cell differentiation and class switch recombination, through a 
mechanism involving the inactivation of the basic leucine zipper transcription factor 
2 (Bach2)(Watanabe-Matsui et al., 2011). Bach2 is a transcriptional repressor of B 
lymphocyte-induced maturation protein-1 (Blimp-1), expressed in the progenitors 
and mature B-cells, and containing at least four heme-binding domains. Heme 
binding inactivates Bach2, promoting its nuclear export and degradation through the 
ubiquitin/proteasome system (Hira et al., 2007;Zenke-Kawasaki et al., 2007). 
Thereby, expression of Blimp-1 increases, presumably inducing B-cell maturation, 
while acting as a repressor of antibody class switch recombination. Moreover, 
Bach2 is required for Ig somatic hypermutation, suggesting that Bach2 inactivation 
by heme affects antigen-specific antibody production. This suggests that heme is 
involved in the modulation of activated B cells responses, an effect that might be 
relevant on the pathogenesis of diseases (Watanabe-Matsui et al., 2011). Once 
more, further studies are required to address these questions. 
 
7 HEME IN THE PATHOGENESIS OF IMMUNE MEDIATED INFLAMMATORY DISEASES 
 
Several immune mediated inflammatory diseases are associated with hemolysis 
and subsequently with the release of heme from cell-free hemoglobin (Gozzelino et 
al., 2010;Larsen et al., 2010). Presumably, heme contributes to the pathogenesis of 
these diseases, as illustrated for malaria caused by Plasmodium infection, severe 
sepsis caused by polymicrobial infections and sickle cell disease cause by 
mutations in the β chain of hemoglobin. Several methods were developed for total 
heme quantification, i.e. heme bound or not to molecules such as proteins or lipids, 
including formic acid assay (Kuross et al., 1988;Regan et al., 2001), pyridine 
hemochrome assay (Berry and Trumpower, 1987) and fluorescent assay (Vinchi et 
al., 2013). However, no further methodology was developed to determine and 
quantify unequivocally heme in its free state, i.e. not bound to other molecules, 
which limits our understanding of the pathologic rule of this molecule in diseases 
associated with hemolysis.  
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7.1  Heme and Malaria 
Malaria is an infectious disease caused by Plasmodium parasites that affects 
around 300–400 million people per year with an associated 1–3 millions of deaths 
per year, mainly in children under 5 years old (Murray et al., 2014). Plasmodium 
falciparum is responsible for most of the severe forms of disease cases and deaths 
associated with malaria (Miller et al., 2002). Plasmodium transmission to the human 
host starts by subcutaneous injection of the parasite by an infected Anopheles 
mosquito. The parasite migrates to the liver and infects hepatocytes, to initiate the 
liver stage of infection that occurs without discernible clinical symptoms. 
Multiplication of the parasite inside hepatocytes produces and releases merozoites 
that infect RBC, initiating the blood stage of infection (Miller et al., 2002). 
Multiplication of Plasmodium in RBC leads to hemolysis and as such, to the 
accumulation of cell-free hemoglobin in plasma and production of non-hemoglobin 
bound heme (Ferreira et al., 2008;Seixas et al., 2009). This so-called “blood stage” 
of infection is associated with the appearance of all the clinical manifestations of 
malaria (Idro et al., 2005). Several studies in mice argue that accumulation of non-
hemoglobin bound heme in plasma contributes critically to the pathogenesis of 
severe forms of malaria (Pamplona et al., 2007;Ferreira et al., 2008;Seixas et al., 
2009;Ferreira et al., 2011). This pathologic effect is countered by the induction of 
HO-1 and the production of CO, which can suppress the pathogenesis of severe 
forms of malaria, suggesting that this protective effect is achieved via a mechanism 
that inhibits the pro-inflammatory and cytotoxic effects of “free heme” (Seixas et al., 
2009;Gozzelino et al., 2010;Gozzelino and Soares, 2011). Nevertheless, the 
mechanisms by which heme promotes the pathogenesis of severe forms of malaria 
are still not fully understood. Even though it has been proposed that it relies mainly 
on the pro-oxidant effect of heme, whether this effect is triggered be heme or by Fe 
release from the heme structure by an enzymatic (by HO-1) or non-enzymatic 
mechanism (Nagababu and Rifkind, 2000a;2004) remains to be elucidated (see 
section 4). Fe, similarly to heme, exerts deleterious effects countered by ferritin, 
which can explain the finding that FtH confers protection against the development 
of severe forms of malaria (Gozzelino et al., 2012).  
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Individuals carrying hemizygous sickle cell mutations (see section 7.3) have 
survival advantage against malaria, presumably via a mechanism involving the 
induction of HO-1 by the accumulation of non-pathological concentrations of heme 
(see section 8.2) released from cell-free hemoglobin (Pamplona et al., 
2007;Ferreira et al., 2011). HO-1 provides protection against the pathologic effect of 
heme, not only by favoring its degradation but also by generating CO, limiting heme 
accumulation in plasma (for more details see section 7.3). 
 
7.2 Heme and Sepsis 
Sepsis is a clinical syndrome defined as systemic inflammatory response syndrome 
(SIRS) triggered by a systemic inflammatory response to a suspected or proven 
infection (Angus and van der Poll, 2013). Sepsis can progresses to severe sepsis 
that emerges due to the development of acute organ dysfunction or to septic shock, 
when also associated to refractory hypotension (Angus and van der Poll, 2013). 
Sepsis mortality ranges from approximately 24% to 52% (Silva et al., 2004) and is 
associated with approximately 20x106 of deaths per year worldwide, accounting for 
one of the most frequent causes of death in hospitalized patients (Angus and van 
der Poll, 2013). It is currently believed that the pathogenesis of sepsis is 
predominantly driven by an unfettered immune response to infection that acts in a 
deleterious, i.e. pathological, manner in the host parenchyma, irrespectively of its 
effect on the pathogen (Larsen et al., 2010;Medzhitov, 2013). Considering the high 
rate of mortality and despite clinical treatment (Silva et al., 2004), the long term 
consequences in sepsis survivors (Wang et al., 2014) together with the emergence 
of a post-antibiotic era with decreasing availability of anti-microbial drugs (Angus 
and van der Poll, 2013), it is crucial to understand the complex physiological and 
molecular mechanisms that promote the pathogenesis of this disease.  
Similarly to malaria, sepsis is associated with more or less overt hemolysis 
(Loran et al., 2006), such as driven by the production of pore-forming bacterial 
cytolysins that damage RBC membranes (Bhakdi et al., 1996), e.g. Escherichia coli 
hemolysin (Bhakdi et al., 1996). This leads to the accumulation of extracellular 
hemoglobin in plasma, similarly to malaria, which upon oxidation releases its 
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prosthetic heme groups. Another process that might lead to hemolysis in the 
context of sepsis is RBC rheology that is promoted by RBC aggregation and 
alteration in its deformability and shape, mainly caused by ROS and NO production, 
impairment of calcium homeostasis and alterations in membrane components 
(Serroukh et al., 2012).   
The contributions of the “free heme” to the pathogenesis of sepsis were 
demonstrated using an experimental mouse model, where sepsis is induced 
through a cecal ligation and puncture (CLP) (Larsen et al., 2010). Disease severity 
was associated with RBC rheology and accumulation of hemoglobin as well as 
heme in plasma. Expression of HO-1 provided tolerance against polymicrobial 
infection, presumably by preventing the pathologic effect driven by heme (see 
section 5), as demonstrated using Hmox1 knockout mice. Moreover, administration 
of the heme scavenger hemopexin to mice subject to CLP also provided protection 
against sepsis, further supporting the role of heme in the pathogenesis of this 
disease (Larsen et al., 2010). Interestingly, patients with sepsis were also shown to 
develop Rhadomyolysis, suggesting myoglobin as an alternative source of heme 
other then cell-free hemoglobin (Kumar et al., 2009).  
The view that, in a similar manner to mice, heme contributes to the 
pathogenesis of human sepsis is supported by the observation that low levels of 
hemopexin in plasma at the onset of sepsis are correlated with increased organ 
dysfunction and mortality (Larsen et al., 2010;Janz et al., 2013). Accumulation of 
extracellular hemoglobin, such as associated with low levels of expression of the 
hemoglobin scavenger haptoglobin, also correlates to higher sepsis mortality (Janz 
et al., 2013). This suggests that hemolysis, cell-free hemoglobin, decrease of 
hemoglobin and heme scavengers as well as a possible increase on “free-heme” 
exacerbate oxidative stress and inflammation (see section 6), promoting disease 
progression and ultimately death. In this study the generation of “free heme” and its 
contribution for the disease is still controversial as the methodology used for its 
quantification in plasma samples of the individuals has some limitations, which 




7.3 Heme and Sickle Cell Disease 
Sickle cell disease is a common and inherited genetic disease associated with 
conformational alterations imposed to RBC, resulting from mutations in the genes 
encoding for the globin chains of hemoglobin. There are several sickle point 
mutations in the β-chain of hemoglobin including HbS (β6Glu>Val)(Jallow et al., 
2009), hemoglobin C (HbC) (β6Glu>Lys) (Verra et al., 2007) and hemoglobin E 
(HbE) (β26Glu>Lys)(Hutagalung et al., 1999). Sickle cell disease is estimated to 
affect about 7% of the world population, and every year approximately half a million 
of newborns carry homozygous single or composite mutations leading to severe 
forms of the disease (Weatherall and Clegg, 2001). Hemizygous sickle mutations 
are non-pathologic per se, while conferring a strong protection against malaria, 
explaining why these mutations have been so stringently selected through evolution 
of human populations in endemic areas of malaria (Arif, 2007).  
Mortality associated with the occurrence of sickle cell disease, as driven by 
homozygous sickle mutation or by composite hemizygous mutations, is age 
dependent, with an estimated frequency of 90 % at 20 years of age and dropping to 
50% after fifty years of age (Platt et al., 1994). The clinical symptoms of sickle cell 
disease are associated with low-oxygen pressure promoting hemoglobin 
polymerization, RBC deformation and reduced RBC half-life that eventually lead to 
hemolysis (Uzunova et al., 2010). Clinical symptoms include susceptibility to severe 
infections, severe pain during so-called "sickle-cell crisis", high risk of stroke, renal 
failure and chronic episodes of hemolysis, all associated with acute chest syndrome 
and high mortality risk.  
Presumably, cell-free hemoglobin accumulates in plasma during hemolysis and 
consequently, “free heme” is generated via its oxidation (Hebbel et al., 1988;Reiter 
et al., 2002). This is associated with Fe overload of tissue (Hebbel et al., 
1988;Reiter et al., 2002;Nagababu et al., 2008) and inflammation, promoting the 
pathogenesis of the disease. Heme can act in a pro-inflammatory manner in the 
vascular endothelium eventually promoting transient vaso-occlusion episodes, 
associated with painful crises and other sickle cell disease symptoms (Wagener et 
al., 2001). Vaso-occlusion is also induced by heme via a TLR4/Myd88 driven 
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mechanism, leading to P-selectin and VWF release as well as by the expression of 
adhesion molecules (Fig. 12) (Belcher et al., 2014). Heme driven TLR4 signaling is 
also correlated with the development of acute chest syndrome, a hallmark of sickle 
cell disease (Ghosh et al., 2013;Belcher et al., 2014).  
A recent study suggests that heme induced NETs formation is also involved in 
the pathogenesis of sickle cell disease (Chen et al., 2014). NETs are formed in the 
lungs as well as in the plasma of sickle cell disease mice, contributing to 
hypothermia and later to the incidence of lethality. This notion is supported by the 
observation that sickle cell disease patients accumulate NETs in plasma during 
acute chest syndrome and other painful crisis, thus supporting the pathologic effect 
of heme-driven NETs in the clinical outcome of sickle cell disease (Schimmel et al., 
2013).  
Other pathologic mechanisms that contribute to the outcome of sickle cell 
disease, include NO scavenging by cell free-hemoglobin, followed by a decrease in 
NO concentration, which leads to vasoconstriction (Reiter et al., 2002). Besides 
that, in vivo the binding of NO to the heme group of hemoglobin presumably 
promotes heme oxidation and hence its release from cell-free hemoglobin (Reiter et 
al., 2002). Moreover, in the vascular endothelium, oxidized hemoglobin might have 
per se a pro-inflammatory effect (Silva et al., 2009), presumably contributing to the 
pathogenesis of sickle cell disease. 
The pathologic effect of heme in the context of this disease can be countered 
by an adaptive response associated with the induction of the heme catabolizing 
enzyme, HO-1, and the production of heme catabolism end-products CO and the 
antioxidant bilirubin, all of which have been shown to suppress the pathologic 
outcome of sickle cell disease (Soares et al., 2004;Seldon et al., 2007). The finding 
that this salutary effect is exerted via a mechanism that targets heme is supported 
by the observation that hemopexin administration prevents vascular dysfunction 
associated with hemolytic diseases (Vinchi et al., 2013). Presumably, heme release 
from cell-free hemoglobin is also involved in a crucial way in the pathogenesis of 
other blood disorders besides sickle cell disease, such as β-thalassemia 
(Nagababu et al., 2008;Vinchi et al., 2013).  
48 
 
It is well established that when present in hemizygous form sickle hemoglobin 
mutations (sickle cell trait) are protective against malaria. This presumably occurs 
via a mechanism involving the induction of HO-1 by non-toxic levels of heme that 
accumulate chronically in plasma (see section 8.2) (Ferreira et al., 2011). Upon 
infection, Plasmodium triggers hemolysis and the accumulation of heme in plasma, 
which induces HO-1, promoting heme degradation. However in sickle cell trait 
individuals, HO-1 expression is induced before infection, therefore preventing heme 
accumulation in plasma. This presumably protects sickle cell trait individuals from 
the pathologic effects of heme and progression of the disease to severe forms of 
malaria (Pamplona et al., 2007;Ferreira et al., 2011).  
 
8 TARGETING HEME IN THE TREATMENT OF IMMUNE MEDIATED INFLAMMATORY 
DISEASES 
 
Given the contribution of heme to the pathogenesis of several immune mediated 
inflammatory diseases, therapeutic approaches targeting heme have been 
investigated with the purpose of limiting the pathologic outcome of these diseases. 
Such approaches include the administration of compounds that inhibit heme 
release from hemoproteins (e.g. CO, NO) (Pamplona et al., 2007;Cabrales et al., 
2011;Ferreira et al., 2011), induction of HO-1 (Abraham, 2003;Soares and Bach, 
2009), heme scavenging (Grinberg et al., 1999), heme transport (Jonker et al., 
2002;Doty et al., 2010) or directly targeting heme by using antibodies generated 
against heme (Leavy, 2010). These different approaches will be discussed below 
(Fig. 13). Nevertheless, it is important to mention that other approaches can be 
considered such as the inhibition of TLR4 using specific inhibitor, allowing the 
inhibition of the pro-inflammatory effect of heme mediated by TLR4 (Figueiredo et 
al., 2007;Dutra and Bozza, 2014). Alternatively, the combination of different 
approaches should also be considered as such might increase the efficiency of the 




8.1  Pharmacologic Administration of Gasotransmitters 
Several studies support the therapeutic action of CO (Pamplona et al., 
2007;Ferreira et al., 2008;Ferreira et al., 2011) and NO (Cabrales et al., 2011) in 
hemolytic diseases, such as malaria, sickle cell disease and sepsis (Jeney et al., 
2014). The salutary effects of CO rely on its cytoprotective effect (Brouard et al., 
 
Figure 13: Targeting “free heme”. Several mechanisms might be used therapeutically to target 
directly or indirectly extracellular or intracellular “free heme”. The Hb scavenger, Hp prevents the 
release of heme from Hb while preventing Hb accumulation in the plasma. CO binds the heme 
groups of Hb with high affinity and prevents its release from Hb. Extracellular heme can also be 
targeted by two other plasma proteins, i.e. albumin and HPX. Inhibition of intracellular transporters, 
e.g. HCP-1, HRG-1 and FLCVR-2 and induction of extracellular heme transporters, e.g. ABCB6, 
FLCVR-1a and ABCG2, might also afford protection against the deleterious effect of free heme. 
Induction of the heme degradation HO-1 coupled with FT prevents the deleterious effects of heme 
and Fe, respectively, while generation of bilirubin from heme degradation acts as a potent anti-







2002), its ability to modulate pro-inflammatory responses associated with Mø 
activation (Silva et al., 2006) and to modulate cell proliferation (Song et al., 
2002;Song et al., 2004). In addition, CO can bind to the heme groups of 
hemoproteins (Queiroga et al., 2012) and suppress their oxidation (Pamplona et al., 
2007;Pena et al., 2012;Queiroga et al., 2012). Therefore, when bound to Fe-heme, 
CO prevents heme release from those hemoproteins, suppressing the pathologic 
effects associated with this process (Pamplona et al., 2007;Jeney et al., 2014). This 
protective mechanism should not be limited to hemoglobin, presumably targeting  
other hemoproteins, such as myoglobin (Kumar et al., 2009). This effect of CO is 
highly protective against the development of experimental cerebral malaria in mice, 
suggesting that a similar protective effect maybe operational in humans (Pamplona 
et al., 2007;Pamplona et al., 2009;Pena et al., 2012). CO exerts salutary effects in 
other pathologic conditions such as sepsis or sickle cell disease and possibly in 
other hemolytic disorders associated with more or less severe hemolysis (see 
section 7) (Pamplona et al., 2007;Ferreira et al., 2011). There are however, some 
limitations to the therapeutic use of CO in that binding of CO to a number of 
hemoproteins can be cytotoxic (Queiroga et al., 2012). For instance, the high 
binding affinity of CO to hemoglobin renders it almost irreversible, compromising 
the ability of hemoglobin to function and carry O2 to tissues, eventually leading to 
anoxia and death. Similarly, the binding of CO to heme in myoglobin also 
compromises its physiologic function, inhibiting not only O2 storage but also its 
delivery to muscle cells when high levels of energy are required, such as during 
exercise.  
There is strong evidence for an overall protective action of CO when applied 
exogenously at sub toxic levels in the context of several immune mediated 
inflammatory diseases. As such possible therapeutic applications of CO have been 
explored, even though they still carry numerous limitations (Motterlini and Otterbein, 
2010). One of the possible therapeutic applications of CO involves gas inhalation at 
non-lethal levels (Motterlini and Otterbein, 2010). Alternatively, CO can be 
administrated using CO-releasing molecules (CORMs) allowing for controlled CO 
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delivery into cells and tissues (Motterlini and Otterbein, 2010;Garcia-Gallego and 
Bernardes, 2014).  
NO produced by nitric oxide synthases (NOS) can also be applied 
therapeutically. NO is known to act as a signal transduction molecule involved in 
diverse physiological processes, such as leukocyte recruitment and migration, 
smooth muscle and endothelial cell proliferation and migration as well as platelet 
aggregation. Moreover, NO modulates vascular function through the induction of 
cGMP production by guanylyl cyclase, which promotes smooth muscle relaxation. 
On the other hand, NO induces the expression of HO-1  via the activation of 
transcription factor Nuclear factor (erythroid-derived 2)-like 2 (NRF2) (see section 
8.2) (Jeney et al., 2014). Pharmacologic administration of NO provides protection 
against severe forms of malaria via the induction of HO-1 and the production of CO 
(Jeney et al., 2014). While the protective effect of NO against cerebral malaria 
suggests that this molecule can be used therapeutically (Serghides et al., 2011), 
further studies are required to elucidate the therapeutic benefit of this approach.  
 
8.2  Induction of HO-1 
Another therapeutic alternative against the pathologic effect of heme is the 
induction of HO-1 (Abraham, 2003;Takahashi et al., 2004;Soares and Bach, 2009). 
This notion is supported by the recurrent observation that HO-1 confers protection 
against a broad range of pathologic conditions, including malaria, severe sepsis 
and sickle cell disease (see section 6). Induction of HO-1 can be achieved through 
the administration of non-cytotoxic levels of heme, inhibiting the transcription 
repressor BACH1 and promoting HO-1 transcription/expression while generating 
the end-products of heme degradation, CO and bilirubin (see section 5.2) (Alam et 
al., 2003). Alternatively, hemoglobin can be used therapeutically to induce HO-1 
(Balla et al., 1995) and prevent the pathogenesis of ischemia/reperfusion injury 
(Zhou et al., 2002), endotoxic shock (Otterbein et al., 1995) or kidney failure 
associated with rhabdomyolysis (Nath et al., 1992). This protective effect is 
mediated by heme release from oxidized hemoglobin (Balla et al., 1995) a 
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mechanism that underlies the protective effect of sickle cell trait against malaria 
(see section 7.3) (Ferreira et al., 2011). 
HO-1 gene therapy, via the expression of HO-1 cDNA using recombinant 
adenovirus is protective against subarachnoid hemorrhage (Abraham, 2003), 
Ischemia/reperfusion injury (Coito et al., 2002), kidney transplantation (Blydt-
Hansen et al., 2003), hyperoxia-induced lung injury (Gaine et al., 1999) or occlusive 
vascular lesions (Liu et al., 2002), as demonstrated in rodent models of these 
diseases. Whether this protective effect is related to heme degradation remains to 
be elucidated.  
Several therapeutic agents induce HO-1, including statins, rapamycin, 
paclitaxel, NO, aspirin and probucol, among others. For instance, statins induce 
HO-1 through the modulation of stress responses controlled by p38 MAPK and AKT 
and involved in the control of cell survival (Lee et al., 2004). This is directly 
correlated with the inhibition of inflammation and cell proliferation, an effect that 
should contribute to the ability of statins to provide protection against coronary heart 
disease. Other drugs have also been shown to regulate HO-1 expression, such as 
isoflurane, which prevents ischemia/reperfusion injury (Schmidt et al., 2007); 
paclitaxel, which inhibits atherosclerosis development (Choi et al., 2004) and 
pyrrolidine dithiocarbamate, which provides ischemic tolerance in the liver (Hata et 
al., 2003). These drugs might also be considered for the treatment of diseases in 
which “free heme” acts in a pathologic manner, such as malaria, sepsis and sickle 
cell disease.  
Even though HO-1 induction may prove to be a valuable therapeutic approach 
there are some limitations that should be considered. For example, polymorphisms 
in the HMOX1 gene modulating HO-1 expression as well the response to 
pharmacological HO-1 inducers are highly prevalent in humans (Exner et al., 2004). 
Additionally, the physiological consequences of HO-1 over-expression and activity 
are not fully elucidated, raising questions related to the safety of such therapy. 
Finally, sustained HO-1 over-expression can promote oxidative stress and 




8.3 Hemoglobin and Heme Scavengers 
In pathological condition associated with hemolysis, cell-free hemoglobin 
accumulation can exhaust the scavenging capacity of haptoglobin. Excess cell-free 
hemoglobin accumulates in the plasma and eventually undergoes oxidization, 
leading to the release of heme. This process is inhibited by haptoglobin as 
suggested by its protective effect against severe sepsis (Janz et al., 2013). 
Association between cell-free hemoglobin accumulation and higher mortality in 
sepsis suggests that hemoglobin might act in a deleterious manner, promoting the 
pathogenesis of this disease, while higher levels of haptoglobin in plasma are 
correlated with a low mortality rate, presumably related to the ability of haptoglobin 
to scavenge cell-free hemoglobin (Janz et al., 2013). Moreover, haptoglobin 
administration is protective against lung injury and inflammation in an experimental 
model of sepsis in mice (Yang et al., 2003). 
When released from extracellular hemoglobin “free heme” can be cleared by 
specific scavengers such as hemopexin or albumin (Grinberg et al., 1999). Several 
studies suggest that pharmacologic administration of these heme scavengers 
improves the outcome of pathologic conditions associated with hemolysis. For 
example, when used pharmacologically, albumin ameliorates the clinical outcome 
of severe sepsis (Wiedermann and Joannidis, 2014) as well as that of severe forms 
of malaria (Maitland et al., 2005). The mechanism via which albumin provides 
protection against the pathogenesis of these diseases remains to be established 
but this may as well involve the inhibition of the cytotoxic effects of heme.  
Alternatively, hemopexin administration might be used to prevent the 
pathologic effects of “free heme”, as demonstrated for severe sepsis in mice 
(Larsen et al., 2010). Low levels of hemopexin in patients with severe sepsis, are 
also associated with increased disease severity (Larsen et al., 2010). Whether 
hemopexin administration will suppress the pathogenesis of sepsis in humans 
remains to be established. The beneficial effect of hemopexin might be expanded to 
other hemolysis-associated pathologies, such as malaria and sickle cell disease. 
Similarly to albumin, whether the protective effect of hemopexin is explained 
exclusively by its heme binding capacity remains to be established.  
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8.4 Heme Transporters 
Targeting heme transporters may be of therapeutic relevance. For instance, the 
induction of heme exporters such as ABCG2 may be used to promote cellular heme 
secretion while the inhibition of heme importers such as FLVCR1 might prevent 
heme cellular uptake (see section 4.2). However, this therapeutic application 
requires a better understanding of the heme transporter mechanism(s).  
 
8.5 Therapeutic Application of Antibodies, Abs 
A possible therapeutic alternative to prevent heme cytotoxicity is the development 
of antibodies (Abs) that target “free heme” specifically. These may be applied to 
neutralize the pro-oxidant and pro-inflammatory effects of heme and hence 
minimize its participation in the pathogenesis of immune mediated inflammatory 
diseases associated with hemolysis. This type of therapy has several advantages, 
such as specificity of Abs towards “free heme”, instead of targeting heme in 
hemoproteins, thereby not impairing their biologic function.  
The therapeutic administration of antibodies begun in 1986 with the first 
approval for the use of an anti-CD3-specific mAb (Orthoclone OKT3; Janssen-
Cilag) by the US Food and Drug Administration, for acute transplant rejection 
treatment in humans (Emmons and Hunsicker, 1987;Leavy, 2010). Since then 
several Abs were developed and used therapeutically against cancer, autoimmunity 
and inflammatory diseases (Elvin et al., 2013). Furthermore, Abs are also widely 
used in medical diagnostics (Ellmark et al., 2008). The development and production 
of monoclonal Abs (mAbs) was made possible by the implementation of the 
hybridoma technology (Yagami et al., 2013), based on mouse (alternatively rat and 
more recently rabbit immunization and generation of immortalized Ab-producing B 








Figure 14:  Hybridoma and Phage display technology for the development of Abs. In 
traditional hybridoma technology, a mouse is immunized and B cells are harvested and 
immortalized by fusion with myeloma cells to generate hybridomas. These are tested for their ability 
to produce Abs against the Antigen used in the immunization. Phage display technology amongst 
other display techniques (Ribosome or bacteria, yeast and mammalian cells) is used in the 
development of conventional antibodies as well as different constructed Ab (Fig. 18). The Abs can 
be selected from in constructed immune, naïve or synthetic libraries (human, mouse, rabbit, shark 




variants) displayed in the phage 
surface. Selection against a given antigen is performed using immobilized antigen in cycles in which 
the non bounding Abs are washed away and the binding Abs are amplified by infection of E. coli 
bacteria.  After several cycles, the selected Abs are screened for Ag specificity. These can be 
humanized by cloning of the CDR genes into a whole human IgG expression vectors for the 





8.5.1 Abs Structure and Function 
Abs or Ig (s) are high molecular weight plasma proteins (around 150 kDa) produced 
by B cells and recognizing a vast repertoire of antigens (Ags) (Davies et al., 1990). 
 
 
Figure 15: Schematic representation of the five different classes of Abs (IgA, IgD, IgE, IgG 
and IgM) and some of their basic properties (Table). The different classes of Abs confer 
protection to the organism against foreign antigens to which they are constantly exposed. While 
having a similar structure, these Abs differ in the immunological function. The monomers IgD can 
act as antigen receptor for B cells and activators of mast cells and basophils, inducing the 
production of antimicrobial molecules, while IgE is involved in host protection against parasitic 
worms and stimulation of the histamine release by mast cells and basophils. The most abundant Ig 
in plasma is IgG providing protection against innumerous pathogens, mainly through the activation 
of the complement system and phagocytosis. This Ig is also capable to cross the placenta of a 
mother into the fetal circulation providing protection to the fetus. IgA can be mainly found as a 
monomer in serum and as a dimer in the secretions and is the most common Ig in external 
secretions, such as mucous, saliva, breast milk and tears, providing protection against invading 
pathogens. IgM is predominantly found in pentameric form, typically secreted into serum by plasma 
cells, although it can be expressed on the B cells surface as a monomer. This Ig is also involved in 





There are five Abs isotypes in mammals: IgA, IgD, IgE, IgG and IgM, with different 
effector functions (Fig. 15). IgGs are the most abundant in plasma while IgA is 
more abundant in the intestinal tract. Abs have a “Y” shape, comprising a constant 
(Fc) fragment region containing two heavy (H) chains with two or three constant 
domains, depending on the isotype, linked via disulfide bonds to two Ag binding 
fragments (Fabs) composed by one heavy (H) and light (L) variable (V) domains 
(also named variable fragment; Fv) and one light and heavy constant (C) domain 
(Fig. 16) (Jakob et al., 2013). The Fv region is essential for Ag recognition and 
binding, while the Fc region regulates the immune response via interaction with a 
specific class of Fc receptors as well as with others immune components, e.g. 
complement proteins (Heyman, 1996). The Fc region modulates the half-life of the 
Ig, presumably by its interaction with the Fc receptor, which controls Ig catabolism 
(Hinton et al., 2004). The variable domains of IgG are composed by three loops 
containing a hypervariable sequence in amino acid composition and size, named 
complementarity-determining regions (CDR), present on variable H and L chain. 
These determine Ab specificity for a given Ag, i.e. recognition as well as binding 
affinity (i.e. KD; binding affinity constant) (North et al., 2011). These CDR loops are 
inserted in the framework region (FR) that is primarily associated with β-strands 
conformation, providing an essential structural support, which helps in the 
preservation of Ig affinity and specificity (Masuda et al., 2006).  
Abs can act in two different manners: through direct binding to the pathogen for 
their neutralization or indirectly via the activation of the complement cascade and/or 
via Fc recognition by effector immune cells. The activation of complement cascade, 
i.e. the classical complement pathway, occurs when the Ab bound to the pathogen 
is recognized through its Fc region by the complement component C1q molecule, 
triggering a series of events that lead to the generation of opsonins, anaphylatoxins, 
chemotatic agents as well as the generation of a membrane attack complex that 
kills pathogens (Diebolder et al., 2014). On the other hand, the Ab-mediated 
activation of effector immune cells, e.g. mast cells, neutrophils, natural killer cells 
and Mø, occurs when an Ab is recognized through Fc receptors (FcRs), promoting 




8.5.1.1  Ab Fragments 
Abs used for therapeutics are in most cases full length IgG, which are also the most 
abundant in blood and have longer serum half-life as well as the ability to activate 
complement as well Fc-dependent immune responses. However, IgG Abs can also 
lead to the inappropriate complement activation and Fc mediated responses 
associated with production of cytokines, which might trigger uncontrolled 
inflammation (Chames et al., 2009). Furthermore, the relative size of the Ab does 
not allow for their removal through the kidneys, which has a clearance threshold of 
around 40-60 kDa. Additionally, full-length Abs have a low diffusion rate, that might 
compromise tissues and the extracellular matrix access. For that reason, Ab 
 
Figure 16:  Structure of IgG and its schematic representation.  Structure of a anti-canine IgG2a 
antibody (Mab231) (PDB ID: 1IGT) as representative of a typical “Y” shape form of Ig (left) and its 
schematic representation (right). IgG are composed by constant (Fc) and an antigen binding 
fragment (Fab) region. The Fc region is composed by two heavy chain formed by the constant 
heavy domains 2 and 3 (CH2 and CH3) and it is linked to the Fab region via disulphide bonds 
between the CH2 of Fc and the constant heavy domains 1 (CH1) of Fab. In Fab region beside the 
CH1 there is a variable heavy domain (VH) and a light chain composed by a constant (CL) and 
variable domain (VL). The variable domains, VH and VL together form the variable fragment (Fv) 
and are responsible for the antigen recognition and binding. The Fc region of the Ig controls 





fragments are used as an alternative to overcome such limitations, as they have 
lower molecular sizes while maintaining their ability to bind antigens. These include 
the monovalent Ab fragments (Fab, single chain Fv; scFv) and engineered variants 





Figure 17: Schematic representation of different types of Abs. Fabs and Fv are based on the 
Fab and Fv domains of the Ab, respectively while sdAb VL or VH are generated from the VL or VH 
domains, respectively. The camelid/shark Igs contain only the heavy chain. These include the camel 
heavy chain antibody composed by two C like constant domains (CH2 and CH3) and a homodimer 
of the variable heavy domain (VHH) and the sharK IgNar antibody with a homodimer of  a variable 
domain (NAR) and five constant heavy domains (CH1 to CH5) (lower). Other variants include the 







8.5.1.2 Single Domain Abs 
Single domain Abs (sdAbs) have small sizes (12 to 15 kDa) and are usually 
composed by a VL or VH single domain, retaining their Ag binding capacity (Fig. 
17). However, sdAbs have a high tendency for aggregation, mainly due to the 
exposure of the hydrophobic interface. This drawback can be overcome though 
genetic engineering, reducing their hydrophobic exposure and increasing stability 
(Davies and Riechmann, 1996). Alternatively, this can be achieved through 
generation of dimers via the introduction of a flexible linker between two sdAb, e.g. 
VH and VL, a methodology also used to produce scFv (Holliger et al., 1993).  
The discovery of functional and highly stable VH sdAbs in camelids (camels, 
dromedaries and lamas) (Hamers-Casterman et al., 1993) and cartilaginous fish 
(wobbegong and nurse chark) (Greenberg et al., 1995), suggests that sdAbs 
engineered to mimic these natural sdAbs have a high potential for biotechnological 
and eventually therapeutic applications. In fact, sdAbs derived from camelids are 
widely used in biotechnological applications, because they are easily manipulated 
and can be obtained through animal immunization (van der Linden et al., 2000) or 
by other display technologies (Gronwall and Stahl, 2009), such as phage (Binyamin 
et al., 2003), yeast (Scholler, 2012), ribosome (Yau et al., 2003) or mRNA display 
(Tabata et al., 2009), using immune (Kim et al., 2008), naïve (Wen et al., 2007) and 
semi-(de Kruif et al., 1995) or synthetic (Silacci et al., 2005) Ab libraries.  
SdAbs provide several advantages in comparison to the full-length Abs and 
other conventional Ab’ fragments (Holt et al., 2003). For example, sdAbs have a 
higher capacity to reach a wide variety of antigens, including small molecules 
(Spinelli et al., 2000), as well as specific epitopes in high molecular weight proteins 
(Arbabi Ghahroudi et al., 1997), interacting specifically with the active site of 
enzymes, inhibiting their activity (Desmyter et al., 2002). Furthermore, sdAbs 
penetrate into tissues and are rapidly cleared from the blood through the kidney. 
Another considerable advantage is that they allow for rather easy genetic 
manipulation.  
The therapeutic application of sdAbs have been explored with some promising 
results, for instance against cancer and immune mediated diseases, including 
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infectious diseases (da Silva et al., 2008). The potential targets of the sdAbs are 
mainly cell surfaces, secreted and intracellular proteins and cytokines, as well as 
bacterial components.  
 
8.5.2  Ab Production using Phage Display 
In 1985, George P. Smith described for the first time the phage display (Fig. 14), a 
technique based on the fusion of foreign DNA sequences into the gene III of the 
phage, thus promoting the expression of the coated protein pIII, localized in the 
surface of the virion of the filamentous phage (Smith, 1985) (Fig. 18). Interestingly, 
the fusion of foreign DNA sequences does not change the infectious properties of 
the phage, while the respectively encoded (“foreign”) protein is simultaneously 
expressed and linked to the coated protein pIII on the virion surface. Through the 
insertion of a given gene encoding a peptide or protein of interest, e.g. Abs, into a 
phage it is possible to express those in the phage surface. This technology has 
been explored and developed for screening and selection of a wide variety of Abs, 
such as fragment Abs, with potentially therapeutic relevance (Hairul Bahara et al., 
2013). Thus, phage display technology is currently recognized as a very powerful 
technique for the selection of Abs (da Silva et al., 2008). It allows to generate phage 
libraries with a highly diverse repertoire, in the range 106-1012 variants (Tikunova 
and Morozova, 2009), that can be applied for screening and selection based on the 
detection of Ags of interest (Tonelli et al., 2012), including biological as well as 
inorganic compounds (Kriplani and Kay, 2005). On the other hand, phage display 
technology also allows for genetic manipulation of the libraries and consequently, 





Figure 18: Schematic representation of a filamentous phage expressing sdAb on their 
surface fused with pIII protein and the structure and amino acid sequence of sdAbs. The 
filamentous phage (upper) displayed in its phagemid, the DNA sequence of the sdAb (in orange) 
fused into the gene III that codifies for the coated protein III and both genes are expressed from a 
common promoter. SdAb is expressed fused with the coated protein pIII on the surface of the 
phage, making accessible to the sdAb the target molecule, such as heme. Besides the coated 
protein pIII, there are other coated proteins such as pVI, pVII, pVIII and pIX that can also be used to 
display foreign proteins/Abs. 3D structure of three sdAbs, namely VL,  generated based on the aa 
sequence of the anti-heme sdAbs 1A6, 2H7 and 2H10 using SWISS-MODEL software 
(http://swissmodel.expasy.org/interactive)(lower, left). Crystal structure obtained for a human sdAbs 
VL (PDB ID: 3LRG) against the huntingtin protein (lower, middle). An example of an aa sequence 
encoding a rabbit based VL, containing a starting amino acid (M), a peptide leader (gray) that 
conduct the new synthesized protein towards the secretory pathway, two restriction enzyme site 
(green; SfiI enzyme), the framework of the Ab (black) with the CDR1 (orange), CDR2 (yellow) and 
CDR3 (pink) and a Histidine (light pink) and HA tag (blue) that are incorporated in the sdAbs for its 
detection and capture (lower, right). The CDR1 and CDR3 contain a SGGGS followed by n number 
of X which indicates that each of them can be any of the 23 amino acids, conferring variability 






8.5.2.1 Selection and Screening of Abs using Phage Display Technology 
The screening and selection of Abs, e.g. sdAbs, using phage display technology is 
dependent on the efficacy of inserting and maintaining the gene encoding the 
protein of interest into the phage genome, as well as the phage capacity to express 
that protein on its surface. Therefore, an intrinsic connection between the genotype 
and the phenotype of the expressed protein should be taken into consideration, as 
to allow the enrichment of a phage population containing the protein of interest 
during selection (Li and Caberoy, 2010). The selection process for sdAbs can be 
divided in several steps, comprised into a cycle (Fig. 19) (Frenzel et al., 2014): 
 
1st step: Ag coating onto a solid or liquid phase; 
  
2nd step: exposure and incubation of a phage library repertoire with the Ag, 
i.e. phages that express the Abs are allowed to bind specifically to the Ag; 
 
 3rd step: Removal of unbound phages through a series of wash-off rounds; 
 
4th step: Elution of Ag-bound phages using methods allowing for the 
disruption of the ligation between the displayed Ab and Ag; 
 
 5th step: Re-amplification of the eluted phages by infection into host bacterial 
cells. 
 
Generally, this cycle is repeated three to six times for the generation of Abs with 
high affinity and specificity for a given Ag. Nevertheless, the quality of the Abs 
selected is highly dependent on the characteristics of the phage library used, such 





Figure 19: Schematic representation of a phage display cycle, also named phage display 
panning, applied in the selection of Abs. A phage display library is constructed through the 





 variants), namely Ab that is B. fused into the gene encoding a phage coat protein in the 
phagemid genome of the phage, allowing the expression of the protein of interest linked to the 
phage coated protein (Fig. 16). C. The phage display library is exposed to an Ag (such as heme) 
and the phages expressing the Abs with the appropriated specificity are captured. There are several 
methods for the immobilization of the target. In this work, we biotinylated the target i.e. heme (C.) 
and D. immobilized it using streptavidin beads after exposure with the phage library. E. A series of 
wash-off rounds is applied to remove non bound Abs-phage. F. The ligation between the phage 
displaying the Ab and the antigen are disrupted by enzymatic digestion (e.g. tripsin). G. After the 
disruption, phages are eluted and H. used to infect host bacterial cells (e.g. E.coli) for I. phage 
amplification.  Generally, this cycle is repeated three to six times, decreasing the phage diversity 
while increasing affinity and specificity for the target. After several cycles, the individual phages from 






8.5.2.2  Libraries used in Phage Display Technology 
The success of Ab selection using phage display technology relies essentially on 
the quality of the Ab library. Therefore, several types of phage Ab libraries, with 
high degree of protein variance have been constructed, including immune (Kim et 
al., 2008), naïve (Wen et al., 2007) and semi- (de Kruif et al., 1995) or synthetic 
(Silacci et al., 2005) libraries. 
The immune libraries are constructed based on the sequence acquired from 
the IgG mRNA from B cells, obtained through different lymphoid sources (peripheral 
blood, bone marrow, tonsils lymphoid nodes and, predominantly, from spleen) of 
immunized donors (McCafferty et al., 1990). Usually, these libraries are enriched in 
Abs with a higher affinity and specificity for a specific Ag (Winter et al., 1994), 
including virus components (Barbas et al., 1992b), bacterial and other derived 
toxins (Pelat et al., 2009) as well as tumor antigens (McWhirter et al., 2006;Siva et 
al., 2008). Nevertheless, several limitations are associated with these libraries, such 
as i) long waiting periods due to donor immunization, ii) limited availability of human 
B cells which limit human Abs generation, iii) restricted or absent immune response 
to certain Ag (self or toxic), iv) uncertainties in the immune response against the 
target Ag and, most importantly, v) it is required to generate a new library for each 
Ag (Hairul Bahara et al., 2013).  
The generation of naïve libraries does not require immunization; instead it is 
constructed based on rearranged V genes from IgM mRNA of B-cells from healthy 
donors (Sommavilla et al., 2010). The choice of IgM instead of IgG is mainly due to 
the lack of somatic mutation in V genes of naive and generally IgM (Bradbury and 
Marks, 2004). Furthermore, previous experiments demonstrated that certain Abs 
could only be isolated from IgM-and not from IgG-based libraries (de Haard et al., 
1999) and since then the libraries used are essentially IgM-based (Sblattero and 
Bradbury, 2000). The main advantage of these libraries is the possibility to use the 
same library for the Abs screen against a wider range of antigens (Hairul Bahara et 
al., 2013). However, the success of such screen is highly dependent on the size 
and diversity of the naïve libraries (Marks and Bradbury, 2004). Moreover, these 
libraries can be used to obtain human Abs against self, non-immunogenic, toxic 
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antigens or chemical haptens (Griffiths et al., 1993;Hairul Bahara et al., 2013). On 
the other hand, most of the Abs selected in naïve libraries exhibits lower or 
moderate affinity for the Ag in comparison to those selected in immunized libraries, 
and little or no information exists about the exact nature of the V-gene repertoire 
used to generate these libraries. Moreover, because the genetic information 
generated about the Abs is representative of the human immunological repertoire, 
there is a high probability that gene expression and protein stability in the bacteria 
are compromised (Swartz, 2001). Thereby, several methodologies have been 
developed to overcome such limitations, including improvements in bacterial 
expression systems (Rouet et al., 2012) or rearrangement of the V-genes from 
germline B cells (Griffiths et al., 1994) or from a single germline Ab segment (Pini et 
al., 1998) through CDR randomization, resulting in a semi-synthetic library.  
Semi-synthetic libraries are thus generated by the combination of naïve and 
synthetic derived CDR repertoires, in which the variations are restricted to the CDR 
regions, while the main framework is obtained from the naïve library (Hoet et al., 
2005). Contrastingly, synthetic libraries are usually generated based on a specific 
(e.g. human, rabbit) derived framework with randomized synthetic CDR regions to 
provide Abs diversity (Nahary and Benhar, 2009). Among the three CDRs (Fig. 18), 
heavy chain CDR3 (CDR-H3) is used predominantly for randomization to increase 
diversity, since it is the main contributor for Ab-Ag binding interaction (Barbas et al., 
1992a). This randomization of the CDR-H3 follows certain rules (Shirai et al., 1999), 
used to determine the tertiary structure of the CDR, particularly important upon 
substitution of a specific amino acid, which might comprise the Abs structure 
(Kuroda et al., 2008). Apart from modifications in aa sequence composition and 
consequently structure, the sequence size itself also generates diversity (Oliva et 
al., 1998;Almagro, 2004). These, however, were revealed not to be an exclusive 
property of the CDR-H3, but also of other CDRs, as demonstrated upon the 
discovery of residues directly involved in the recognition of the Ag, named 
specificity-determining residues (Almagro, 2004). Therefore, through the 
randomization of key residues in the CDRs, it is possible not only to increase the 
diversity of the library, but also to select Abs with higher affinity (Huls et al., 1999), 
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as demonstrated for the human combinatorial Ab library, a full synthetic library 
(Knappik et al., 2000). The main advantages of the synthetic libraries rely on the 
fact that they easily allow for generating highly diverse libraries without requiring a 
natural immune repertoire. Moreover, the Ab frameworks can be chosen to improve 
the stability and expression yield accordingly to the expression system and to 
prevent Abs driven immunogenicity. These libraries also retain some of the 
characteristics of the naïve libraries, such as multi-Ag targeting by one library alone. 
However, there are still some limitations, such as the higher frequency of unnatural 
amber stop codons and glycosylation sites during the scFvs randomization process, 
which may compromise the structure and specificity of the Ab (Solforosi et al., 
2012).  
 
9  AIM OF THE THESIS 
 
The research work presented in this PhD thesis was developed to overcome the 
current limitations in the detection and quantification of “free heme”, once released 
from hemoproteins. For that purpose, we developed sAbs, using phage display 
technology that recognizes specifically heme that is not bound to hemoproteins. 
These sdAbs were characterized for their specificity to bind heme and selected 
according to their binding specificity and affinity. The selected sdAb were then 
further characterized and tested for their ability to recognize cellular heme, to 
provide a quantitative detection of “free heme”, as well as to function as modulators 
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Heme acts as a prosthetic group in a number hemoproteins that support core 
biologic functions essential to sustain life. When exposed to different forms of stress 
hemoproteins that bind heme non-covalently, can release their heme groups. This 
produces “free heme”, which acquires unfettered redox activity as it binds loosely to 
other proteins or molecules. The “free heme” generated in this manner exerts pro-
oxidant, pro-inflammatory and cytotoxic effects that contribute critically to the 
pathogenesis of immune mediated inflammatory diseases, associated with 
hemolysis. There are current methodological limitations that restrain the qualitative 
and quantitative analyzes of “free heme” as it is generated in the context of these 
pathologic conditions. Some methods have been developed to access the presence 
of “free heme”, however, the controversy has been raised regarding the precision of 
those methods to detect and quantify it. To overcome this hurdle, we have 
generated and characterized a panel of single domain antibodies (sdAb) 
recognizing specifically “free heme”. We demonstrate that heme binding by these 
sdAbs requires the iron atom contained in the protoporphyrin ring, as they fail to 
recognize other related tetrapyrrole structures from which the iron was released 
such as biliverdin or bilirubin. Qualitative and quantitative analyzes of cellular “free 
heme” using these sdAbs, reveals that cellular “free heme” exists essentially in the 
mitochondria and to some extent in the cytoplasm, where “free heme” is in close 
association with the heme catabolizing enzyme heme oxygenase-1. We used these 
sdAbs to develop ELISA based assays that allow for qualitative and quantitative 
characterization of “free heme” as it accumulates in plasma during acute hemolytic 
conditions. Finally we demonstrate that binding of these sdAbs to “free heme” in 
solution reduces heme redox activity, potentially therefore overcoming some of the 
pathologic effect exerted by “free heme”. In conclusion, our findings contribute to 
overcome the current limitations in the quantitative assessment of “free heme” 
under different biologic contexts and allow targeting “free heme” therapeutically to 






Heme consists of a tetrapyrrole ring bound via different nitrogens to a central iron 
(Fe) atom (Fischer and Zeile, 1929). Heme is found essentially as a prosthetic 
group of hemoproteins (Tsiftsoglou, 2006), including some that sustain core biologic 
functions essential to support most if not all life forms. Specific alterations in the 
vinyl and methyl group composition of the tetrapyrrole ring define different types of 
heme, namely, heme a (C49H56O6N4Fe), b (C34H32O4N4Fe) and c (C34H36O4N4S2Fe). 
Heme a, associates to hemoproteins, such as cytochrome c oxidase (Tsukihara et 
al., 2003), via hydrogen bonds between the tetrapyrrole formyl and 
hydroxyfarnesylethyl groups and different amino acid (aa) residues such as arginine 
and serine. The less abundant heme c binds covalently to cysteine via its vinyl 
groups, as illustrated for cytochrome c (Bushnell et al., 1990). Heme b is the most 
abundant form of heme in mammals and associates to proteins via van der Waals 
contacts formed between heme-face and different hydrophobic aa, as well as 
through electrostatic interactions with positive side chains and the negative charged 
propionate groups of heme via salt-bridges (Schneider et al., 2007). Heme b is 
found essentially as a prosthetic group of hemoglobin (Hb) and myoglobin (Mb), 
accounting for the major pool of bioavailable Fe in mammals (Hunt, 2003).  
The Fe contained within the tetrapyrrole ring of different types of heme can 
bind to histidine, methionine and lysine, which control Fe redox status and stabilize 
heme/hemoprotein binding and activity. Moreover, modification of heme Fe 
oxidation state, i.e. ferrous (Fe2+), ferric (Fe3+) or higher oxidation states up to Fe5+, 
also regulate heme/hemoprotein binding and activity (Chapman et al., 1997). The 
redox active Fe in the heme group of those hemoproteins provides optimized 
binding to gaseous molecules such as O2 as well as gasotransmitters (Mustafa et 
al., 2009) such as nitric oxide (NO) (Moncada and Erusalimsky, 2002) or carbon 
monoxide (CO) (Dioum et al., 2002), via effective back-donation of Fe dπx electrons 
to low-lying π* orbitals of these diatomic molecules. Hemoproteins can fine-tune this 
interaction in order to modulate i) catalysis of reductive and oxidative chemistry, ii) 
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storage and/transport of gaseous molecules, or iii) signalling processes underlying 
the biologic activities of gasotransmitters (Mustafa et al., 2009). 
Non-covalently bound heme b can be released from hemoproteins (Balla et al., 
1993), as demonstrated for Hb when exposed to hydrogen peroxide (H2O2) 
generated by activated polymorphonuclear leukocytes (Bunn and Jandl, 
1968;Hebbel et al., 1988;Balla et al., 1993;Pamplona et al., 2007). Non-Hb bound 
heme is often referred as “free heme” (Ferreira et al., 2008;Larsen et al., 2010). 
However, considering that heme is probably never found in free form in biologic 
systems, the term “free heme” is used hereafter to refer to the pool of labile redox 
active heme that is loosely bound to proteins or to other molecules. 
Once released from hemoproteins heme b can act in a vasoactive, 
pro-inflammatory (Graca-Souza et al., 2002;Figueiredo et al., 2007) and cytotoxic 
manner (Seixas et al., 2009;Gozzelino et al., 2010;Larsen et al., 2010) to promote 
the pathogenesis of immune mediated inflammatory diseases associated with 
hemolysis, as illustrated for sickle cell disease (Ghosh et al., 2013;Vinchi et al., 
2013;Belcher et al., 2014), malaria (Pamplona et al., 2007;Ferreira et al., 2011) or 
severe sepsis (Larsen et al., 2010). It has been challenging to ascertain 
unequivocally the pathologic role of “free heme”, largely due to the current 
limitations in the available methodologies allowing its quantification and/or providing 
information on its chemical environment. Here we used a phage display screening 
to identity single domain antibodies (sdAb) recognizing specifically redox active 
heme that is loosely bound to proteins or to other molecules, i.e. “free heme”. We 
describe and characterize a panel of such sdAbs and illustrate their binding 
properties as well as usage for quantitative detection of “free heme” and modulation 











3.1 Development and selection of sdAbs against “free heme”  
We generated a synthetic phage-display single domain antibody (sdAb) 
(Goncalves, 2008;Santos, 2014) derived from a highly soluble and stable VL 
scaffold (Goncalves et al., 2002). The synthetic VL library repertoire, consisting of 
8x109 independent clones, was generated by randomization, accommodating a 
maximum of 22 aa in complementary determining region 1 (CDR1) and 3 (CDR3) 
(Santos, 2014). The library cloned into the pComb3x phagemid vector (Barbas et 
al., 1992) was previously screened against several targets (Santos, 2014). In the 
present study this library was screened against heme b, biotinylated in a single 
carboxylic group (Fig. 1A and Suppl. Fig. 1). Phages expressing sdAbs 
recognizing heme-biotin were selected using streptavidin-magnetic beads (Fig. 1B 
and 1C), essentially as described (Barbas, 2001). Phages were then re-selected 
according to their relative heme binding activity and expression, as assessed by 
ELISA using a monoclonal antibody (mAb) directed against the human influenza 
hemagglutinin (HA) epitope (YPYDVPDYA) expressed in the C-terminus of the 
sdAb. Eleven sdAbs were selected (Fig. 1C), expressed in E. coli BL21, purified 
under denaturing conditions and refolded by step-wise dialysis (Umetsu et al., 
2003). Protein yield was typically around 10 mg/L with >90% purity, as assessed by 
SDS-PAGE (Fig. 1D). Expression of a ~15 kDa protein corresponding to the full-
length sdAb containing the leader peptide sequence (MKKTAIAIAVALAGFATV) 
and a ~13kDa protein, corresponding to the leaderless sdAb was confirmed by 
Western blotting (Fig. 1D).  
The selected sdAbs bound heme with an affinity in the range of 10-7M with the 
exception of sdAb 1E4, which had an affinity in the range of 10-5M, as assessed by 
ELISA (Fig. 1E) and surface plasmon resonance (SPR; BIAcore system)(Fig. 1F). 
In Suppl. Fig. 2 is shown a sensogram of heme binding to sdAb 2H10 obtained by 
BIAcore, used to determine the affinity constant (KD), as a representative of sdAb 
binding to heme. In silico analyses revealed the presence of potential heme binding 




Figure 1. Selection of heme binding sdAbs. (A) MALDI-TOF/TOF analysis of biotinylated heme. Mass-
to-charge (m/z) 969.2 Da corresponds to the biotinylation of a single carboxylic acid residue of hemin. (B) 
Output of elution cycles, selecting bacteria infected with phages displaying sdAbs recognizing heme. (C) 
Ratio of heme binding vs. protein expression, as determined by ELISA. Each circle represents one sdAb 
among 1721 tested. SdAbs 2H10, 2H7 and 1A6, corresponding to the highest heme binding vs. protein 
expression, are highlighted. (D) SDS-PAGE of purified sdAbs detected by coomassie-based stain or by 
western blot using an anti-HA mAb. (E) Relative binding of sdAbs to heme detected by ELISA. Control 
sdAb (Ctrl) does not recognize heme. (F) CDR1 aa sequences corresponding to each sdAbs, as 
determined by DNA sequence analysis. Binding affinity of SdAbs towards heme, determined by BIAcore 
surface Plasmon resonance. 
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These include cysteine-X-X-cysteine-Lysine (CXXCK; were X is any aa) 
characteristic of hemoproteins binding heme c (Pearson et al., 2007), i.e. sdAb 1A6, 
cysteine-asparagine (CN), characteristic of hemoproteins binding heme b, i.e. sdAb 
2H7 or cysteine-serine (CS) also characteristic of hemoproteins binding heme b, i.e. 
sdAb 2H10, 1G3, 2A12, 1C2 and 2H5 (Fig. 1F). None of the sdAbs selected 
presented CDR3 sequences. Based on their relatively higher affinity towards heme 
and the presence of potential heme binding motifs, we focus our analyses on sdAbs 
1A6, 2H7 and 2H10. 
 
3.2 Heme sdAb specificity  
To determine the specificity of sdAbs 1A6, 2H7 and 2H10 towards heme, we 
developed an ELISA in which the sdAb were pre-incubated with heme (Iron 
protoporphyrin; FePP), gallium protoporphyrin (PP) IX (GaPP; a non-iron metalled 
porphyrin containing a similar sized but redox inert gallium atom) or PP IX (PP; the 
metal-free precursor of heme). As expected pre-incubation with FePP abolished 
binding to solid-phase heme by all three sdAbs (Fig. 2A). Pre-incubation with PP 
inhibited heme binding by sdAb 1A6 but not by sdAbs 2H7 and 2H10 (Fig. 2A). 
This indicated that the sdAbs have intrinsic differences in their binding properties 
and that a metal center is essential for heme binding by sdAbs 2H7 and 2H10. Pre-
incubation with GaPP abolished heme binding by all three sdAbs (Fig. 2A), 
indicating that Fe redox state has little or no effect on the capacity of these sdAbs to 
recognize heme.  
Similar results were obtained using tin PP (SnPP) or cobalt PP (CoPP), 
containing Sn or Co instead of Fe as the metal ion (Fig. 3A). Pre-incubation of 
sdAbs with zinc PP (ZnPP), which is produced physiologically by the heme 
synthesis enzyme ferrochelatase during iron deficiency, inhibited heme binding by 
2H7 sdAb but not by sdAb 1A6 and 2H10 (Fig. 3A). The small binding to ZnPP in 
sdAb 1A6 was considered no significant when compared with the other heme 
analogs. This might suggest that the presence and the physical/chemical properties 
of this metal, for example the ionic radii, oxidation state, may be important 
determinants for heme recognition by the sdAb 2H7. Indeed, it was shown that Zn 
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is usually coordinated with four ligands in a tetrahedral molecular geometry and it is 
limited to a redox state Zn2+ which confers some inertiness to the protoporphyrin. 




Figure 2. SdAbs heme binding specificity. (A-C) Increasing concentrations of different tetrapyrroles 
were tested for their ability to interfere with sdAbs binding to solid phase bound heme, as measured by the 
ELISA. Tetrapyrroles tested include: (A) PP and GaPP, (B) DeutP and FePPCH3, (C) biliverdin (BV) and 




We verified whether the porphyrin side chains are involved in heme 
recognition, and pre-incubated the sdAbs with Fe deuteroporphyrin IX (DeutP) or 
Fe PP IX dimethyl ester chloride (FePPCH3), two synthetic heme derivatives 
lacking the heme vinyl groups or in which two propionates side chains are 
methylated, respectively. DeutP inhibited heme binding by all sdAbs 1A6 (Fig. 2B), 
while FePPCH3 prevented sdAb 1A6 and 2H7, but not 2H10 heme recognition. 
This suggests that heme b recognition by sdAb 2H10 involves a carboxylic acid of 
one of the two propionate side chains (Fig. 2B). We also verified whether the sdAbs 
recognize biliverdin and bilirubin, two tetrapyrrole products of heme degradation by 
heme oxygenase and biliverdin reductases, respectively. Pre-incubation with 
biliverdin or bilirubin failed to inhibit heme binding by sdAb 2H10 but not by sdAb 
1A6 and 2H7, which failed to recognize heme when pre-incubated with biliverdin 
but not bilirubin (Fig. 2C). This partial inhibition by biliverdin suggests that full 
inhibition might only by be achieved when this heme end-product is at higher 
concentration. Thus in vivo inhibition of heme binding to these sdAbs can occur 
when biliverdin is at higher concentration than heme. Nevertheless, further studies 
are required to address this issue.  Iron (III) sulfate (Fe2 (SO4)3) failed to inhibit 
heme binding by these sdAbs (Fig. 3B). Pre-incubation of sdAbs with Hb, oxidized 
hemoglobin, Mb, albumin containing heme b or cytochrome c also failed to inhibit 
heme binding by all three sdAb (Fig. 3C). This suggests that, under the 
experimental conditions used, these sdAbs do not recognize bound heme, as 
present in hemoproteins. This might be justified by the higher affinity of those 
hemoproteins for heme when compared with the sdAbs, or heme in those 
hemoproteins is not accessible to the sdAbs because when incorporated in their 
heme pocket, it may be shield from the sdAb by the protein structure., We cannot 
exclude however, that these sdAbs might recognize heme when bound to other 
hemoproteins, not tested hereby. Table 1 summarizes these results. 
These results suggest that each of the sdAbs can recognize heme in a distinct 
manner, while the sdAb 2H7 and 2H10 required the iron metal for heme 
recognition, the sdAb 1A6 does not. Besides that heme recognition by sdAb 2H10 
involves its interaction with a carboxylic acid group of heme. These allow us to 
99 
 
speculate that the three sdAbs can be used in simultaneous to target different 
epitopes of heme without competing against each other, which might improve their 




Figure 3. SdAbs heme binding specificity to other heme analogs and hemoproteins. (A-C) Increasing 
concentrations of different compounds were tested for their ability to interfere with sdAbs binding to solid 
phase bound heme, as measured by the ELISA. (A) ZnPP, CoPP and SnPP. (B) Fe2(SO4)3. (C) Hb, 
oxidized Hb (MetHb), Mb, Cytochrome c (Cytc) and human serum albumin bound to heme (HSAH). Hemin 




   
 
3.3 Structural characterization of sdAbs/heme complexes 
To determine whether the sdAbs bind heme in solution, we used a heme-biotin 
pull-down assay. All three sdAbs bound heme in solution, with sdAbs 1A6 and 
2H10 showing a higher binding capacity, as compared to sdAbs 2H7 (Fig. 4A), 
which is consistent with the affinities of these sdAbs towards heme (Fig. 1F). 
We then used UV-Visible spectroscopy to monitor heme (Fig. 4B) and heme 
binding to sdAb 2H10 (Fig. 4C). The binding of heme to sdAb 2H10 was associated 
with the appearance of several bands, including a δ band at 360nm, a very intense 
Soret band at 412 nm, two weak Q bands at 530 and 565 nm, and a band in the 
charge transfer region at 624 nm (Fig. 4C). Within the heme/sdAb complex, we 
observed a Soret band at 412 nm (Fig. 4C), which indicates the presence of Fe3+. 
The 530 and 565 nm bands (Fig. 4C) reveal a six-coordinated low spin Fe3+ state. 
The δ band at 360 nm (Fig. 4C) suggests the presence of a thiol axial heme ligation 
in the complex (Marvin et al., 2008). The 624nm band is indicative of either S (Cys) 
to Fe3+ charge transfer or porphyrin to high spin Fe3+ charge transfer. With the 
exception of the charge transfer band, UV-Vis features of the sdAb/heme complex 
were remarkably similar to the spectra of ferric cytochrome P450cam, which carries 
Cys and H20 axial ligands (Mouro et al., 1997). Similar results were obtained for 
sdAbs 1A6 and 2H7 (Suppl. Fig. 3A and 3B). The UV-Vis spectrum of heme (Fig. 
Table 1: Summary of the sdAbs binding specificity against different tetrapyrroles. SdAbs 1A6, 2H7 






4B) shows two overlapping bands, at ~ 363 and 383 nm, in the Soret region and a 
charge transfer band at 622, indicating high spin Fe3+ state. 
Alterations in the secondary structure of sdAb 2H10 upon heme binding were 
ascertained by circular dichroism (CD) and Attenuated total reflection Fourier 
Transform infrared (ATR-FTIR) spectroscopies. The far-UV CD spectrum of sdAb 
2H10 revealed a negative band centered at 218 nm, indicative of a β-sheet protein 
fold. Heme ligation resulted in broadening of this band, suggesting a conformational 
rearrangement of secondary structure elements upon cofactor binding (Fig. 4D). 
Analysis of the Soret region of the spectra reflects heme coordination via 
appearance of a positive CD band at 412 nm, absent in apo-2H10 sdAb (Fig. 4D, 
inset). The impact of heme coordination on the secondary structure of sdAb 2H10 
was further analyzed by ATR-FTIR, which is sensitive to different types of β-sheet 
structures. A comparison of the absorption spectra of sdAb 2H10 in the 
presence/absence of heme, in the amide I region (1700-1610 cm-1) is also 
indicative of structural alterations upon heme coordination (Fig. 4E, top). Second 
derivative analysis of the ATR-FTIR spectra was performed to identify individual 
components under the intrinsically broad amide I band envelope (Barth and 
Zscherp, 2002). It revealed major contributions typical of β-sheet structures for apo-
2H10, in agreement with CD data (Fig. 4E, bottom). The presence of 1633 and 
1693 cm-1 bands simultaneously is most likely associated with an anti-parallel 
arrangement of β-strands in sdAb 2H10, which are typically characterized by a 
strong band at ~1630 cm-1 and a weaker one at ~1690 cm-1 (van de Weert et al., 
2001;Barth and Zscherp, 2002). Upon heme ligation, there was a rearrangement in 
β structures with the β-turn band at 1668 cm-1 shifting to 1678 cm-1 and a lack of the 
contribution at 1693 cm-1, which denotes a loss of the anti-parallel β-sheet 
fingerprint. In addition, a prominent feature arose at 1653 cm-1, at a position in 
which both α-helices and disordered segments contribute and which cannot be 
further resolved at this stage. In summary, the combination of both CD and FTIR 
reveals that the sdAb 2H10 was composed of predominantly anti-parallel β-sheets, 
which undergo conformational changes upon heme binding.  
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We employed Resonance Raman (RR) spectroscopy to characterize further 
the heme moiety in the heme-2H10 sdAb complex. Upon excitation into the Soret 
electronic transition band, RR spectra display in the high frequency region (1300-
1700cm-1) core size marker bands (e.g. ʋ4, ʋ 3, ʋ2 and ʋ10), which are sensitive to 
coordination, spin and redox state of the Fe-heme. A comparison of RR spectra of 
hemin versus the 2H10/heme complex (Fig. 4F and 4G) demonstrates that sdAb 
2H10 binds to heme b in a specific manner. This was particularly evident from the 
changes in frequency and relative intensity of spin state sensitive ʋ3, ʋ2 and ʋ10 
modes. Also, the bandwidth of the well defined ʋ3 mode revealed a presence of one 
spin species (i.e. one type of ligation) in the complex. The ʋ4 at 1377 and
 1373 cm-1 
in the heme-2H10 complex and heme, respectively, indicated a Fe3+ state of the 
heme Fe in both cases. The heme-2H10 complex revealed the ʋ3 and ʋ2 at 1508 
and 1585 cm-1 respectively, characteristic for six coordinated low spin Fe-heme 
(Fig. 4G). These modes were found at 1492 and 1571 cm-1, respectively in heme 
spectra, indicating a five-coordinated high spin (Fig. 4F) state, with most likely a Cl- 
ion acting as the fifth axial ligand. The most probable candidates for heme axial 
ligands in the six coordinated low spin 2H10/heme complex were tyrosine and 
lysine besides cysteine, as suggested by the UV-Vis spectra. These aa are present 
as axial ligands in several hemoproteins as well as in the CDR1 of sdAb 2H10 (Fig. 
1F) (Ferrer et al., 1993;Rosell et al., 1998;Li et al., 2011). Also, H2O molecule, 
which in some heme proteins acts as a strong axial ligand, cannot be excluded as a 
potential 6th ligand. However, other amino-acids in the sdAb sequence cannot be 
excluded as candidates for coordinating heme Fe. Further experiments are required 
to disclose their nature, such as site-direct mutagenesis on those amino acids 
which were identified as the most likely candidates, and their subsequent  






Figure 4. Characterization of sdAb binding to heme. (A) SdAbs bound to biotinylated heme in solution 
were pull- down using streptavidin (SA) beads and detected by western blot using anti-HA mAb. Input was 
measured by coomassie-based stain. (B) UV-Visible spectra of hemin. Soret region at approximately 363 
nm and 383 nm and a CT band at 622 nm are shown. Data shown is representative of three independent 
experiments. (C) UV-Visible spectra of sdAb 2H10 incubated with increasing heme concentrations. Soret 
(412 nm), Q1 (530 nm), Q0 (565 nm) and CT (624 nm) bands are highlighted. Similar results were obtained 
for sdAb 1A6 and 2H7 (Suppl.Fig. 2A and 2B). (D) Far UV CD spectra of sdAb 2H10 in the apo (black) and 
heme-bound (red) forms. Shift from 212 to 218 is due to a heme-driven conformational rearrangement of 
the sdAb secondary structure. The inset shows the Soret region, with the appearance of 412 nm band, due 
to heme binding to the sdAb. (E) ATR FTIR absorption spectra (top) and second derivative (bottom) of 
sdAb 2H10 in the apo (black) and heme-bound (red) forms in the amide I region (1700-1610 cm
-1
), 
showing structural modification upon heme coordination. High frequency RR spectra of (F) hemin and (G) 
sdAb 2H10 bound to hemin, obtained with 413 nm excitation.  
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3.4 Detection of cellular heme  
We tested the sdAbs for their ability to detect intracellular heme in situ by 
immunofluorescence microscopy. Heme was readily detected in human HeLa cells 
using all three sdAbs, while background signal was obtained using a control sdAb, 
which does not recognize heme (Fig. 5A). Detection of cellular heme was 
confirmed by flow cytometry (Fig. 5B), and was fully inhibited when sdAb 2H10 was 
pre-incubated with increasing heme concentrations (Fig. 5C). Heme pre-incubation 
also reduced detection of cellular heme by sdAb 2H10 in immunofluorescence 
microscopy (Fig. 5D). Consistent with the in vitro data (Fig. 2A), pre-incubation of 
sdAb 2H10 with PP failed to inhibit cellular heme recognition, as assessed by flow 
cytometry (Fig. 5E). These data supports the notion that sdAb can be used to 
detect cellular heme, presumably "free heme". Further studies are required to fully 
understand whether the detected heme is “free”. Ideally, cells depleted of heme but 
with the capacity to incorporate exogenous heme should be used. Therefore, “free 
heme” would only be detected when provided exogenously. This  would mimic the 
organism Caenorhabditis elegans that do not synthesize heme, acquiring it from 
exogenous sources (Sinclair and Hamza, 2015).  However, such cells do not exist 
and the usages of drugs, such as succinylacetone for heme synthesis inhibition 
might not to be sufficient to reduce significantly intracellular heme and prolonged 
treatment with this drug leads to increased cell death.  
Furthermore, we cannot exclude that the heme detected by the sdAb might be 
released from intracellular hemoproteins that were denaturated during cell 
treatment for immunoFluorescence/Flow Cytometry assay. Thus the   
methanol/paraformaldehyde and eventually triton X-100 used for cell fixation and 
permeabilization, respectively, will induce protein denaturation. These treatments 
might also promote some conformational changes in the hemoproteins which might 
expose their heme groups that become accessible to the sdAb. To address these 






Figure 5. Detection of intracellular heme by sdAbs. (A) Intracellular heme (red) and DNA (blue) were 
detected by immunoflurescence in HeLa cells using anti-heme sdAbs 1A6, 2H7 and 2H10 and DAPI, 
respectively. Staining with a control sdAb (Ctr.) that does not recognize heme is also shown. Images are 
representative of three independent experiments. Scale bar, 10 µM. (B) Intracellular heme detection by 
flow cytometry in HeLa cells, using the same sdAbs as in (A). Histograms are representative of three 
independent experiments. (C) Same as (B) with pre-incubation of sdAb 2H10 with increasing 
concentrations of hemin (0-160 µM) in solution. Data is representative of three independent experiments. 
(D) Same as (A) using sdAb 2H10 pre-incubated or not with hemin (160 µM) in solution. Data is 
representative of three independent experiments. (E) Same as (C) with sdAb 2H10 pre-incubated with 
heme (160 µM) or PP (160 µM). Data is representative of three independent experiments. (F) Same as (A) 
in HeLa cells co-stained with MitoTracker® for mitochondria localization (Green). Heme was detected by 
the sdAb 2H10 (red) and DNA with DAPI (blue). Merged images show co-localization of heme with 





Considering that sdAb are detecting cellular “free heme”, we asked whether 
"free heme" can be detected in different intracellular compartments, HeLa cells 
were co-stained for heme and for specific cellular compartments, including nucleus 
(DNA/DAPI), mitochondria (MitoTracker), endoplasmic reticulum (calnexin), early 
endosomes (EEA1) and cytoskeleton (F-actin)( Fig. 5F and Fig. 6). The majority of 
 
Figure 6: Detection of heme in different cellular organelles. Heme (red) and DNA (blue) detected by 
immunoflurescence in HeLa cells using the sdAb 2H10 and DAPI, respectively. Cells were co-stained 
(Green) with (A) anti-Calnexin for endoplasmatic reticulum (ER) (B) anti-EEA-1 for endosomes, (C) a toxin 
phalloidin–tetramethylrhodamine B isothiocyanate phalloidin for F-actin, (D) anti-bilirubin mAb and (E) anti-
HO-1 polyclonal Ab. Merged figures show co-localizations (yellow). Data shown is representative of three 
independent experiments. All images with a scale bar, 10 µM. 
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sdAb 2H10 signal, corresponding to the presence of "free heme", overlapped with 
the mitochondria (Fig. 5F), the main organelle for heme biogenesis and a minor 
portion overlapped with the ER and endosomes (Fig. 6A and 6B). In addition, sdAb 
2H10 signal was also co-localized with the heme-degrading enzyme HO-1 and to a 
lesser extent with bilirubin (Fig. 6D and 6E). These observations reflect most 
probably the relative affinity of sdAb 2H10 to “free heme” (~10-7M; Fig. 1F) plausibly 
revealing the presence of a major cellular heme pool within the mitochondria as well 
as associated with HO-1, outside the mitochondria. 
The different patterns observed in the cellular heme detection by the sdAb (Fig, 
6 A-E) are in agreement with inherent variations on the assays as those were 
performed in different days and consequently with different cells and the images 
between the different assays were not normalized.     
 
3.5 Quantitative analyzes of circulating heme after acute hemolysis in vivo. 
Having characterized the heme binding properties of sdAb, we set to test whether 
these sdAbs can be used to monitor, in a quantitative manner, heme accumulation 
in the plasma during hemolytic conditions. To address this, we used a well-
established experimental model in which phenylhydrazine (PHZ) administration 
induces acute hemolysis in mice (Itano et al., 1975). Under steady state conditions, 
the mean plasma concentration of heme in adult C57BL/6 mice was 23,4 µM, as 
assessed using a formic acid based assay and consistent with similar values 
obtained using different assays (Vinchi et al., 2013). Heme concentration in plasma 
increased to an average of 95.6 µM, as assessed 3 hours after PHZ administration, 
a value maintained for 12 hours thereafter, the last time point analyzed (Fig. 7A). 
To further characterize heme concentration in plasma, we developed a sandwich 
ELISA in which heme is captured by solid phase bound sdAb 1A6 and detected by 
sdAb 2H7 (Suppl. Fig. 4). Given the affinity of sdAb 1A6 towards heme, i.e. 10-7 M, 
this assay detects heme only if not bound to other plasma proteins or ligands with 
an affinity higher than 10-7 M, i.e. “free heme”. Under steady state conditions “free 
heme” in plasma remained undetectable, <0.15 µM (Suppl. Fig. 4) and induction of 
acute hemolysis by PHZ did not result in detectable accumulation of “free heme” in 
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plasma, which confirms the physiological capacity of plasma heme-binding proteins 
to scavenge heme, with an affinity higher than 10-7 M.  
We then asked whether the accumulation of heme in plasma associated with 
acute hemolysis increases heme bioavailable for cellular uptake (White et al., 
2013). Under steady state conditions, cellular heme uptake was negligible, as 
assessed by HRP reporter activity in HEK293 cells exposed to plasma derived from 
PHZ-untreated animals (Fig. 7B). Hemolysis was associated with increased heme 
bioavailability, as revealed 3 to 12 hour after PHZ administration (Fig. 7B). Only a 
small fraction, ~ 4 µM corresponding to 4% of the total heme detected in plasma, 
became bioavailable for cellular uptake, plausibly reflecting the high buffering 
capacity of plasma heme scavenging proteins.  
To monitor heme buffering capacity (HBC) in plasma we reemployed a similar 
sandwich ELISA with one major modification: the plasma was first pre-incubated 
with increasing amounts of heme prior to the assay, so as to measure the 
concentration of “free heme” at which plasma reach half-saturation of its total HBC. 
Plasma HBC in adult C57BL/6 mice at steady state was in average ~23.8 mM (Fig. 
7C), exceeding by ~100 times the total amount of heme detected in plasma (Fig. 
7A). Acute hemolysis was associated with a decrease of plasma HBC, to an 
average 16,8 mM, as assessed 6 hours after PHZ treatment, returning to steady 
state levels 12 h later (Fig. 7C). This provides further confirmation that although 
acute hemolysis is clearly associated with the accumulation of heme in plasma, 
plasma does have an extremely high buffering capacity, which presumably 
safeguards against the deleterious effect of “free heme”. This higher HBC most 
probably is provided by proteins or other molecules in the plasma with capacity to 
binding heme, such as albumin, immunoglobulins, hemopexin and lipoproteins 
(Camejo et al., 1998;Paoli et al., 1999;Wardell et al., 2002;Dimitrov et al., 





3.6 Modulation of heme biologic activity by sdAb 
We next asked whether heme binding by sdAb 2H10 interferes with the redox 
activity of heme, as assessed by the modulation of electron exchange between 
heme and ascorbic acid in the presence of H2O2. As expected, heme catalyzed 
ascorbic acid oxidation in a dose-dependent manner, that is, higher heme 
concentrations (0-5 µm) increased the extent of ascorbate depletion, as detected by 
HPLC (Fig. 8A and 8B). This pro-oxidant effect of heme was significantly 
attenuated in the presence of sdAb 2H10, as compared to equimolar concentrations 
of control sdAb or human serum albumin (Fig. 8A). Importantly, sdAb 2H10 also 
inhibited the pro-oxidant activity of heme/H2O2 in a concentration-dependent 
manner that is, higher sdAb concentrations reduced ascorbate depletion, as 
detected by HPLC (Fig. 8B). At each concentration tested, the sdAb 2H10 was 
more effective than the control sdAb or human serum albumin in terms of 
preventing ascorbate depletion (Fig. 8B). 
To determine whether heme binding to sdAb 2H10 prevents cellular heme 
uptake, we used a horseradish peroxidase (HRP)-based heme reporter assay 
previously shown to reflect intracellular heme availability in mammalian cells (White 
 
Figure 7. Heme accumulation in plasma during acute hemolysis in mice. (A) Heme concentration in 
plasma of control mice (0) and mice receiving PHZ. (B) Cellular heme uptake from the plasma of control 
mice (0) and mice receiving PHZ, monitored by the HRP-reporter HEK 293 cells. (C) Heme binding 
capacity (HBC) of plasma from control mice (0) and in mice receiving PHZ. *p < 0.05, ** p < 0.01, ***p < 
0.001. Each circle corresponds to an individual mouse. Red bars represent mean ± STD,  
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et al., 2013). HEK293 cells were treated with succinylacetone, an inhibitor of heme 
synthesis to prevent “ de novo” synthesize of heme and consequently its 
incorporation into apoHRP and restored its activity, As expected, treated cell 
showed greatly reduced levels of HRP activity, while supplementation with either 
exogenous heme (0.5µM) or sdAb 2H10 bound to heme fully restored HRP activity 
(Fig. 8C). This was not recapitulated when cells were provided with heme bound to 
the heme scavenger hemopexin (HPX)(Fig. 6C). Consistent with this observation, 
heme-2H10 complexes sensitized primary mouse hepatocytes to undergo 
programmed cell death in response to tumor necrosis factor (TNF) in a similar 
manner as heme alone(Larsen et al., 2010;Gozzelino and Soares, 2011) (Fig. 8D). 
This suggests that heme binding by sdAb 2H10 does not inhibit heme intracellular 










Figure 8. Targeting heme biologic activity with sdAbs. Ascorbate oxidation by heme in the presence or 
absence of the sdAb 2H10, Ctrl sdAb or human serum albumin (HSA). (A) Increasing heme 
concentrations. (B) Increasing protein concentrations. Results shown are the mean ± SEM from three (B) 
and four (A) independent experiments. (C) Cellular heme content in HRP reporter HEK 293 cells treated 
(+) or not (-) with SA and exposed (+) or not (-) to “free heme”, heme bound to sdAb 2H10 (2H10-H) or 
heme bound to HPX (HPX-H). Results shown are the mean ± STD from three replicates in one experiment 
representative of three independent experiments. (D) Viability of primary mouse hepatocytes exposed (+) 
or not (-) to “free heme” (5µM), 2H10-H and exposed or not TNF (5ng/mL) as indicated. Results shown are 
the mean ± SD from six samples in one experiment representative of three independent experiments. *p < 
0.05, ***p < 0.001 Asterisks (***) indicate that the mean value of each point of sdAb 2H10 differs from the 
corresponding mean point value of Ctrl sdAb at the p < 0.001. 
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4. DISCUSSION  
75-80% of bioavailable Fe in mammals is contained inside heme, whereas the 
remaining 20-25% is present in the form of non-heme Fe (Gozzelino and Soares, 
2014). Heme is found essentially within hemoproteins and specifically in Hb 
contained inside red blood cells (RBC) (Schneider et al., 2007). Several pathologic 
conditions are incompatible with the maintenance of RBC integrity thus leading to 
release of Hb in plasma, i.e. hemolysis. Because of the sheer number of RBC (~2-
3x1013 in adult humans) as well as their high Hb (~3x108 molecules/RBC) and 
heme (~1.2x109 heme per RBC) (Smith, 1980), undetectable levels of hemolysis 
clinically can be associated with release of significant amounts of biologically active 
Hb. Upon release from RBC, tetramers of cell-free Hb dissociate into dimers that 
are readily oxidized, releasing their non-covalently bound heme b (Gozzelino et al., 
2010). Several lines of evidence suggest that once released from Hb, heme b can 
act in a cytotoxic (Seixas et al., 2009;Gozzelino et al., 2010;Larsen et al., 2010), 
vasoactive and pro-inflammatory (Graca-Souza et al., 2002;Figueiredo et al., 2007) 
manner, promoting the pathologic effects of hemolysis. This appears to be true for 
pathologic conditions associated with varying levels of hemolysis, such as, malaria 
(Pamplona et al., 2007;Ferreira et al., 2011), severe sepsis (Larsen et al., 2010) or 
sickle cell disease (Ghosh et al., 2013;Vinchi et al., 2013;Belcher et al., 2014). It 
becomes apparent that mechanisms controlling heme homeostasis are likely to 
regulate the pathogenesis of these and probably other related diseases (Schaer et 
al., 2013). 
From the context of these pathophysiologic conditions, there are currently no 
analytical methods available that provide quantitative and qualitative information on 
the pathologic effect of heme, as it accumulates in plasma when released from cell-
free Hb. Here we describe a panel of sdAbs that detect specifically heme upon its 
release from hemoproteins (Fig. 1, 2 and 3). The affinity of these sdAbs is in the 
range of 10-7 M (Fig. 1F), such that the sdAbs detect only heme which is not bound 
to scavenging systems with an affinity higher than 10-7 M. This makes these sdAbs 
specific for what we refer to as “free heme”, i.e. redox active heme that is loosely 
bound to proteins or to other biologic compounds with an affinity lower than 10-7 M. 
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We identified three sdAbs, i.e. 1A6, 2H7 and 2H10 that recognize heme, of which 
sdAb 2H10 appears to be the most specific (Fig. 1, 2 and 3). The sdAb 2H10 does 
not recognize other closely related molecular structures, such as the tetrapyrroles 
biliverdin, bilirubin, metal-depleted or Zn PP (Fig. 2 and 3). Moreover, sdAb 2H10 
does not recognize heme when contained within several tested hemoproteins or 
bound to human serum albumin (Fig. 3C). Structural properties of the 2H10/heme 
complex reveal that this sdAb interacts specifically with heme, presumably via a 
cysteine as the fifth ligand and a lysine or tyrosine as the sixth axial ligand (Fig. 4C 
to 4G) (Li et al., 2011). We cannot exclude that others ligands, such as water or aa 
from sdAb sequence act as a sixth ligand of heme Fe. From a biological 
perspective, immunofluorescence microscopy revealed that sdAb 2H10 detects the 
“free heme” in human cells, mainly in the mitochondria while a minor portion was 
also detected in the secretory pathway (Fig. 5F). This is consistent with the notion 
that endogenous cellular heme is synthesized in the mitochondria while 
extracellular heme is obtained via endocytic pathways (White et al., 2013). 
Furthermore, sdAb 2H10 also detected “free heme” in close vicinity to the heme-
degrading enzyme HO-1. We can speculate that this sdAb is detecting the 
substrate of HO-1 in cells, and that heme bound to ligands with affinity higher than 
10-7 M is probably not a substrate for HO-1 (Fig. 6D). Cellular “free heme” was also, 
although less frequently, detected in the vicinity of bilirubin, an end product of heme 
catabolism no longer associated with HO-1 (Fig. 6E). This suggests that “free 
heme” can be found in the vicinity of heme catabolizing events, where substrate, 
enzyme and end-product are in the same region. While consistent with the notion 
that sdAb 2H10 recognizes specifically cellular “free heme”, we cannot exclude that 
this sdAb may also react with heme when loosely or transiently bound with low 
affinity (<10-7 M) to cellular proteins or lipids. We also need to consider that the 
sdAb might be detecting heme that was released from denaturated hemoproteins 
during cell treatment for immunoFluorescence/Flow Cytometry assay. Besides that, 
this type of treatment could also induce conformational changes in the 
hemoproteins, making their heme groups accessible to the sdAb. Nevertheless, 
further studies are required to elucidate it. 
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The development of methodologies allowing for the quantification and 
eventually the specific targeting of “free heme” as it accumulates in plasma during 
hemolysis, should provide further information not only about the participation of 
“free heme” in the pathogenesis of hemolytic conditions, but presumably also allow 
for its specific therapeutic targeting.  
Using a newly developed sdAb-based sandwich ELISA (Suppl. Fig. 4) we 
found that despite heme accumulation during acute hemolysis, there is very little or 
no “free heme” in plasma; the assay has a linear range between 0.15-2.5 µM 
(Suppl. Fig. 4). This result is in contradiction with previous results that described an 
increase in “free heme” associated with the pathology of hemolytic diseases 
(Pamplona et al., 2007;Ferreira et al., 2008;Seixas et al., 2009;Larsen et al., 
2010;Gozzelino et al., 2012). The discrepancies between those studies seem to be 
correlated with the methodologies used to detect “free heme”. In one of those 
studies, “free heme” is defined as protein-free heme and was determined after 
removing the proteins from plasma by filtration to retain all protein with a molecular 
weight higher than 3kDa (Pamplona et al., 2007;Seixas et al., 2009). The protein-
depleted plasma was then used for heme quantification using a chromogenic assay 
from a QuantiChrom heme assay kit (Biosystems). Although the major plasma 
proteins are removed by this method, it does not allow to assess whether heme is 
“free” as it still might be associated with other molecules of lower molecular weight 
than 3kDa. The authors of those papers did not determine whether some proteins 
were still present in the filtered plasma, thus excluding this possibility. While in 
another study, “free heme” in plasma is defined as non-hemoglobin bound heme 
and was determined by subtracting the value of total heme, determined by a 
peroxidase assay, from total hemoglobin concentration, determined through UV-
visible spectra in which purified hemoglobin was used as standard (Larsen et al., 
2010;Gozzelino et al., 2012;Jeney et al., 2014). This method has several limitations 
that can compromise the precision of “free heme” quantification; i) peroxidase 
activity is not directly proportional to the heme concentration, since the peroxidase 
activity of heme is dependent of the protein to which it is bound as well as to the 
solvent, as exemplified for heme vs cytochrome c (Laszlo and Compton, 2002), 
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albumin or hemopexin (Grinberg et al., 1999); ii) the UV-visible spectra of the 
different hemoproteins are very similar, displaying the typical Soret and Q bands 
and sometimes CT band, and the absorption peaks vary with for instance the 
solvents, heme ligands and hemoproteins oxidation state (Brill and Sandberg, 
1968;Kuzelova et al., 1997;Zijlstra and Buursma, 1997;Mauk et al., 2007;Nicoletti et 
al., 2008). Considering that in plasma there are several hemoproteins, including 
hemoglobin (mainly upon hemolysis) the UV-visible obtained from plasma will not 
be specific for hemoglobin (Zijlstra et al., 1991;Zijlstra and Buursma, 1997) and 
other hemoproteins will interfere. All together, these results might lead to 
misinterpretation of the values obtained for “free heme” quantification.  For that 
reason, this project was developed aiming to overcome those limitation and better 
understand the role of “free heme” in the pathology of immune mediated 
inflammatory diseases.   
Nonetheless, acute hemolysis is associated with increased of total heme and 
heme bioavailability reflected by cellular heme uptake as well as reduced plasma 
HBC, as revealed using another sdAb based sandwich ELISA (Fig. 7). This 
confirms that acute hemolysis is associated with heme accumulation in plasma, and 
consequently with an increase of reactive heme available for cellular uptake. 
Despite a transient decrease in plasma HBC during acute hemolysis, heme is 
probably always bound to plasma compound(s) with an affinity >10-7 M, hence not 
detectable by the sdAbs based ELISA. The observation that plasma HBC 
decreases only transiently, upon which it rapidly returns to steady state (Fig. 7), 
argues for a tight regulatory mechanisms restoring systemic heme homeostasis. 
This mechanism is probably not mediated by HPX, given that deletion of the HPX 
gene has no effect on the overall plasma HBC in mice (data not shown).  
When bound to soluble heme, sdAb 2H10 inhibited its pro-oxidant activity (Fig. 
8A and 8B), as assessed by ascorbate oxidation, used hereby as a proxy of heme 
redox activity. While plasma heme scavengers such as albumin also diminish heme 
pro-oxidant activity, sdAb 2H10 is more efficient in that respect (Fig. 8A and 8B). 
This may be particularly useful when envisaging the use of anti-heme sdAb as a 
therapeutic approach to target the pro-oxidant effects of extracellular soluble “free 
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heme” and prevent its pathogenic effects in the context of immune-mediated 
inflammatory diseases. The observation that the described sdAb do not target 
heme when contained in Hb, Mb or cytochromes should make such an approach far 
less toxic, as compared to other approaches affecting heme stability in these 
hemoproteins (Pamplona et al., 2007;Gozzelino et al., 2010). The use of albumin to 
target heme could also be considered, however little is known about its role in 
prevention of the cytotoxic effect of heme. For instance, it was demonstrated that 
albumin can also bind other molecules that modulate its heme binding, such as fatty 
acids (Fasano et al., 2005;Ascenzi and Fasano, 2009), which can compromise the 
efficiency of albumin to prevent the cytotoxic effect of heme. 
 In conclusion our present study reveals that anti-heme sdAbs can be used to 
detect and quantify “free heme” as well as to modulate its biologic activity. Further 






5. EXPERIMENTAL PROCEDURES 
 
Tetrapyrroles preparation - Concentration of different tetrapyrroles (Frontiers 
Scientific®, Utah, USA) in solution was determined spectrophotometrically using 
appropriated solvents. Briefly, heme (i.e. hemin) stock solutions were prepared in 
0.1 M NaOH, buffered with 0.1 M HCl to pH 7.4. Alternatively, hemin was diluted, as 
for all other tetrapyrroles, in dimethyl sulfoxide (DMSO). Hemin concentration was 
determined at λ405nm using a extinction coefficient (EmM) of 85,82, DeutP (λ392nm; 
EmM=170) and GaPP (λ413nm, EmM=249) (43). PP (λ408nm; EmM=297) concentration 
was determined in 1.5 M HCl (43), ZnPP (λ415nm; EmM=150) in ethanol (43); biliverdin 
(λ377nm; EmM=51,5) in methanol (44) and bilirubin (λ451nm, EmM=60) in chloroform (45). 
CoPP, SnPP and FePPCH3 concentrations were calculated gravimetrically 
according to their molecular weight (MW) =654.6, 750.26 and 679.99, respectively.  
 
Heme biotinylation – The procedure used was modified from the original protocol 
(46). Briefly, hemin in dimethylformamide (DMF; 4.4 mg/mL) was incubated with 2- 
(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate 
methanaminium (HATU) and N,N-diisopropylethylamine (30-60 min.; RT). N-[-5- 
(Hydrazinocarboxy) pentyl]-D-biotinamide (biotin) in dimethylsulfoxide (DMSO) was 
added and after 60 min. at RT the reaction mixture was applied onto a C18 reverse-
phase analytic high performance liquid chromatography (HPLC) column 
(COSMOSIL 5C18-ARII, Nacalai Tesque) to separate biotinylated heme from “free 
heme” and biotin. Fractions were dryed in a SpeedVac (SpeedVac Plus SC110A 
attach to Vaccum System Plus UV400A) at <15ºC.  
 
 (MALDI)-Time-of-flight mass spectrometry (TOFMS) Analysis – Hemin and 
biotin in 0.2M NaOH were spotted directly onto the MALDI target plate and mixed 
1:1 with 2,5-dihydroxybenzoic acid (DHB; 10 mg/mL) in 50% v/v acetonitrile (ACN) 
with 5% v/v formic acid and air dried. Heme-biotin in 50% (v/v) ACN was spotted 
directly onto a MALDI plate using the Maldi matrix described above. Data was 
acquired in positive reflector MS mode in a mass spectrometer (4800 plus MALDI-
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TOF/TOF; AB Sciex) and collected (4000 Series Explorer Software v.3.5.3; Applied 
Biosystems). Mass spectrometer calibration was performed using angiotensin II 
(1046.542 Da), angiotensin I (1296.685 Da), Neurotensin (1672.918 Da), 
Adrenocorticotropic hormone (ACTH)(1–17)(2093.087 Da) and ACTH (18–
39)(2465.199 Da)(Peptide Calibration Mixture 1, LaserBio Labs). Each reflector MS 
spectrum was collected using 500 laser shots per spectra and a fixed laser intensity 
of 3300 V.  
 
Phage library and selection (47) – To select sdAb´s against heme we used a 
synthetic VL sdAb phage display library previously tested successfully against 
several targets (Goncalves et al, submitted). The library repertoire (8x109 
independent clones) was generated on a highly soluble and stable VL scaffold by 
randomization and accommodating a maximum of 26 aa in CDR1 and 22 aa in 
CDR3 (25). The selection process was divided into four main steps: (i) incubation of 
phage-sdAb repertoire with heme-biotin; (ii) streptavidin capture and washing to 
remove non-specific phages-sdAb; (iii) heme competition for phage-sdAb elution 
and (iv) re-amplification of antigen-specific phages-sdAb. Five rounds of binding, 
elution and amplification were performed to generate sdAbs with high binding 
activities and specificity. Briefly, heme-biotin (1µg/µL) was pre-incubated (2h; RT) 
with the sdAb VL phage library (1010/mL). The selection procedure consisted in 
using streptavidin coated magnetic beads (Dynabeads; M280) to capture under a 
magnetic field those phages bound to the heme-biotin. Unbound or low affinity 
bound phages were washed out (PBS 0.5% tween 20, 5x). Bound-phages were 
released from the heme-biotin with a competition step by addition of excess hemin 
(100µM in PBS; 1h; RT; 2x). The recovered phages were used to infect E. coli 
ER2738 (phage display optimized strain; 600nm=0.6; Biocat; 4mL; 15-30 min. 37ºC). 
Phage-infected ER2738 bacteria were grown in Super Broth (10µg/mL tetracycline, 
100µg/mL ampicillin) and plated in Luria Broth (LB) agar (100µg/mL ampicillin) at 
37ºC. Single clones were randomly selected and screened by PCR to insure the 
presence of VL sequences. Bacteria growing in liquid medium were then infected 
with VCSM13 helper phages (1012-1013 pfu in 4 mL; 15-30 min.; 37ºC), re-selected 
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for kanamycin (100µg/mL) resistance and left overnight at 37ºC for phage 
production. After 16h, the selected phages were precipitated using PEG-8000 (4% 
w/v), NaCl (3% w/v)(1 h on ice), centrifuged (8000g; 30 min. 4ºC), re-suspended 
(PBS, 15% Glycerol, 1 h in ice), centrifuged (16000g, 10-20 min. 4ºC) and filtered 
(0.22µm). The resulting “purified phages” were used for one additional panning with 
ten washing cycles (PBS 0.5% Tween 20) and three more additional pannings with 
fifteen washing cycles (PBS 0.5% Tween 20). E. coli (TOP10F’ strain; 600nm=0.6) 
were infected with phages selected from the fourth panning (4mL; 15-30 min. 
37ºC), grown (Super Broth, 10µg/mL tetracycline and 100µg/mL ampicillin), plated 
(LB agar, 100µg/mL ampicillin) and the presence of VL sequences was confirmed 
again by PCR. Phage-infected bacteria were grown (Super Broth, 10µg/mL 
tetracycline and 100µg/mL ampicillin, ON), pcomb3x phagemid DNA was extracted 
(Midi prep. Quiagen), isolated and digested with SfiI (Fermentas) for the extraction 
of DNA encoding sdAb fragments. These were purified from agarose 
electrophoresis, cloned into a modified PpT7-FLAG vector (Sigma)(Technophage 
SA, Portugal and used to transform E. coli (BL21 (DE3), Promega). Bacterial clones 
were grown in auto induction medium (Novagen), lyzed (PBS, 20% Bugbuster, 
Novagen, ON, 4ºC) and protein extracts containing the sdAb fragments were 
obtained (16000g, 15 min., 4ºC) for selection according to heme binding capacity. 
 
SdAb expression and purification – Twenty His-HA-tagged sdAbs were selected 
according to heme binding capacity and ten of those were expressed and purified, 
based on a modified protocol (Goncalves et al, manuscript submitted). Briefly, the 
sdAbs cloned in a pT7 expression vector were transformed in E. coli BL21 (DE3) 
cells and sequences were confirmed (Macrogen DNA Sequencing service), before 
expression and further purification. For protein expression, one liter of LB, 
containing 50 µg/mL carbenicillin was inoculated with 10 mL of overnight culture of 
bacterial cells transformed with pT7-VL´s plasmids and grown to exponential phase 
(600nm=0.6-0.9) at 37ºC. Expression was induced by the addition of 1mM isopropyl 
β-ᴅ-1-thiogalactopyranoside (IPTG) and growth during 6 h at 37ºC. Cells were 
harvested by centrifugation (4000 g for 15 min at 4 ºC) and resuspended in 50 mL 
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equilibration buffer (50 mM HEPES, 1 M NaCl, 5 mM CaCl2, 10 mM imidazole, pH 
7.8) supplemented with protease inhibitors (Roche).  
Cells were lysed by sonication (20min., ice) and the inclusion bodies containing the 
sdAbs were recovered by centrifugation (12096g, 30 min., 4ºC). Then, the pellet 
was washed (50mM HEPES, 1M NaCl,10mM imidazole, 5mM CaCl2, 2M urea, 
1mM -mercaptoethanol (-ME) pH 7.8), sonicated (20 min., ice) and collected by 
centrifugation (12096g, 30 min., 4ºC). The inclusion bodies were then re-suspended 
in a 6 M Urea buffer containing benzonase (>250U, Sigma)(50mM HEPES, 1M 
NaCl, 10mM Imidazole, 5mM CaCl2, 6M urea, 1mM -ME, pH 8.0) and incubated 
overnight (4ºC, under agitation) for protein denaturation. Next day, the denatured 
sdAbs were purified under denaturing conditions using a His Trap Fast Flow (FF) 
column (GE Healthcare), and washed twice with 20 and 30 mM of imidazole to 
remove contaminants (i.e. non specific proteins)(50 mM HEPES, 1M NaCl, 6M 
Urea, 1mM -ME, 5mM CaCl2, and 20 or 30 mM Imidazole pH 7.8). The sdAb were 
eluted in high concentrated imidazole buffer (50 mM HEPES, 1M NaCl, 500 mM 
Imidazole, 6M urea, 1mM -ME, 5mM CaCl2, pH 7.8). Re-folding was done using a 
step-wise dialysis protocol on previous described protocols (30). Briefly, purified 
sdAb was initial dialyzed to Tris buffer containing 10 mM -ME to maintain the 
reduction state of protein and 6M Urea protein (50 mM Tris-HCl, 1mM EDTA and 
200 mM NaCl)(24h, 4ºC). The 10mM -ME was then removed by dialysis using the 
same buffer without -ME, to promote thiol groups oxidation and consequently 
disulfide bond formation (48h, 4ºC). The protein was then refolded by sequential 
dialysis against 3, 2, 1, 0.5 and 0 M urea with or without additives (24h, 4ºC, each 
dialysis step). In the buffers containing 1 and 0.5 M of urea 0.4 mM oxidized 
(GSSG) and 4mM of reduced (GSH) glutathione and 400mM L-arginine were add. 
These additives were proven to help in the protein refolding (30). The refolded 
proteins were then centrifuged to remove protein precipitates (4000g, 4ºC, 10 min.), 
aliquoted and stored (-80ºC) until used. The purity of the sdAbs was assessed by 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel with 
121 
 
15% acrylamide composition under denaturating conditions followed by based 
coomassie stain (Instant Blue, Gentaur, 30 min., RT) and by Western blotting. 
 
SdAb biotinylation – It was performed using EZ-Link NHS-PEG4-Biotinylation kit 
(Pierce). Briefly, 20-fold molar excess of biotin was added to 1.1 mg/mL of sdAb 
2H7 (in PBS) and incubated (ice, 2h). Free biotin and protein were removed using a 
desalting column (Thermo Zeba Spin Desalting column, Pierce)(1000g, 2 min.) pre-
equilibrated in PBS. The biotinylated-sdAb was stored at -80ºC until used. Biotin 
incorporation was confirmed using 4'-hydroxyazobenzene-2-carboxylic acid (HABA) 
assay. Briefly, biotinylated-sdAb was mixed (1/10) with a solution of HABA/Avidin 
(0.5 mg/mL avidin, 0.3 mM HABA, PBS) in a 96 well plate and 500nm was measured 
after and before addition of biotinylated protein using a microplate reader (Vitor 3 
luminometer; Perkin Elmer). 
 
Western Blotting – Proteins were subjected to 15% SDS-PAGE gel 
electrophoresis (15 V, 60 min.), transferred into methanol activated 
polyvinyldifluoridine membrane (2 min.), washed (3x in H2O and 3x T-TBS; 20 mM 
Tris pH 7.5, 150 mM, 0.05% Tween-20) and blocked (5%-skim milk in T-TBS; 1h-
overnight; RT). sdAbs were detected with a horseradish peroxidase (HRP) 
conjugated rat anti-HA monoclonal Ab (mAb)(1/2000, Roche ®). Peroxidase activity 
was revealed using SuperSignal West Pico Chemiluminescent substrate (Pierce) in 
a photoradiograph (Kodak Biomax Light Film; Eastman Kodak). ExPASy - 
ProtParam tool was used to estimate the MW and isoelectronic point of sdAbs.  
 
ELISAs – To screen sdAb for heme recognition, 96 well ELISA plates (Costar 
3690) were coated with hemin (100µM) in carbonate buffer (0.1M NaHCO3, pH 
8.6)(1h, RT or overnight at 4ºC), washed (3x, PBS, 0.1% Tween 20) and blocked in 
protein free blocking buffer (Pierce; 1h, RT). Plates were washed (4x, PBS, 0.1% 
Tween 20) and purified sdAbs diluted in PBS were added (1h 30 min., RT). Plates 
were washed (5x PBS, 0.1% Tween 20) and heme-bound sdAbs were detected 
using a rat anti-HA mAb (3F10; Roche; 0.1µg/mL in protein-free blocking buffer). 
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Plates were washed (5x PBS, 0.1% Tween 20) and the primary mAb was detected 
using an alkaline phosphatase labeled rabbit anti-whole rat IgG (Sigma) polyclonal 
Ab (1 hour, RT) diluted (1/2000 dilution) in protein free blocking buffer (Pierce). 
Alkaline phosphatase was revealed with para-Nitrophenylphosphate (pNPP, 
1mg/mL; Sigma). To evaluate the total amount of protein, sdAb were coated in 50 
mM carbonate/bicarbonate, pH 9.6 (1h; RT or 16; 4ºC) in 96 well ELISA plates 
(Costar 3690) and the rest of the procedure was performed as described above. 
Absorbance was measured in a microplate reader at 405nm (Vitor 3 luminometer; 
Perkins Elmer). 
 
Sandwich ELISA was developed to measure “free heme” – SdAb 1A6 (5 µg/mL 
in 50 mM carbonate/bicarbonate, pH 9.6) was used to coat (overnight 4ºC) 96 well 
ELISA plates (Costar 3690). Plates were washed (5x 0.1% Tween 20 PBS) and 
blocked (2h, RT) using protein free blocking buffer (Pierce). Hemin (0.15-2.5 µM; 
used as standard) or plasma diluted in PBS were added (1h30, RT) and plates 
were washed (5x 0.1% Tween 20 PBS). The captured “free heme” was detected 
using biotinylated sdAb 2H7 (5 ng/µL in PBS), plates were washed (5x 0.1% Tween 
20 PBS) and the biotinylated sdAb was detected using Alkaline phosphatase 
conjugated ExtrAvidin (1/2500 dilution, Sigma) in protein blocking buffer. Plates 
were washed (5x 0.1% Tween 20 PBS) and Alkaline phosphatase was revealed 
using para-Nitrophenylphosphate (1mg/mL; Sigma). Absorbance was measured in 
a microplate reader at 405nm (Vitor 3 luminometer; Perkins Elmer). 
 
Heme binding capacity – Heme binding capacity was determined based on the 
same sandwich ELISA as described above. Plasma diluted in PBS was pre-
incubated (1h30, RT, agitation) with increasing concentration of hemin and added 
to the plates.  
 
Heme competition assays – SdAbs (2.5 µg/mL) were pre-incubated (90 min., RT, 
mild agitation) with different tetrapyrroles or hemoproteins and ELISA was 
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performed as described above. Concentrations of tetrapyrroles or hemoproteins 
used for pre-incubation are expressed as heme molar equivalents. 
 
Biacore – The affinities of sdAbs towards heme were obtained using surface 
plasmon resonance (SPR)(BIAcore 2000, BIAcore Inc.). Briefly, sdAbs were 
captured on a CM5 chip using amine coupling at ~800 resonance units (RU). Heme 
at 0-3000 nM was injected for 4 min and sdAb-bound heme was allowed to 
dissociate (10 min.) before matrix regeneration (10 mM Glycine, pH 2.5). The signal 
was subtracted from that of an immobilized cell to generate sensorgrams of the 
amount of bound heme as a function of time. The running buffer, HBS-P (0.01 M 
HEPES pH 7.4, 0.15 M NaCl, 0.005% v/v Surfactant P20; BIAcore) was used for all 
sample dilutions. BIAcore kinetic evaluation software (version 3.1) was used to 
determine dissociation constant (KD) from the association and dissociation rates 
using a one-to-one binding model. An irrelevant sdAb was used as a negative 
control. 
 
SdAb pull-down assay – SdAb binding to soluble hemin was assessed by a pull-
down assay. Briefly, sdAbs were incubated (5h, 4ºC, agitation) with or without 
heme-biotin and half of the reaction mixture was incubated (2h, RT, agitation) with 
of Streptavidin-Dynabeads (M-280 Streptavidin, Invitrogen), previously blocked (5h, 
RT) with protein free blocking buffer (Pierce). Mixture was washed (3x; 5 min.; 0.05 
Tween 20 in PBS) and magnetic beads were captured (5 min. magnetic field) 
according to manufacture instructions. SdAbs-heme-biotin complexes were 
collected (1 min., magnetic field) and incubated (20 min., 100ºC, agitation) in 
loading buffer (50mM Tris-HCl pH 6.8, 2%SDS, 10% Glycerol, 1% -ME, 12,5 mM 
EDTA, 0.02% Bromophenol blue)(pull-down). The other half of the reaction mixture 
was denaturated (100ºC, 10 min.) in loading buffer. Proteins were applied into a 
15% SDS-PAGE gel under denaturating conditions and stained with a coomassie-
based stain (Instant Blue, Gentaur, 30 min., RT). Alternatively, sdAb were detected 
by Western blotting using a rat anti-HA horseradish peroxidase (HRP) conjugated 




Spectroscopy assays – UV-Visible spectra were recorded on a PerkinElmer 
Lambda 25, UV/Vis spectrometer, using a concentration of 10 µM of sdAb in PBS 
(Dulbecco's Phosphate Buffered Saline). Increasing amount of hemin (stock 
dissolved in 0.1M NaOH and pH adjust to 7.4 with 0.1M HCl) was added and the 
incubated (5 min.) before recording the next spectra. Resonance Raman (RR) 
spectra were obtained using Raman spectrometer (Join Yvon U1000) coupled to a 
confocal microscope equipped with 1,200 lines/mm grating and a liquid nitrogen-
cooled back-illuminated charge coupled device (CCD) detector. The spectra of 40 
µM protein bound to heme and 50 µM heme in PBS buffer were obtained using a 
rotating cell (Hellma) to avoid photoreduction and measured with λ413nm excitation 
line from a Krypton ion laser (Coherent Innova 302) with 4.5 mW laser power and 
60 s accumulation time, at RT; typically 10 spectra were co-added to improve S/N 
ratio. After polynomial background subtraction, spectra were subjected to 
component analysis to determine the band-widths and positions, using in-house 
created software. Circular Dichroism (CD) Spectroscopy measurements were 
performed using a Jasco J-815 spectropolarimeter equipped with a Peltier-
controlled thermostated cell support. CD spectra were recorded with sdAb 2H10 
(240 μg/mL in 35% 50mM TRIS, 200 mM NaCl, 0.1 mM EDTA, 10% glycerol; pH 
7.4 in PBS). Spectra were collected (50nm/min.) and acquired (10x) to improve the 
signal to noise ratio. Attenuated total reflectance (ATR) Fourier transform infrared 
(FTIR) spectra were measured on a Bruker IFS 66/S spectrometer equipped with a 
MCT detector and a thermostatized Harrick BioATR II cell. All measurements were 
obtained using an ATR cell with sdAb 2H10 (700 μg/mL in 50mM TRIS, 200 mM 
NaCl, 0.1 mM EDTA, 10% glycerol at pH 7.4) dissolved in PBS (1x), with and 
without heme. Each spectrum comprises the mean of 150 scans taken at a 
resolution of 4 cm-1. Spectral assignments for specific secondary structure elements 
were made as in (35). 
 
Immunofluorescence – HeLa (ATCC) cells, grown in DMEM supplemented with 
10% fetal bovine serum (Life Technologies) and 1% antibiotics (Life Technologies), 
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were seeded onto coverslips (24 well plate) to reach 80% confluence 24h 
thereafter. Cells were washed (1x, PBS), incubated (5min., RT) in a hypotonic 
solution (85.5 mM NaCl, 5 mM MgCl2, pH 7.0), fixed (ice cold methanol, 10 min., -
20ºC or 4% paraformaldehyde for 10 min at RT), washed (1x, PBS), permeabilized 
(0.1% triton X-100 in PBS, 5 min.), washed (3x, PBS) and blocked (Protein-Free 
Blocking Buffer, Pierce, 1h, RT). For heme detection, HeLa cells were incubated 
with sdAb (2,5 ng/µL; 3h, RT), washed (3x, blocking buffer) and incubated (1h, RT) 
with Alexa Fluor ®647 conjugated HA-Tag (6E3) mouse mAb (1/200, Cell Signaling 
Technology). Cells were rewashed (3x, PBS, 1x milli-Q Water), dried and mounted 
in Mowiol-Dabco media with DAPI (Sigma). SdAb 2H10 was immunostained in 
combination with anti-Calnexin (integral protein of endoplasmic reticulum) Ab 
produced in rabbit (C4731, Sigma), anti-EEA-1 (localizes exclusively to early 
endosomes), phalloidin–tetramethylrhodamin.e B isothiocyanate phalloidin (a toxin 
that binds F-actin)(P1951, Sigma), anti-bilirubin mAb (A420, Dojindo) and anti-HO-1 
polyclonal Ab (SPA-896, Stressgen). Mitochondria were stained with MitoTracker® 
Red (Life Technologies). Nuclei (DNA) were counterstained with DAPI. Images 
were acquired on a Leica DMRA2 upright microscope, equipped with a CoolSNAP 
HQ CCD camera, using a 100x 1.4NA Oil immersion objective, DAPI + FITC + CY5 
fluorescence filter sets, controlled with the MetaMorph V7.5.1/ software. The 
analysis was done with ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2014). 
 
Flow Cytometry – HeLa cells were tripsinized (0.05% Trypsin-EDTA, Life 
Technologies), washed (1x, PBS), fixed (ice cold methanol, 10 min., -20ºC), re-
suspended, washed (1x, PBS), permeabilized (0.1% triton X-100 in PBS, 5 min.), 
washed (1x, PBS) and blocked (Protein-Free Blocking Buffer; Pierce)(1h, RT). 
Intracellular heme was detected using anti-heme sdAb (2.5 µg/mL in blocking 
buffer, 2h30min., RT, shaking) followed by Alexa Fluor® 647 conjugated HA-Tag 
(6E3) mouse mAb (1/200, Cell Signaling Technology). Cells were washed (1x, 
PBS), re-suspended (PBS) and acquired in a FACScan (Becton Dickinson) with 
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CellQuest software (BD Biosciences). The analysis was done with FlowJo (Tree 
Star, Inc.). 
 
Ascorbate oxidation assay – Ascorbate oxidation was used as a readout for 
oxidation activity of heme in the absence or presence of albumin or sdAb (48). 
Briefly, the reaction was initiated by the addition of heme (0-5 µM), without or with 
protein/sdAb (0-5µM) and hydrogen peroxide (800µM), to ascorbate (10 µM) in PBS 
pH 7.4 containing a metal chelator DETAPAC (50 µM) that does not inhibit heme 
mediated oxidation. The reaction was carried out under air at 37ºC and after a 
certain time, stopped by the addition of one volume of 0.5% metaphosphoric acid to 
one volume of reaction mix. The final solution was centrifuged and the supernatant 
collected and analyzed using HPLC with electrochemical detection (49)  
 
Heme bound proteins preparation – Rabbit HPX (kindly provided by Ann Smith, 
University of Missouri, Kansas City, USA) (15) in PBS was incubated with hemin in 
DMSO at 1:2 molecular ratio (4h30 min., 4ºC, agitation). Non bound heme was 
removed by gel filtration chromatography (microcon YM-3; Milipore)(2x 30 min., 
500uL PBS 1x) according to the manufacture instructions. SdAb in PBS was 
incubated with 2x molar excess hemin in NaOH/HCl pH 7.4 (ON, 4ºC). Non bound 
heme and free sdAb were removed using a PD10 column (GEHealthcare) pre-
equilibrated in PBS. Heme binding to HPX or sdAb was confirmed 
spectrophotometrically. Concentration of HPX-heme complex was determined 
spectrophotometrically (λ414nm; EmM=141,6) (50). Concentration of sdAb-heme 
complex was determined using formic acid assay, as described above. Total 
amount of protein was determined using Quick Start Bradford Protein Assay 
(Biorad), according to manufacture instructions.  
 
Heme depleted serum medium (HD) – The medium was prepared as described 
(51). Briefly, DMEM (Life Technologies) was supplemented with 10% heat 
inactivated fetal bovine serum (FBS; Life Technologies). Serum as pre-depleted 
from heme using ascorbic acid (10 mM; 37ºC, 50 rpm) until 405nm=0.6-0.8 (~7 h), 
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dialyzed (3x) in sterile PBS and filtered (0.2µm). Final culture medium was 
supplemented with 1% penicillin (10000 U/mL) and streptomycin (10000 µg/mL).  
 
Golgi-HRP reporter assay was adapted from (37) – Briefly, HEK293 cells (ATCC; 
5x104 cells/well in a 24 well plate) were grown overnight in DMEM, 10% FBS, 1% 
penicillin (10000 U/mL) and streptomycin (10000 µg/mL) and transiently transfected 
(4h-6h, lipofectamin 2000; Invitrogen) with an expression vector encoding the HRP 
gene under the control of the EF-1α promoter (pEF5/FRT/V5-DEST-Golgi-HRP) in 
opti-MEM reduced serum (Gibco) (37). HRP was confined to the Golgi with a 
targeting sequence from galactosyltransferase. Control HEK293 cells were 
transiently transfected with the pEF5/FRT/V5-DEST vector. Transfected cells were 
cultured in heme-deplete culture DMEM with or without 0.5 mM of succinylacetone 
(SA)(24h) and when indicated exposed to hemin, hemin-sdAb 2H10 or hemin-HPX 
(0.5 µM heme equivalents) in opti-MEM 0.5 mM SA (overnight). Peroxidase activity 
was assessed as a red-out of cellular heme content, given that the activity of the 
transfected HRP is dependent on the insertion of intracellular heme into apo-HRP. 
Briefly, cells were lysed (20 mM HEPES pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 
2,5X protease inhibitor cocktail set; Calbiochem®)(ice, 20 min.), centrifuged 
(13.500 rpm, 4ºC, 5min.) and peroxidase activity was quantified in a 96 well plate 
using of 3,3’,5,’-Tetramethylbenzidine (TMB) substrate reagent set (BD OptEIA). 
Reaction was stopped (2N H2SO4) and absorbance was measured in a microplate 
reader at 450nm (Vitor 3 luminometer). Peroxidase activity was determined based on 
the calibration curve generated with the serial dilution of HRP (type IV, Sigma) and 
normalized to the total amount of protein as determined using Quick Start Bradford 
Protein Assay (Biorad). HRP concentration was determined based on Beer-Lambert 
law using the extinction coefficient (λ403nm; EmM=100). Cellular heme uptake was 
determined based on the heme dependent peroxidase activity assay as describe 
previously, to generate a calibration curve using serial dilution of heme normalized 
to the total amount of protein as determined using Quick Start Bradford Protein 




Western blotting for HRP activity and protein detection – Protein collected from 
transfected HEK293 cells (50 µg) in loading buffer (20 % v/v Glycerol, 0.2 M Tris-
HCl, pH 6.8; 0.05% w/v Bromophenolblue) was loaded onto 7% SDS-PAGE (50 µg) 
and transferred into polyvinyldifluoridine membrane, washed (1x, T-TBS) and HRP 
activity revealed immediately using peroxidase substrate (SuperSignal West Pico 
Chemiluminescent substrate) in a photoradiograph (Kodak Biomax Light Film; 
Eastman Kodak). Membrane was blocked (Protein-Free Blocking Buffer; 2-16h; RT) 
and re-probed with rabbit anti-HRP polyclonal Ab (Sigma, 1/2000; 1h, RT), washed 
(5x, T-TBS) and probed with Alakaline Phosphatase-conjugated goat anti-rabbit 
polyclonal Ab (Pierce; 1/5000; 1h, RT). Alakaline Phosphatase signal was detected 
using Lumi-Phos WB chemiluminescent Substract (Pierce) in a photoradiograph. 
Membranes were re-probed with anti-vinculin mouse mAb (1/3000, ON, 4ºC; 
Abcam) detected by HRP conjugated goat anti-mouse IgG polyclonal Ab (1/2500; 
1h, RT). HRP signal was detected as described above. All Abs were diluted in 
Protein-Free Blocking Buffer.  
 
Primary hepatocytes isolation – The isolation of Primary hepatocytes was 
performed as described (15). Briefly, the right liver lobe was extracted from 10-12 
weeks C57BL/6 mice and perfused through the portal vein with liver perfusion 
medium (20 mL; 4mL/min.; Gibco) and liver digestion medium (20 mL/lobe; 
4mL/min.; Gibco). Liver was disrupted in liver perfusion medium, filtered (100 µM 
strainer) and collected (130g, 60 sec, RT, no break) in liver perfusion medium. Cells 
were re-suspended (24 mL) in William´s E medium (Gibco) supplemented with 4% 
FBS, 1% penicillin (10000 U/mL) and streptomycin (10000 µg/mL) and added (6 
mL) to a 1.06 (5 mL)/1.08 (5 mL)/1.12 (4 mL) g/mL Percoll gradient (750g, 25 min., 
RT, no break)(Amersham, Buckinghamshire, UK). Hepatocytes were collected, 
washed twice (1x 40 mL, 1x 10 mL; 200g, 10 min., 4ºC) and re-suspended in 
William’s complete medium. Hepatocytes were seed in a gelatin (0.2%) coated 




Cytotoxic assay – The cytotoxic assay was performed essential as described (15). 
Briefly, primary hepatocytes were seeded (3.5x104 cells/well; 24 h) in a 96 well 
plate and exposed to heme, sdAb-heme or HPX-heme (5 µM heme-equivalent, 1 h, 
37ºC) in Hank´s Balanced Salt Solution (HBSS, Gibco). When indicated 
hepatocytes were exposed mouse recombinant tumor necrosis factor alpha (TNF, 
R&D Systems)(5 µg/mL; 16h, in William’s complete medium. Cell viability was 
assessed by crystal violet assay (15).  
 
Mice – Experiments in mice were performed in accordance with protocols approved 
by the Ethics Committee of the Instituto Gulbenkian de Ciência and the Portuguese 
National Entity (DGAV Direção Geral de Alimentação e Veterinária) and with the 
Portuguese (Decreto-Lei nº 113/2013) and European (Directive 2010/63/EU) 
legislation related to housing, husbandry and animal welfare. C57BL/6 mice were 
bred and maintained under specific pathogen-free conditions under ethical approval 
by the Instituto Gulbenkian de Ciência animal care committee.  
 
Animal samples – Mouse plasma was obtained by cardiac puncture under heparin 
(EDTA anti-coagulated blood), centrifuged (2x; 1600g, 5min., 4ºC). Samples were 
maintained at -80ºC until be used. 
 
Phenylhydrazine (PHZ) treatment – Age matched (10-12 weeks) male C57BL/6 
mice were injected (s.c.) with freshly prepared phenylhydrazine hydrochloride 
(Sigma)(1xPBS, pH7.4; 90 mg/Kg; BW).  
 
Total heme measurement – Performed essential as described (52). Briefly, 
samples were diluted in H2O in 96 well plate and heme concentration was 
determined by comparison to a hemin standard curve (0.5-16 µM in H2O). Formic 
acid (150 µL/well; 98-100%, Merck) was added and absorbance measured at 405nm 




Statistical Analysis – In the comparison of the means of more than two groups, 
we used the analysis of variance (ANOVA) and significance between groups was 
estimated using Bonferroni post-test, when Gaussian distribution was observed. For 
samples with non-Gaussian distribution, comparison between groups was 
performed using a Kruskal-Wallis test, followed by post test Dunns to compare all 
pair groups. Statistical analysis were performed using the GraphPad v.5.0a 
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Suppl. Figure 1. MALDI-TOF/TOF zoom analysis of biotinylated heme. (A) Mass-to-charge (m/z) 969.2 
Da showing an isotopic cluster pattern similar to the theoretical pattern calculated for the heme-biotin 
molecule in which a single carboxylic acid residue of heme is biotinylated. (B) MALDI-TOF/TOF analysis of 






Suppl. Figure 3. Characterization of heme binding to sdAb 1A6 and 2H7 by UV-Visible 
spectrophotometry. UV-Visible spectra of sdAbs (A) 1A6 and (B) 2H7, pre-incubated with increasing 
concentrations of hemin. Soret (412 nm), Q1 (530 nm), Q0 (565 nm) and CT (624 nm) bands are 
highlighted. 
 
Suppl. Figure 2. Sensogram of heme binding to sdAb 2H10. For the determination association and 
dissociation kinetic rate constants, used to calculate the constant of affinity (KD) from the sdAb was 
immobilized in a CM5 chip using using amine coupling at ∼800 resonance units (RU) and different 
concentration of heme (from 0 to 1000 nM) infected for 4 min. The symbol * indicates the start and # the 





Suppl. Figure 3. Sandwich ELISA for heme detection. Soluble hemin was captured by sdAb 1A6 and 













Regulation of Fe metabolism is critical for maintenance of homeostasis (Gozzelino 
and Soares, 2014). In mammals, 75-80% of bioavailable Fe is contained inside 
heme and the remaining 20-25% exists in the form of non-heme (labile) Fe 
(Gozzelino and Soares, 2014). Around 80% of total heme is contained in the 
erythroid lineage where it is used to produce hemoglobin, while 15% is present in 
liver and the remaining in other tissues. Several pathologic conditions are 
associated with variation of homeostatic parameters that are incompatible with the 
maintenance of RBC integrity thus leading to hemolysis and to the release of 
hemoglobin into plasma. The shear number of total RBC (2-3x1013 in humans) 
combined with their high hemoglobin content (3x108 molecules/RBC) and the 
corresponding heme amount (1.2x109 molecules/RBC) makes that clinically 
undetectable levels of hemolysis are associated with the release of significant 
amounts of hemoglobin into plasma. Tetramers of cell-free hemoglobin dissociate 
into dimers when oxidized (Bunn and Jandl, 1968;Hebbel et al., 1988;Balla et al., 
1993;Pamplona et al., 2007) releasing their non-covalently bound heme b. The non-
hemoglobin bound heme is commonly referred as “free heme” (15-16). However, 
heme is most probably never found as a free molecule, being bound to a series of 
heme binding molecules, including proteins and lipids. Heme binding proteins in the 
plasma include hemopexin (Tolosano et al., 2010), albumin (Fanali et al., 2012) and 
lipoproteins (Camejo et al., 1998). Along this work, we use the term “free heme” to 
refer to labile, redox active heme which is loosely bound to proteins or other 
molecules but can presumably act in a deleterious manner. 
Several studies suggest that once released from hemoglobin, heme b can act 
in a vasoactive (Adisa et al., 2013;Vinchi and Tolosano, 2013;Belcher et al., 2014), 
pro-inflammatory (Graca-Souza et al., 2002;Figueiredo et al., 2007) and cytotoxic 
manner (Seixas et al., 2009;Gozzelino et al., 2010;Larsen et al., 2010) promoting 
the development and progression of immune mediated inflammatory diseases, such 
as sickle cell anemia (Nagababu et al., 2008;Vinchi et al., 2013), malaria caused by 
Plasmodium infection (Pamplona et al., 2007) or severe sepsis caused by 
polymicrobial infections (Larsen et al., 2010;Gozzelino et al., 2012). Therefore, 
mechanisms controlling heme homeostasis are likely involved in the pathogenesis 
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of these diseases and probably others (Schaer et al., 2013;Gozzelino and Soares, 
2014). While the pathologic effects of “free heme” are most probably associated 
with its release from cell-free hemoglobin, we cannot exclude that other sources of 
heme might act in a similar manner, such as the heme released from myoglobin 
during the process of rhabdomyolysis (Nath et al., 1992). Current limitations in the 
methodological approaches allowing qualitative and quantitative analyzes of heme, 
when released from hemoproteins, have hindered the capability to determine 
unequivocally its pathologic effects as well as an eventual therapeutic targeting. 
This PhD Thesis aimed to overcome such limitations through the development of 
methodologies that would allow the qualitative and quantitative analyses of heme in 
biologic system.  
Abs have been extensively used for the development of bioassays (Engvall and 
Perlmann, 1971;Konishi et al., 1985) as well as for targeting potentially pathogenic 
molecules (Leavy, 2010), aiming to enhance human health (Elvin et al., 2013). 
Phage display technology has been recognized as a very powerful approach in the 
development and selection of Abs directed against a wide range of antigens 
(Chapter 1 Fig. 14 and 17) (Winter et al., 1994;de Kruif et al., 1995;Boel et al., 
2000;Benhar and Reiter, 2002;Gargir et al., 2002;Binyamin et al., 2003;Silacci et 
al., 2005;da Silva et al., 2008;Kim et al., 2008;Beer and Liu, 2012). Another 
important advantage related to this technique is the possibility to make an in vitro 
screen instead of in vivo, which is conventionally used in other antibody generation 
techniques. This does not require special equipment and has a higher flexibility and 
versatility in terms of the selection conditions and stringency (Hoogenboom, 
1997;Watters et al., 1997;Rodi et al., 2002). Once performed in vitro, the selection 
can be performed against biological as well as inorganic compounds (Whaley et al., 
2000;Kriplani and Kay, 2005). This was a crucial aspect to raise Abs against “free 
heme”. In addition, the traditional techniques for antibody generation rely on the 
injection of the antigen into a host, i.e. mouse, rat or rabbit and thus are to some 
extent limited by the toxicity of the antigen. As the administration of high dose of 
“free heme” are known to be cytotoxic (Larsen et al., 2010;Gozzelino and Soares, 
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2011), compromising the viability of the host, we use of phage display technology to 
generate Abs against heme.  
We decided to raise single domain Abs (of small size; about 15 kDa) against 
heme which can be generated based on the VH or VL domains of a classical 
antibody (Chapter 1 Fig. 16) and can be genetically manipulated thereafter. The 
single domain format offers several advantages when compared with conventional 
antibodies and other recombinant antibody fragments as the single-chain antibody 
(scFv) (Holt et al., 2003). These include higher capacity to recognize rather small 
epitopes in antigens or the ability to bind the active site of enzymes. In vivo, they 
were shown to have higher capacity of tissue penetration (da Silva et al., 2008), 
allowing their access to antigens localized or hidden in region difficult to reach by 
conventional antibodies. Production of sdAb can reach high levels without loss of 
solubility, be produced in different systems including bacteria. This makes their 
production simpler, faster and cheaper, as compared to full length antibody with 
limited expression efficiency in E. coli expression system (Mazor et al., 2007). 
Furthermore, the therapeutic applications of sdAbs were already demonstrated in 
several diseases (Harmsen and De Haard, 2007;da Silva et al., 2008;Wesolowski 
et al., 2009) and therefore we rationalized that this technology might offer a good 
alternative to more classical methods used for antibody production to target “free 
heme” in vivo (Chapter 2 Fig. 1).  
The development of sdAbs against heme could be further used to develop 
methodologies that would allow “free heme” quantification in biological system as 
well as its cellular detection. Recently, the VL single domain type has been 
described as a suitable alternative, although, the most common type of sdAbs used 
is VH single domain due to its well documented properties, such as high stability, 
production levels and binding efficiency. The first VL sdAbs with fully binding activity 
against huntingtin, a protein associated with the pathology of Huntington's disease 
were described and developed in 2004 by Colby and co-workers (Colby et al., 
2004). These sdAbs were presumably more stable and active than the associated 
VH single domain, suggesting that this type of single VL domain antibodies can be 
more efficient against certain antigen. This study provided evidences supporting the 
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usage of this type of domain, at least against certain type of antigens. This was 
further supported by other studies (Brinkmann et al., 1993;Kim et al., 2014). 
Therefore, as a first trial, we used a synthetic VL sdAbs phage display library for the 
selection of sdAbs against heme. Nevertheless, the VH single domain was also 
considered in case that no VL- sdAbs could be raised against heme. Amongst the 
different types of phage display libraries (da Silva et al., 2008) we decided to use a 
synthetic library of sdAbs since it allows the exact construction and controlled 
genetic manipulation of paratope sequences that are not present in the germline 
antibody repertoire. This is expected to provide higher and/or more stringent 
diversity amongst the sdAbs, therefore allowing to guide the sdAbs selection 
against new or challenging epitopes, such as heme, which are conceivably hard to 
select from naïve Abs. Besides that, these sdAbs frameworks can be genetically 
manipulated to decrease or inhibit sdAbs immunogenicity (e.g. by humanizing 
frameworks) and to improve not only the sdAbs stability but also the expression 
yields in different systems, such as bacteria. 
The VL synthetic library used in the sdAbs selection against heme has a high 
diversity range of 109 variants and was previously tested successfully to raise 
sdAbs against other targets, such as viral gp41 in HIV (Gonçalves et al, submitted) 
(Chapter 2, Fig. 1B and 1C). From these phage display screens, we were able to 
select and purify around eleven heme-binding sdAbs (Chapter 2, Fig. 1C and 1B). 
These sdAbs typically showed high expression and solubility in bacterial systems, 
and we could verify that the selected sdAbs had a high expression yield. However 
they displayed low solubility as assessed by their association with inclusion bodies. 
In order to improve the sdAbs solubility, we modified several expression conditions 
known to improve protein solubility in bacteria. These include different bacteria 
growth temperature, media, expression plasmid and strain; however no 
improvement was observed (data not shown). Consequently, we resorted to a 
purification method under denaturing conditions to collect sdAbs from the bacterial 
inclusion bodies and then processed to their renaturation. The denaturation 
approach used was based on a standard method in which the proteins are isolated 
from inclusion bodies by a series of sonication and centrifugations steps, followed 
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by solubilization using higher concentration of a solubilizing agent (6 M urea). 
These sdAbs contain cysteines in their backbone, therefore for the complete protein 
denaturation, it is highly recommended to add a reducing agent, such as β-
mercaptoethanol, for cysteine reduction and disulfide bond cleavage. The sdAbs 
were purified using a His trap column, which allows obtaining a high yield and a 
reasonably good quality of purified protein. We could also use a HA tag column to 
have a more pure protein, however the yield obtained is lower and the anti-HA 
antibody is expensive. Although we successfully obtained a higher yield of purified 
protein, the next step: protein folding, revealed to be the major challenge. We were 
confronted with substantial protein precipitation (> 90%) upon refolding, employing 
typical and widely used method for fast removal of the denaturing buffer to non 
denaturing, which promote protein folding (such as PD10 desalting column or 
Protein desalting spin columns). Therefore, we decided to use a step-wise dialysis 
method that although time consuming (several days) allows for protein folding. This 
step-wise dialysis protocol was slightly modified based on previously described 
methods (Tsumoto et al., 1998;Umetsu et al., 2003;Tsumoto et al., 2004;Tsybovsky 
et al., 2007). These included the initial removal of the reducing agent to promote 
thiol groups oxidation and consequently disulfide bond formation, followed by 
sequential overnight dialysis with decreased concentration of the solubilizing agent 
(urea) until complete removal and medium supplemented with additives, namely L-
arginine and oxidized/reduced glutathione in the antepenultimate and penultimate 
dialysis steps. The use of additives in the dialysis revealed to be crucial to promote 
protein stabilization and refolding (Tsumoto et al., 1998;Umetsu et al., 
2003;Tsumoto et al., 2004;Tsybovsky et al., 2007). Presumably, the beneficial 
effect of L-arginine relays in its capacity to interact with certain amino acids in the 
proteins, namely to aromatic side chains and predominantly to Tyr and Trp, leading 
to an increase of protein surface tension of water (Arakawa et al., 2007;Das et al., 
2007). This effect presumably prevents protein/protein interaction and aggregation 
(Arakawa et al., 2007;Das et al., 2007). On the other hand, the redox GSSG/GSH 
pair apparently promotes the folding of protein by thiol (RSH)-disulfide (R’SSR’) 
interchange reaction, leading to the formation of disulfide bonds and most probably 
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to the rearrangement of the secondary and tertiary protein structure. Further studies 
are required to better understand the molecular mechanisms that lead to their 
effectiveness. In this work, the improvement of the process of protein purification 
and recovery allowed us to obtain high yields of protein folding (>90%) with higher 
purity (Chapter 2 Fig. 1B), which was crucial to perform this project.  
The purified sdAbs were analyzed for their ability to bind heme, using an ELISA 
protocol in which hemin was coated on the plate. All the sdAbs bound heme in to a 
similar extent, with exception of sdAb 1E4. The negative control, which was a sdAb 
with the same backbone but raised against an irrelevant antigen, showed no 
binding, supporting the specificity of the sdAbs raised against heme. We analyzed 
further the binding of these sdAbs to heme using BIAcore which is a surface 
plasmon resonance (SPR) based technology, highly used in the studies of 
biomolecular interactions such as protein-protein, protein-DNA and allowing for the 
determination of their affinity parameters (Stenlund et al., 2006;Rich and Myszka, 
2008). The determination of heme binding affinity of the sdAbs allowed us to make 
a comparative study to other heme scavengers with known heme binding affinity 
constant (KD), such as hemopexin (KD=10
-12M) (Shipulina et al., 2000) and others 
with lower affinity such as human serum albumin (KD=10
-8M) (Adams and Berman, 
1980) and α1-microglubolin (KD=10
-6M) (Larsson et al., 2004). The heme binding 
curves, shown for sdAb 2H10 (Chapter 2 Suppl. Fig. 2) are representative of those 
obtained for all sdAbs and reveal that a fast on rate (association) for heme is 
followed by its considerable rapid rate of dissociation, suggesting that rapid “in and 
out” kinetics for heme. From a putative therapeutically perspective, the fast release 
of heme might be advantageous by facilitating heme excretion through the urinary 
track and/or for its metabolism by HO-1, contrarily to heme binders with a slow or 
limited dissociation rate. However, if desirable, the rapid dissociation constant can 
be limited or controlled though a more frequent and/or more concentrated sdAb 
administration. We could determine the heme affinity constant (KD) of the sdAbs as 
the association and dissociation constants fitted in a kinetic model of 1 to 1, which 
revealed that all the sdAbs bind heme with a similar affinity of 10-7 M with exception 
of sdAb 1E4 with the value of 10-5 M (Chapter 2 Fig. 1F). When compared with the 
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known extracellular heme binding protein, we verified that the sdAbs have a lower 
affinity than the major and most abundant known extracellular heme binding 
proteins in plasma: hemopexin, lipoproteins, human serum albumin, but higher than 
α1-microglobulin, suggesting that the sdAbs can only bind heme when it is not 
bound to those proteins. Therefore, sdAb most probably bind to heme only when it 
is bound to other proteins that have a heme binding affinity lower than 10-7M or 
when present in free form, which is unlikely to occur in vivo (Chapter 2 Fig. 1). We 
also need to consider that the sdAbs might not recognize heme in the hemoproteins 
because it is contained inside of them and therefore not accessible to the sdAb.  
Hemoproteins and heme scavengers contain a sequence of key amino acids 
that interact with heme, referred as Heme Binding Motifs (HBM). Amongst the most 
common HBM demonstrated to bind heme b, there are two recently proposed HBM 
Cys-Ser (CS) and Cys-Asn (CN) (Yang et al., 2010;Westberg et al., 2011) that we 
found in the region of heme recognition, in the CDR1 amino acid sequence of the 
sdAbs. The CS is present in sdAb 2H10 and CN in 2H7 (Chapter 2 Fig. 1F), which 
most probably participate in heme binding. In the sdAbs 2H10, there are other 
amino acids beside cysteine that might be involved in its binding to heme, namely 
tyrosine and lysine, as it is known that in certain hemoproteins tyrosine and lysine 
can participate as heme b axial ligands (Ferrer et al., 1993;Schneider et al., 2007;Li 
et al., 2011). We also identified a HBM correlated to the covalently binding of heme 
c in cytochrome P460, namely the CXXCK, in the sdAb1A6 (Chapter 2 Fig. 1F). 
However, this motif is most probably not correlated to the binding of heme to the 
sdAbs, since this binding requires the enzymatic activity of a chaperone to catalyze 
the thiol attachment of cysteines to the vinyl groups of heme as demonstrated in 
bacteria, archaea and plants (Verissimo et al., 2013). Instead, we propose a new 
HBM composed of the amino acids CK, responsible for heme b binding in this 
sdAbs. This hypothesis is supported by observation that in several hemoproteins 
both amino acids cysteine and lysine can act as axial ligands of heme-Fe (Ferrer et 
al., 1993;Rosell et al., 1998;Li et al., 2011). We however did not explore this 
hypothesis and thus further studies are required. This might include the 
construction of a range of mutated sdAbs by site directed mutagenesis at the levels 
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of the amino acids previously proposed to be in the HBM, followed by their 
functional analysis by ELISA, heme-biotin pull-down or BIAcore. Additionally, 
spectroscopic studies can be done in a similar manner to what was performed for 
the non mutated sdAbs (Wilks, 2002). Otherwise, we can collect detailed structural 
information on the original sdAbs bound to heme via Nuclear Magnetic Resonance 
(NMR) spectroscopy and X-ray crystallography, and thus further elucidate the 
structure-function of sdAb-Heme (Wilks, 2002). Furthermore, these techniques will 
allow us to identify the amino acids interacting with heme b and details of this 
interaction occurs. This might provide insights, once compared to genomic data, to 
the range of proteins that contain HBM.  
Another important characteristic of the sdAbs developed under this PhD work is 
the absence of the CDR3 region, even though the library used to select sdAbs 
against heme contains diversity in the range of 109 in which the variability is 
restricted to the antigen recognition CDR1 and CDR3 amino acid sequence in VL 
domains. During phage display screen against heme, there was an enrichment of 
sdAb that do not contain diversity in CDR3 amino acids sequence. We cannot fully 
explain why the selected sdAbs do not have this CDR3 sequence. However, 
preliminary results (data not shown) suggest that the initial library contained 
diversity of sdAbs with variability in CDR1 and CDR3 or only in their CDR1, 
therefore during the pannings the sdAbs containing variability in CDR1 were 
enriched while the other were removed. The diversity in this synthetic library, i.e. at 
the levels of CDR sequence and composition was most probably generated during 
the library construction. Diversity was generated in two different steps, first 
randomization in CDR1 and then in the CDR3 region; therefore it is possible that in 
some of the sdAb the diversity in the CDR3 was not successfully achieved 
(Gonçalves et al, submitted) and consequently some of the sdAbs only have 
diversity in their CDR1. This however was not investigated, hence further 
experiments are required and possibly re-calculation of the library diversity 
considering not only the diversity in the CDR but also the presence/absence of 
CDR3. The enrichment of sdAbs against heme without the CDR3, might be justified 
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by a higher sdAb stability and affinity upon heme binding or that the affinity of the 
sdAbs is negatively affected by the presence of the CDR3.  
We selected three sdAbs (1A6, 2H7 and 2H10) that recognize heme, of which 
sdAb 2H10 appears to be the most specific (Chapter 2 Fig. 1, 2 and 3). These 
sdAbs have different binding properties for heme (Chapter 2 Fig. 2 and 3; Table 1) 
that might be correlated with their different HBM in the CDR sequence., namely 
CXXCK or most probably CK for sdAb 1A6, CN for sdAbs 2H7 and CS (or CK; CY) 
for sdAb 2H10 (Chapter 2 Fig. 1F). Although, all the three sdAbs have a similar 
heme binding affinity, their interaction with heme is established by different heme 
epitopes. Our results shown that sdAb 1A6 interacts with heme independently of 
the presence of Fe and the availability of the propionate groups (Chapter 2 Fig. 2 
and 3; Table 1). This suggests an interaction with heme independent of the vinyl 
groups as well as the propionate groups, so other regions in the heme should 
interact with the sdAb. Further studies are required to understand this interaction 
and whether the presence of the CXXCK motif in the sdAb is required for heme 
interaction. The sdAbs inability to bind ZnPP might be correlated with its 
physicochemical properties. Indeed, this metal is commonly found coordinated with 
four ligands, establishing a tetrahedral molecular geometry and can only acquire an 
oxidation state Zn2+ and thus usually lacking redox activity. This might confer some 
inertiness to the protoporphyrin thus limiting its protein binding (Pace and 
Weerapana, 2014). On the other hand, the sdAb 2H7 can interact with ZnPP but 
not with empty PP, suggesting that the binding requires its interaction with central 
metal in the PP (Chapter 2 Fig. 2 and 3; Table 1). It was demonstrated that 
cysteines can coordinate with Fe but also with Zn and Co (Gavel et al., 2008;Pace 
and Weerapana, 2014). It is therefore possible that the cysteines are part of the 
HBM and can be coordinated with the Fe as well as with other metals in the 
protoporphyrin. The sdAbs 2H10 differs from the other sdAbs by its inability to bind 
to empty PP, ZnPP and to heme analog with propionate groups blocked by a 
methyl group, indicating that the binding to heme requires the simultaneous 
interactions of the sdAb with the Fe and the propionate groups of heme (Chapter 2 
Fig. 2 and 3; Table 1). We propose the cysteine of the HBM as one of the axial 
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ligands and lysine or tyrosine as another (Chapter 2 Fig. 4), however further 
studies are required to assess which amino acids interact with the propionate 
groups. We conclude from these assays that the sdAb 2H10 is the most specific for 
heme, a result that is further supported by its lack of interaction with the heme 
degradation products, biliverdin and bilirubin (Chapter 2 Fig. 2; Table 1). We also 
verified that this sdAb failed to recognize heme when contained within several 
hemoproteins (hemoglobin, myoglobin and cytochrome c) or even when bound to 
the heme scavenger, human serum albumin (Chapter 2 Fig. 3). This property of 
the sdAb prevents a possible toxic effect, if used in vivo, possibly caused upon 
binding to heme in hemoproteins that would presumably impair their biological 
function. Amongst several hemoproteins, we decided to test sdAb binding to 
hemoglobin and myoglobin as certain immune mediated inflammatory diseases are 
associated with hemolysis and accumulation of cell free hemoglobin in plasma 
(Pamplona et al., 2007;Larsen et al., 2010;Ferreira et al., 2011) or with 
rhabdomyolysis and myoglobin accumulation in plasma (Adornato et al., 1978;Nath 
et al., 1992). Besides that, both proteins can release their non-covalently bound 
heme b, presumably contributing to heme accumulation in plasma during those 
pathologic conditions and thus exacerbate disease severity (Adornato et al., 
1978;Pamplona et al., 2007;Larsen et al., 2010;Ferreira et al., 2011). We also 
tested cytochrome c because it contains heme c covalently bound to the protein. 
This hemoprotein is normally present in the outer surface of the inner mitochondrial 
membrane, however, in certain pathologies cytochrome c can be released into the 
cytosol, inducing caspase activation and subsequent apoptosis, followed by its 
release into blood (Jiang and Wang, 2004). Whether this effect is heme dependent 
is not clear, but this is likely the case given that the cytochrome c redox activity is 
required to support its pro-apoptotic effect (Pan et al., 1999;Suto et al., 
2005;Borutaite and Brown, 2007). Moreover, cytochrome c also accumulates in 
plasma in several pathologies, including systemic inflammatory syndrome (Renz et 
al., 2001;Adachi et al., 2004). The other protein tested was the heme scavenger 
albumin, the most abundant protein in the plasma, which binds heme transiently 
with one of the lowest heme binding affinity amongst the known heme scavengers 
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(Chapter 1 section 4) (Adams and Berman, 1980). Therefore, heme released from 
albumin should be more prompt to occur and then to be transferred/bound by 
sdAbs, for instance upon administration in vivo. However, this was not the case, 
suggesting that the sdAbs can only bind heme when it is in its “free” form or bound 
to heme binding proteins with an affinity for heme lower than 10-7M, such as α1-
microglobulin. We did not explore the ability of the sdAbs to bind heme in α1-
microglobulin, because this protein is not commercially available and its expression/ 
purification is challenging. 
In addition from testing the ability of the sdAs to bind heme immobilized into a 
solid surface (ELISA plates) (Chapter 2 Fig. 1E, 2 and 3) we confirmed the ability 
of these sdAbs to bind heme in solution, using a pull down assay with biotinylated 
heme (Chapter 2 Fig. 3A). To further characterize sdAbs binding to heme we 
applied spectroscopic methods, such as UV-Vis absorption spectroscopy, circular 
dichroism (CD), Fourier transform infrared (FTIR) and resonance Raman (RR). The 
use of these complementary techniques, allowed obtaining valuable information on 
the nature of the heme coordination, ligation and oxidation state as well as 
modification in the secondary structure of the sdAb 2H10. Briefly, UV-Vis absorption 
spectroscopy showed a characteristic UV-Vis features which originate from heme-
protein interaction. These include an intense band at around 400 nm, the so-called 
Soret band, and less intense bands (δ, Q0, and Q1 bands), providing information on 
Fe oxidation state. While the CD in far-UV region (>250 nm) gives important 
information about the secondary structure of the protein, the near in UV-Visible 
region provides structural information related to the integrity of the cofactor binding 
sites, such as heme in the proteins. We also employed vibrational spectroscopies, , 
FTIR that provides more detailed information of the secondary structure of the 
protein and RR spectroscopy, which upon excitation using 413 nm laser light 
reveals information specifically about the heme chromophore, its structural 
properties, such as coordination and spin state. We could conclude that heme 
bound to sdAb 2H10 is in a six coordinate low spin state; most probably involving a 
cysteine as the fifth ligand and possibly lysine or tyrosine as the sixth axial ligand 
(Chapter 2 Fig. 4B-E) (Li et al., 2011). Upon heme binding the secondary structure 
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of sdAbs composed mainly by anti-parallel β-sheets, undergoes conformational 
modification, generating new α-helices and/or disordered segments (Fig. 1). 
However, further studies are required to elucidate the complete structure of this 
complex, using, as previously mentioned, site direct mutagenesis followed by the 
several techniques that will provide detailed structural information (e.g. NMR 
spectroscopy or X-Ray Crystallography). 
 
 
Having shown that the sdAbs can bind heme, we then investigated their ability 
to detect heme in vitro by immunofluorescence microscopy (Chapter 2 Fig. 5A, D, 
F and 6) and Flow cytometry (Chapter 2 Fig. 5B, C, E). Both techniques could be 
successfully applied to detect endogenous heme in human HeLa cells (Chapter 2 
Fig. 5 and 6). We could show using the most heme specific sdAb 2H10 that “free 
heme” is mainly localized in the mitochondria (Chapter 2 Fig. 5F), while a small 
portion is in the endoplasmic reticulum (ER), (Chapter 2 Fig. 6B). This suggests 
 
Figure 1: 3D model structure of sdAb 2H10. This 3D structure was generated based on the 
amino acid sequence of the sdAb 2H10 against heme using SWISS-MODEL software 
(http://swissmodel.expasy.org/interactive).In CDR1 are highlighted in orange.  
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that cellular heme is predominantly found in the mitochondria where it is 
synthesized, while only a small portion of “free heme” is found in the ER where we 
can speculate that some heme is incorporated into the heme pocket of folded 
proteins (Chapman et al., 1997;Poulos, 2007;White et al., 2013). We also verified 
that cellular heme was localized in close vicinity of HO-1 (Chapter 2 Fig. 6D) and to 
a less extent in the vicinity of bilirubin (Chapter 2 Fig. 6E), a secondary 
degradation product of heme catabolism produced by the biliverdin reductase 
(Chapter 1 Fig. 9). These observations support the cellular localization of “free 
heme” in the region where it is catabolized by HO-1, where the substrate, enzyme 
and end-product can be found. We cannot exclude that heme might be localized in 
other organelles which were not tested in this work, including Golgi apparatus, 
exosomes, ribosomes amongst other, therefore allowing to better elucidate the 
cellular localization of heme and its biological role.  
As mentioned in the chapter 2 section 4, we cannot exclude the possibility 
that the cellular heme detected by the sdAb is heme that was released by 
hemoproteins denaturated during cell treatment, namely by methanol and/or 
detergent, used in immunoFluorescence/Flow Cytometry assays. Moreover, this 
treatment might also induce conformational changes in the protein structure, 
exposing their heme group thus recognizable by the sdAb.     
Heme cellular localization in different cell, such as red blood cells, renal cells, 
immune cells and other cell types should be address under normal, hemolytic or 
other pathologic conditions in which heme might be involved. This information will 
help to elucidate the pathologic effect exerted by cellular heme accumulation 
(Chapter 2 Fig. 7B), for example in pathologic conditions associated with 
hemolysis. We cannot exclude however, that these sdAbs may react with heme that 
is loosely or transiently bound to cellular proteins or to other biologic molecules with 
an affinity higher than 10-7 M.  
We further investigated whether we could use these sdAbs to develop 
methodologies allowing to overcome the current limitations in “free heme” detection 
and quantification, upon heme accumulation in plasma and/or tissues during 
immune mediated inflammatory disease associated with hemolysis As previously 
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mentioned in the chapter 2 section 4, the methods developed so far for “free 
heme” quantification have several limitations that compromise their efficiency and 
sensitivity in “free heme” detection. These include the method described in 
(Pamplona et al., 2007;Seixas et al., 2009), in which the plasma is filtered to 
remove proteins with a molecular weight higher than 3 kDa, followed by “free heme” 
quantification using a chromogenic assay. However, it cannot be excluded that in 
the collected fraction, there are no proteins or other molecules with low size (below 
3kDa) and heme binding capacity. Moreover, if heme is present as “free”, it can be 
retained by the filter used. On the other hand, the method used in (Larsen et al., 
2010;Gozzelino et al., 2012;Jeney et al., 2014) takes advantage of the peroxidase 
activity of heme alone or when associated to other molecules to measure total 
heme (Grinberg et al., 1999) as well as the UV-visible absorption of hemoproteins 
for hemoglobin quantification, allowing to access the amount of non-hemoglobin 
bound heme, i.e. “free heme” in plasma. The major limitations of this method are 
the variability of the peroxidase activity of heme upon its binding to the different 
molecules as well as the spectra of UV-visible of plasma is not specific for 
hemoglobin (Brill and Sandberg, 1968;Kuzelova et al., 1997;Zijlstra and Buursma, 
1997;Mauk et al., 2007;Nicoletti et al., 2008). For instance, the spectra of all 
hemoproteins or even heme scavengers have common features (soret, Q bands 
and CT bans) and for instance the peaks of spectra can vary with buffer, heme 
ligands and oxidation state.   
Therefore, the development of methodologies allowing “free heme” detection is 
crucial to understand the role of heme in the pathogenesis of those diseases. For 
that purpose, we adapted a well known and widely used biochemical assay, the 
sandwich ELISA, for heme quantification using the sdAbs (Chapter 2 Suppl. Fig. 
3). The assay was designed to have one of the sdAb as a capture antibody and 
another biotinylated sdAb with different heme binding properties, as an antigen 
detecting antibody. We used the sdAb 2H7 as the biotinylated antibody. We used 
this clone because biotinylation of an amide bond occurs at the primary amino 
groups of the amino acids, such as lysines and contrary to 2H7 the two other sdAbs 
contain lysines in the heme recognition region, i.e. in CDR1 sequence and 
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consequently biotinylation could interfere with their binding to heme (Chapter 2 Fig. 
1F). As a coating antibody, we choose sdAb 1A6 instead of 2H10 even though 
2H10 is the most specific against “free heme”. This choice was based on the heme 
binding properties of the sdAbs. The sdAbs 2H7 requires Fe for heme recognition 
similarly to sdAb 2H10, suggesting that both recognize the same heme epitope, 
namely the iron while the sdAb 1A6 does not. Therefore, while the sdAb 2H7 and 
1A6 do not share the same heme epitope, the same is not applied for sdAb 2H7 
and 2H10, and consequently the combination of both sdAb with similar heme 
binding properties most probably would interfered with each other heme binding in 
the ELISA assay (Chapter 2 Fig. 2; Table 1). This is consistent with the 
observation that the combinations 2H10/2H7-biotin provides a lower resolution for 
heme calibration curve in comparison to 1A6/2H7-biotin (data not shown). 
Altogether, this justifies the use of the sdAbs 1A6/2H7 based sandwich ELISA, with 
a linear range between 0.15-2.5 µM (Chapter 2 Suppl. Fig. 3).  
We then addressed the applicability of this method for quantification of “free 
heme” in plasma samples from healthy and hemolytic conditions. To address this 
question we used an experimental model in which acute hemolysis was induced in 
mice by phenylhydrazine (PHZ) administration (Itano et al., 1975). This drug 
induces hemolysis by promoting ROS production with intensive oxidative damage 
of RBC proteins. Moreover, PHZ promotes the formation of methemoglobin and 
consequently the release of heme group which accumulates in the plasma 
(Valenzuela et al., 1977;Berger, 2007). There are however, several caveats related 
to the use of PHZ to induce hemolysis, mainly due to a lack of knowledge about its 
effects in other cell types as well as possible side effect not related with hemolysis 
(Berger, 2007).  
The sandwich ELISA developed to measure “free heme” was combined to 
other methods, to further characterize and understand the role of heme during 
hemolytic conditions. These include total heme measurement, heme biovailability 
and the heme binding capacity of plasma. As some of these methods were 
developed for this work, we will briefly discuss their application and then discuss the 
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results obtained using those methods in the previously described hemolytic mice 
model.  
 Along the years, several methods, including formic acid assay (Kuross et al., 
1988;Regan et al., 2001), pyridine hemochromogen assay (Berry and Trumpower, 
1987) and fluorescence assay based on oxalic acid (Vinchi et al., 2013) were used 
for total heme quantification, i.e. heme bound or not bound to any other molecule. 
Taking in consideration those methods, we decided to use formic acid assay, 
although there is no consensus about the best and most appropriate technique to 
be used for this purpose. The formic acid assay has the main advantages of being 
easy and fast to perform without the requirement of special equipment or hazardous 
chemicals. Importantly, it allows to measure high number (>96) of samples 
simultaneously and independently of the sample type (e.g. plasma, tissues, cells). 
In contrast to this, the fluorescence assay requires the use of potentially dangerous 
chemicals but also the sensitivity of the assay is dependent of the sample/tissue 
(Shaklai et al., 1985). Moreover, porphyrins, including ZnPP and PP or other 
molecules that are fluorescent at the same wavelength, interfere with total heme 
measurement (Shaklai et al., 1985). The pyridine hemochromogen assay, similarly 
to the fluorescent assay, requires the usage of potentially dangerous chemicals and 
its sensitivity depends on the volume, sample heme concentration and the 
presence of lipids and/or photosynthetic pigments that can interfere with the 
measurements (Wilks, 2002). The usage of formic acid assay was further supported 
by the observation that the results obtained by this method were comparable with 
the ones determined by other methods (Spiller et al., 2011), including the 
fluorescence assay (Vinchi et al., 2013) for the same type of sample.  
To measure heme bioavailability, i.e. extracellular heme uptake by cells, as 
readout of heme accumulation in the cells that might be correlated with intracellular 
heme cytotoxicity, we adapted a previous assay referred as horseradish peroxidase 
(HRP) activity assay (White et al., 2013). In this assay, the reporter cells express 
HRP exclusively in the Golgi, that becomes active once “free heme” is provided and 
allows to establish when intracellular heme increases, which is  directly proportional 
to HRP enzymatic activity. To assure that the measurement depends exclusively on 
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exogenous heme, it is required to supplement the cells with succinylacetone, a 
potent competitive inhibitor of ALA dehydratase, the enzyme of heme biosynthesis 
(Chapter 1, section 2).  
The heme binding capacity assay was developed by adapting the previous 
sdAbs-based sandwich ELISA, to determine the heme binding/buffer capacity of 
plasma. The heme binding capacity is defined as the concentration of “free heme” 
required to reach half-saturation of the total heme binding capacity of plasma. 
Heme binding capacity is revealed when by providing increasing concentrations of 
heme to the plasma, presumably mimicking hemolytic conditions in which cell-free 
hemoglobin releases heme and allows it to bind to certain components of the 
plasma for a certain period of time. Once the heme binding capacity of plasma is 
saturated the excess “free heme” becomes available and is bound by sdAb-
sandwich based ELISA. The heme binding capacity of plasma is presumably 
provided by proteins, lipids or other molecules with an affinity higher towards heme, 
thus avoiding the detection of “free heme” by the sdAbs used in the ELISA. This 
newly developed assay should allow for the first time to assess whether under 
pathological conditions associated with hemolysis, the buffer capacity of the plasma 
is changed and test whether this might be correlated with the severity of the 
disease.   
Despite the accumulation of total heme in plasma during acute hemolysis 
induced by PHZ (Chapter 2 Fig. 7A), “free heme” remained undetectable (lower 
than 0.15 µM), as measured by the sandwich-based ELISA (Chapter 2 Suppl. Fig. 
3).  This result contradicts previous studies that described an increase of “free 
heme” associated with the pathology of hemolytic diseases (Pamplona et al., 
2007;Ferreira et al., 2008;Seixas et al., 2009;Larsen et al., 2010;Gozzelino et al., 
2012). As previously mentioned, this might be associated with limitations on the 
methodologies used for this purpose. Nonetheless, it was observed an increase in 
total heme as well as heme bioavailability during acute hemolysis (Chapter 2 Fig. 
7A and B) which is correlated with a decrease in the heme binding capacity of the 
plasma (Chapter 2 Fig. 7C). This is consistent with the notion that acute hemolysis, 
is associated with heme bioavailability which presumably leads to cellular heme 
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toxicity. Despite a transient decrease in plasma heme binding capacity, heme 
released from cell free hemoglobin is most probably always bound to plasma 
compound(s) with an affinity superior to 10-7 M, hence not detectable by the sdAbs 
based ELISA. This transient decrease in the heme binding capacity of plasma is 
followed by a rapid recovery to steady state (Chapter 2 Fig. 7C). Taking into 
consideration these results, we propose the existence of a tight regulatory 
mechanism for restoring systemic heme homeostasis. This mechanism is most 
probably mediated by heme scavenger proteins that by avoiding the generation of 
“free heme” inhibiting its cytotoxic effect. Most probably hemopexin do not 
participate in this mechanism, given that deletion of the hemopexin gene has no 
effect on the overall plasma heme binding capacity in mice (data not shown). 
Therefore, other heme binding proteins, such as albumin, might participate in this 
mechanism.  
Another important observation is that under homeostatic conditions, the heme 
binding capacity of the plasma is very high (104µM range) in comparison with total 
heme measured (101µM range). This further supports the existence of highly 
controlled regulatory mechanisms for maintenance of heme homeostasis that does 
not allow the accumulation of heme in the plasma as a free molecule. However, in 
very preliminary experiments, we observed “free heme” accumulation in urine of 
hemolytic mice, namely in the DBA/2 mouse strain infected with P. chabaudi 
chabaudi, at day seven after infection (parasitimia >60%). The concentration of 
“free heme” in these samples was about 3 µM (data not shown) suggesting that, 
although no “free heme” is detected in plasma, there is a mechanism of heme 
detoxification through the urinary tract. Therefore, the heme released from cell-free 
hemoglobin is not only eliminated by catabolic degradation by HO-1 (Chapter 1 
section 5.1) (Gozzelino et al., 2010), but presumably by its transport and excretion 
in the urinary tract This hints to a new mechanism for the maintenance of systemic 
heme homeostasis, preventing not only the presence of “free heme” in plasma but 
also its prolonged binding to heme scavengers. The undesirable binding of heme to 
some of its scavengers might be correlated to a mechanism to prevent the 
saturation of its scavenger and/or to avoid heme retention by them which might lead 
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to an increase or a low inhibition in heme reactivity and thus not preventing its 
deleterious effect. This hypothesis is supported by the observation that the 
peroxidase activity of heme is partially (50-60%) inhibited by albumin while greatly 
suppressed (80-90%) by hemopexin (Grinberg et al., 1999).  
We cannot exclude other possibilities for detecting heme in the urinary 
excretion, such as kidney damage which might lead to the release and 
accumulation of proteins (i.e. proteinuria), including hemoglobin that would release 
heme upon unfolding due to the high urea concentration, a natural inducer of 
protein denaturation (Hua et al., 2008). Another possibility is the presence of a 
specialized mechanism for heme release through the urinary track. Nevertheless, 
further studies are required to confirm these results and understand further the 
mechanism involved in this process. Future experiments should allow to understand 
whether “free heme” is generated by cell-free hemoglobin in the plasma or by the 
accumulation of hemoglobin in urine where the heme is released.  
In the present work, we have shown that upon hemolysis no “free heme” is 
detected in plasma but a small portion of heme is uptaken by cells, presumably 
leading to heme driven cytotoxity (Larsen et al., 2010;Gozzelino and Soares, 
2011;2014). Heme acts as pro-oxidant molecule (Chapter 1 section 6.1), leading 
to the formation of ROS, an effect that might justify the sensitization of cells to TNF 
mediated programmed cell death (Gozzelino et al., 2010;Larsen et al., 
2010;Gozzelino et al., 2012;Larsen et al., 2012). This notion is further supported by 
the observation that heme bound to certain lipids and proteins from cell membrane 
as well as lipoproteins, such as LDL, cause their oxidation with the production of 
highly toxic substances, such as lipid peroxidase, F2-isoprostanes (Balla et al., 
1991;Camejo et al., 1998;Jeney et al., 2002). For that reason, we assessed 
whether the sdAbs developed during this work would prevent the pro-oxidant effect 
of heme when released from hemoglobin. We performed an in vitro assay to verify 
the biological effects of the sdAbs once bound to heme. Indeed, sdAb 2H10 inhibits 
the pro-oxidant activity of heme (Chapter 2, Fig. 8A and B), as assessed by an 
ascorbate oxidation based assay. This inhibitory effect is even more efficient than 
the plasma heme scavenger albumin, at least on a mol-per-mol basis (Chapter 2 
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Fig. 8A and B). As previously mentioned, the anti-oxidant effect of sdAb might be 
particularly useful when envisioning the use of anti-heme sdAb as a therapeutic 
approach to target the pro-oxidant effects of extracellular and soluble “free heme”, 
presumably preventing its pathogenic effects. Besides that, this sdAb targets heme 
specifically, i.e. not contained in hemoproteins, avoiding a possible toxic effect upon 
sdAbs administration. Therefore, this approach should be less toxic when 
compared to others than might affect heme function in those hemoproteins 
(Pamplona et al., 2007;Gozzelino et al., 2010). Further tests in vivo, such as the 
sdAb treatment of mice models of immune mediated inflammatory disease 
associated with hemolysis, are needed to confirm whether this strategy is viable. 
We asked whether the anti-oxidant effect provided by the sdAbs could be 
complemented by inhibition of heme cellular uptake. The sdAbs 2H10 is inefficient 
to prevent heme cellular uptake, consistent with its inability to prevent heme 
sensitization to programmed cell death (Larsen et al., 2010;Gozzelino and Soares, 
2011) (Chapter 2 Fig. 8D). This contrasts with the high affinity heme scavenger 
hemopexin, which suppresses heme cellular uptake (Chapter 2 Fig. 8D) as well as 
heme driven cytotoxicity (Chapter 2 Fig. 8C). This may be explained by the higher 
affinity of cellular heme importers towards heme, e.g. HRG-1, HCP-1 or FLVCR2 
(Duffy et al., 2010;Le Blanc et al., 2012;White et al., 2013), as compared to the 
sdAb but not as compared to hemopexin. If this was to be the case, then heme may 
be transfer/deliver by the sdAb to these heme transporters. And as such these 
sdAbs might work as anti-oxidant soluble heme transporters rather that as heme 
scavengers, allowing for heme delivery to the cells and degradation by HO-1 
(Chapter 1 Fig. 7).  
In a future work, the sdAb we developed will be further improved, using 
standard procedures to increase affinity towards their cognate ligand (Barbas, 
2001). This would allow the generation of specific anti-heme sdAbs with different 
affinities and as such with the ability to remove heme from distinct compounds to 
which heme binds upon release from hemoproteins. For instance, heme binding to 
lipoproteins, such as LDL, promotes lipid peroxidation with the production of highly 
deleterious products (Balla et al., 1991;Jeney et al., 2002). Generation of sdAbs 
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with an affinity towards heme higher than LDL should avoid this effect and may 
therefore have beneficial effects in countering pathologic conditions in which LDL 
oxidation acts in a pathogenic manner. The same reasoning can be applied to other 
cognate interactions between heme and proteins and/or lipids in plasma. It is 
probably not desirable to develop sdAbs that bind heme with an affinity higher than 
the one of hemopexin since the removal of heme from this physiologic heme 
scavenger might have undesirable biological effects.  
 
In supplementary information, a preliminary work was developed to generate 
constructs based on the developed sdAbs, namely sdAbs 1A6 and 2H7. These 
constructs were obtained by incorporation of a CDR3 region into the sdAbs as well 
 
Figure 2: Model of heme distribution upon hemolysis according to the results obtained in 
this work. In homeostatic conditions, the plasma has a very high heme binding capacity (HBC) 
provided by proteins/lipids or other molecules with heme scavenger capacity. Upon hemolysis, 
cell free-hemoglobin releases its heme that is scavenged/bound by those heme scavengers, 
decreasing the HBC of the plasma. Besides that, some of the heme scavengers presumably 
transfer heme to the cells leading to an increase in intracellular heme that might be cytotoxic. 
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as by dimerization of the sdAbs (Supplementary Information Fig 1). Therefore, 
generating constructs with higher binding avidity (number of heme binding sites per 
sdAb) and with monospecificity or bispecificity characteristics, which might be 
therapeutically desirable (Supplementary Information).    
In conclusion (Fig. 2), this study reveals that anti-heme sdAbs can be used not 
only to detect cellular heme but also to quantify “free heme” in biological samples. 
In this thesis we also showed using a newly developed sdAbs-based assay coupled 
with other methodologies that, under hemolytic conditions, there is an increase of 
total heme associated with a cellular heme accumulation and a decrease of heme 
binding capacity in the plasma, which is rapidly recovered to steady state 
conditions. This heme accumulation in plasma and cells might act in a deleterious 
manner, contributing to the pathogenesis of the disease associated with hemolysis, 
Furthermore, we showed that anti-heme sdAb can modulate heme biologic activity, 
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Single domain antibodies (sdAbs) can target biologic compounds involved in a 
variety of pathologic conditions. However, their small size might compromise 
antigen functional affinity, due to a decrease in avidity. To overcome this limitation, 
sdAbs can be engineered to combine two domains, such as variable light chain 
(VL)-VL domains through a flexible linker thus increasing their avidity (and 
molecular weight) and maybe stability and their intrinsic affinity, which might be 
desirable in certain therapies. In this work, we show preliminary results of 
engineered sdAbs into a multidomain antibody (dimer) as well as sdAbs with a 
CDR3 recognizing heme region, based on the previously described sdAb 1A6 and 
2H7 developed against “free heme” (Chapter 2). Moreover, the engineered sdAbs 
were developed to be monospecific or bispecific, which might improve heme 
recognition. Their constant binding affinity for heme (KD=10
-7M) is similar to the 
parental sdAbs, but with an increased avidity, as expected. Amongst the 
engineered sdAbs, the specificity for heme was tested for CDR1-CDR3 2H7-2H7, 
revealing a decrease in specificity, as compared to parental sdAb 2H7, in that this 
sdAb acquired the capacity to recognize free heme without its iron. Further studies 
are required to better characterize heme binding by all sdAbs constructs as well as 
their possible applications.  
 
2. INTRODUCTION 
Engineering of antibodies to low weight functional antibodies fragment (~15 kDa), 
also known as single domain antibodies (sdAbs), offers several advantages in 
comparison to higher molecular weight conventional antibodies (150-160 kDa) or 
other recombinant antibody fragments (Chapter 2) (Gronwall and Stahl, 2009). 
These include high stability independently of the CDR variability, high expression 
levels or increased solubility and capacity of tissue penetration in vivo. Besides that, 
they are easy and low cost to produce and purify (da Silva et al., 2008). These 
characteristics make them suitable for different biotechnological and therapeutic 
applications. However, decreasing their size to the minimum possible also 
decreases their antigen recognition site, i.e. CDRs, eventually compromising 
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antigen functional affinity, also referred as binding avidity. This limitation can be 
overcome by protein engineering and recombinant DNA technology used for sdAb 
assembling into stable multimeric antibodies with high binding avidity and specificity 
(Holliger and Hudson, 2005;da Silva et al., 2008). These include the generation of 
single chain variable fragments (scFv) usually with two variable domains, light (VL) 
and heavy (VH), joined by a flexible polypeptide linker composed by serines and 
glycines (Bird et al., 1988;Kortt et al., 2001;Simmons et al., 2006;Gronwall and 
Stahl, 2009;da Silva et al., 2012). The scFv has typically a molecular weight of 30 
kDa and a higher antigen functional affinity provided by multiple antigen binding 
sites, i.e. increased avidity. Generally, these type of antibodies are designed to be 
monospecifc, however, they can also be engineered to be bispecific, recognizing 
two different adjacent epitopes in the same antigen which improves their avidity (da 
Silva et al., 2008;Glaven et al., 2012). Alternatively, they can cross-link two different 
antigens which might be advantageous in therapeutic applications (da Silva et al., 
2008;da Silva et al., 2012). In summary, by antibody engineering it is possible to 
fine-tune diverse antibodies features, such as avidity, valency, stability, molecular 
weight and their intrinsic affinity, which all might be desirable therapeutically.  
In this study a panel of constructs were developed based on the previously 
described sdAb 1A6 and 2H7 generated to target “free heme”, a highly reactive 
molecule that contributes critically to the pathogenesis of hemolytic conditions, as 
demonstrated for sickle cell disease (Belcher et al., 2014), malaria (Pamplona et al., 
2007;Ferreira et al., 2011a) or severe sepsis (Gozzelino et al., 2010;Larsen et al., 
2010) (Chapter 2). These include the generation sdAb multidomains, namely 
dimers with a similar size of the scFv and the incorporation of a CDR3 region into 
these sdAbs composed by the amino acids from the CDR1 region of the sdAb 1A6 








3.1 Generation of different constructs of based on previously described 
sdAbs 
Several constructs based on sdAbs 1A6 and 2H7 (Chapter 2) were designed 
simultaneously. These include, four single-chain variable fragments (sc-Fv) 
generated by dimerization of the sdAbs 1A6 and 2H7 through a linker fragment 
composed by glycines (G) and serines (S) in a total 18 amino acids; S G G G G S 
G G G G S G G G G S S G. Other four construct were developed to incorporate into 
the structure of sdAbs 1A6 and 2H7 a CDR3 region that corresponds to the 
previously determined CDR1 sequence of the sdAbs 1A6 and 2H7 (Fig. 1). 
 
Finally, one scFv was generated from the dimerization of two sdAbs containing 





FIGURE 1. Generation of sdAbs constructs. The sdAbs constructs were designed based on the sequences 
of the sdAbs, 2H7 and 1A6 raised against heme (Chapter 2). The CDR1 dimers, also referred as scFv were 
constructed by overlapping PCR of the two sdAb sequences, covalently linked with a long peptide linker of 18 
aminoacids (SGGGGSGGGGSGGGGSSG). The monomers CDR1CDR3 were synthesized by NZYTech® as 




3.2 Constructs expression in different bacteria strains and their purification 
To improve the expression of the different constructs in a bacterial expression 
system, we used different bacterial strains of E. coli known to provide optimized 
conditions for protein expression (Fig. 2). These include the bacterial strains “BL21 
codon plus” that provides tRNAs rarely used in E. coli  , “Tuner” and “Shuffle”, the 
latter being engineered to provide  favorable conditions in the bacteria cytoplasm 
for disulfide bond formation of proteins. The ratio between the protein expressed 
upon induction compared to its base line reveals that between all the constructs 
tested, including the parental sdAb 1A6 and 2H7, the best is obtained for the 
“Shuffle” strain. Therefore, the protein expression for protein purification was 
performed in this bacterial strain (Fig. 2A). The construct expression in larger scale 
(1 liter) shown a higher expression of the protein, however restrained to the 
inclusion bodies fraction (data not shown). For that reason a denaturating protocol 
for protein purification was used followed by the re-folding using a method for fast 
removal of the denaturing buffer to non-denaturing (Fig. 2B). This method led to 
higher percentage of protein precipitation (>90%), however for most of the construct 
it was possible to recover protein aliquots with a concentration of around 1 mg/mL, 
while for CDR1CDR3 2H7-2H7 construct was aliquots of 3 mg/mL (data not 
shown). The issue related with protein precipitation can be overcome by using a 
step-wise dialysis, as shown for the parental sdAbs (Chapter 2). Furthermore, the 
purification protocol used leads to protein purity of about 90% as assessed by SDS-
PAGE (Fig. 2B). This assay also confirms the molecular size of CDR1CDR3 
monomers of about 20kDa, an increase of about 3kDa in comparison to the 
parental sdAbs 1A6 and 2H7 matching expected size of the incorporated CDR3 
region (Fig. 2B). The CDR3 dimer is approximately 40 kDa as it was generated by 
the combination of two CDR1CDR3 monomers (20kDa) while the CDR1 dimers are 







FIGURE 2. Protein expression in different bacteria strains and their purification. (A) The ratio 
between the protein expression upon induction in comparison to the same protein in non inducing 
conditions using the bacterial strains BL21codon plus, tunner and Shuffle. The constructs expressed were 
the dimers and the parental sdAb 1A6 and 2H7. (B) SDS-PAGE of purified constructs detected by 
coomassie-based stain or by western blot using an anti-HA mAb. 
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In the western blot, the lower bands observed for some of the constructs might be 
due to some extent to protein degradation and to the expression of a ~17kDa sdAb 
without the ~2kDa peptide leader (MKKTAIAIAVALAGFATV), similarly to the 
parental sdAbs (Fig. 2B) (Chapter 2 Fig. 1D).   
 
3.3  Heme Binding 
 
The binding of these engineered proteins were assessed by ELISA using an ELISA 
plate coated with heme, showing that all of them can bind heme in a similar manner 
that the parental sdAb 2H7 with exception of the dimer 1A6-1A6 (Fig. 3A, B). 
These results were confirmed by surface plasmon resonance (SPR; BIAcore 
system) (Fig. 3D) and their affinity constant (KD) for heme determined (Fig. 3C). 
The KD of the different constructs are around 10
-7 M, similar to what was obtained 
for the parental sdAb 1A6 and 2H7. The 2H7-2H7 and 2H7-1A6 dimers as well as 
the CDR1CDR3 1A6-1A6 show a drop in KD to 10
-6 M (Fig. 3C). The kinetic of 
heme binding to construct CDR1CDR3 2H7-2H7, which is representative of all the 
others (Fig. 3D), revealed a fast on-rate (association, 100 to 300s) for heme 
followed by a considerable fast off-rate (dissociation, 300 to 900s), similarly to the 
parental sdAbs. These results suggest that while the constructs can scavenge 
rapidly heme, they are also prone to release it.   
Although the heme binding affinity of the constructs does not increase 
compared to the parental sdAbs, they display a higher functional affinity, also 





FIGURE 3. Binding to heme (A) Relative binding of CDR1CDR3 monomers and dimers to heme detected 
by ELISA in comparison to the parental sdAb 2H7. (B) Relative binding of dimer to heme detected by 
ELISA. (C) Binding affinity of construct towards heme, determined by BIAcore surface Plasmon resonance. 
(D) Sensogram of heme binding to CDR1CDR3 2H7-2H7. For the determination association and 
dissociation kinetic rate constants, used to calculate the constant of affinity (KD) from the sdAb was 
immobilized in a CM5 chip using amine coupling at ∼800 resonance units (RU) and different concentration 





3.4 Specificity of the sdAbs constructs 
The specificity towards heme was determined for one of the constructs, the 
CDR1CDR3 2H7-2H7 (Fig. 5). The specificity for the other constructs will be 
determined in future work. For the determination of specificity, a previously 
developed ELISA (chapter 2, section 3.2) was used, in which the sdAbs 
CDR1CDR3 2H7-2H7 was pre-incubated with heme (Iron protoporphyrin; FePP), 
PP IX (PP; the metal-free precursor of heme), zinc PP (ZnPP, produced 
physiologically by ferrochelatase during iron deficiency), cobalt PP (CoPP, contain 
a Co instead of Fe), gallium protoporphyrin (PP) IX (GaPP; a non-iron metalled 
porphyrin containing a similar sized but redox inert gallium atom) or tin PP (SnPP, 
containing Sn instead of Fe) (Fig. 4).  
Pre-incubation of the CDR1CDR3 2H7-2H7 with all the heme analogs inhibit its 
binding to heme (Fig. 5A), while the sdAb 2H7, previously described does not 
recognize PP (chapter 2, Fig. 2). Apparently, the insertion of the CDR3 region 
modify its specify when compared with the sdAb 2H7. These results suggest that 
the central metal is not essential for heme recognition as well as Fe redox state as 
shown by the recognition of GaPP.  
To verify the influence of porphyrin side chains in heme recognition, the 
CDR1CDR3 2H7-2H7 was pre-incubated with Fe mesoporphyrin IX (MesoP) or Fe 
deuteroporphyrin IX (DeutP), synthetic heme derivatives in which the vinyl group 
was protonated or removed from heme, respectively (Fig. 4). The Fe 
tetraphenylporphyrin (FeTPP), a synthetic heterocyclic molecule that resemble 
heme (Fig. 4) was also tested. The synthetic heme derivates were recognized by 
the constructed with exception of the FeTPP, suggesting that heme recognition 
involves a carboxylic acid of one of the two propionate side chains or that the 
presence of the phenyl groups might inhibit its recognition (Fig. 5B). To access 
whether the propionate group of heme are essential for heme recognition by this 
CDR1CDR3 2H7-2H7, the heme analog FePPCH3 should be used, as in Chapter 
2 section 3.1. The recognition of biliverdin and bilirubin, two end-products of heme 
degradation by heme oxygenase-1 and biliverdin reductases, respectively, were 





To test whether the CDR1CDR3 2H7-2H7  can recognize heme when 
incorporated in proteins, it was pre-incubated with Hemoglobin, oxidized 
hemoglobin (MetHb), myoglobin (Mb), albumin containing heme b or cytochrome c, 
which demonstrated that it failed to recognize heme bound to  proteins (Fig. 5D). 
This suggests that, similarly to the sdAb 2H7 that was used to generate this 




Figure 4. Structure of the different heme analogs (A) Heme (FePP, ChEBI: 50385) and heme analogs  
PP (ChEBI: modified 50385), ZnPP, CoPP, GaPP and SnPP as well as MesoP (ChEBI: 50385), DeutP 
(ChEBI: modified 50385) and FeTPP(CAS mol: 16456-81-8). The heme degradation end product biliverdin 
(BV, ChEBI: 17033) and bilirubin (BR, ChEBI: 16990) are also represented (B) Crystalographic structure of 
Hemoglobin, myoglobin,, Cytochrome c and human serum albumin bound to heme (HSAH) and their 
respective protein data base  (PDB) code .  
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We cannot exclude however, that this CDR1CDR3 2H7-2H7 might recognize heme 






Figure 5. CDR1CDR3 2H7-2H7  heme binding specificity to heme, its analogs and hemoproteins. (A-
D) Increasing concentrations of different compounds were tested for their ability to interfere with 
CDR1CDR3 2H72H7 binding to solid phase bound heme, as measured by the ELISA. (A) PP, ZnPP, 
CoPP, GaPP and SnPP. (B) MesoP, DeutP, FeTPP(C) Hb, oxidized Hb (MetHb), Mb, Cytochrome c (Cytc) 
and human serum albumin bound to heme (HSAH). Hemin (FePP) was used as a positive control. Data 




4. DISCUSSION  
SAbs targeting specifically “free heme” were developed and characterized for their 
specificity for heme and heme-sdAbs binding, using a combination of different 
biochemical techniques (UV-visible, Resonance Raman, Circular Dichroism and 
Fourier transform infrared spectroscopy), revealing that sdAbs bind specifically to 
“free heme” (Chapter 2). When released from hemoproteins heme acts as a 
pathogenic compound and becomes vasoactive (Belcher et al., 2014), 
pro-inflammatory(Graca-Souza et al., 2002;Figueiredo et al., 2007) and 
cytotoxic(Seixas et al., 2009;Gozzelino et al., 2010;Larsen et al., 2010), therefore 
promoting the pathogenesis of hemolytic diseases such as sickle cell 
disease(Ghosh et al., 2013;Vinchi et al., 2013;Belcher et al., 2014), 
malaria(Pamplona et al., 2007;Ferreira et al., 2011b) or severe sepsis(Larsen et al., 
2010). These sdAbs were then used to developed bioassays allowing quantitative 
analyzes of “free heme” in biologic samples as well as the detection of cellular “free 
heme”. We also demonstrated that these sdAbs can be used to suppress the labile 
redox activity of “free heme”, which may be relevant when targeting it 
therapeutically (Chapter 2). In the present work, antibody engineering was used to 
developed new constructs based on previously described sdAbs 1A6 and 2H7, 
although the sdAb 2H10 shown to be the most specific against heme (Chapter 2). 
Thus future work should aim at developing new constructs based on this sdAb and 
assess their biologic function. We expect these new constructs to display high 
binding avidity for heme, presumably important for heme-specific targeting. Besides 
that, the stability and expression of these sdAb might be significantly improved. In 
this preliminary work, the several constructs were generated by dimerization of the 
sdAbs 1A6 and 2H7 as well as by the incorporation of a CDR3 region into the 
original sdAbs 1A6 and 2H7 (Fig. 1).   
The incorporation of the individual sdAbs into a dimeric format produced a 
protein with approximately 30 kDa, similar to a scFv. These constructs were 
designed to be monospecific, such as dimers 1A6-1A6 or 2H7-2H7 or bispecific, 
such as the dimers 1A6-2H7 or 2H7-1A6. The bispecific constructs were designed 
with two different order in their protein sequence, first sdAbs 1A6 followed by 2H7 
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and vice-versa, since it might influence the functionality of the construct. However, 
we did not assess this question and further studies are required (Fig. 1). All dimeric 
constructs contain a flexible glycine-serine linker joining them, allowing flexibility 
between the two domains which might be advantageous for their interaction with 
the antigen, however a higher flexibility might also promote the occlusion of the 
binding site to the antigen (Fig. 1). In this work, the linker used seems to affect 
heme recognition by the dimers (Fig. 3). 
Other constructs were developed to accommodate in their structure a CDR3 
sequence, similar with the CDR1 sequence of sdAbs 1A6 or 2H7, generating 
monospecific or bispecific monomeric sdAbs. These constructs have similar 
number of heme binding sites, as compared to equivalent dimers, with exception of 
CDR1CDR3 1A6-2H7, which has four heme binding sites (Fig. 1) and presumably 
the highest functional affinity (avidity) of all sdAbs we have generated. Whether, it is 
more advantageous to have a dimer of sdAb or to incorporate the CDR3 into the 
sdAbs remains to be elucidated.  
Heme recognition by these constructs was assessed by ELISA, showing that 
all contructs can bind heme in a similar manner, as compare to the parental sdAb 
2H7 (Fig. 3). The binding affinity of these constructs was determined, revealing that 
they have a similar affinity in the range of 10-7 M, as compared to the parental 
sdAbs (Fig. 3). Interestingly, sdAbs coupling did not modify their affinity, as 
compared to their parental constructs. However, the dimerization as well as the 
incorporation of the CDR3 region with ability to bind heme, presumably leads to an 
increase in their overall avidity.  Furthermore, the kinetic curve of heme binding 
show a fast rate of association/dissociation, similar to the parental sdAbs (Fig. 3D). 
Although the constant binding affinity is maintained, presumably the heme binding 
avidity increases from one to two and to four with monospecificity/bispecificity 
properties, respectively. Amongst the constructs developed, CDR1-CDR3 2H7-2H7 
was selected to assess their specificity for heme, based on an empirical 
observation in which this construct appears to be the highly stable, with high yield of 
protein expression/production. The specificity of other constructs should be 
determined in future work. The CDR1-CDR3 2H7-2H7 shown to be able to 
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recognize heme analogs, including DeutP but not FETPP (Fig. 5), suggesting that 
the carboxylic groups of heme are required for heme recognition. Alternatively, 
FETPP might be inaccessible to the construct due to a change in the protoporphyrin 
structure with implication in their physical/chemical properties. Similarly to the 
parental sdAbs,  2H7 does not recognize end-products of heme degradation by HO-
1 (Fig. 5C), as well as heme once bound to the hemoproteins tested (Fig. 5D), 
therefore avoiding any putative cytotoxicity associated to heme binding in 
hemoproteins which might compromise their biologic activity.  The characterization 
of these constructs requires further experiments (chapter 2), including the study of 
their biological effect upon heme targeting. 
In conclusion, these preliminary results suggest that it is possible to engineer 
sdAbs into multimeric proteins without losing their ability to target heme, which 
might be therapeutically advantageous.  
 
5. EXPERIMENTAL PROCEDURES 
 
Tetrapyrroles preparation - Concentration of different tetrapyrroles (Frontiers 
Scientific®, Utah, USA) in solution was determined spectrophotometrically using 
appropriated solvents. Briefly, heme (i.e. hemin) stock solutions were prepared in 
0.1 M NaOH, buffered with 0.1 M HCl to pH 7.4. Alternatively, hemin was diluted, as 
for all other tetrapyrroles, in dimethyl sulfoxide (DMSO). Hemin concentration was 
determined at λ405nm using a extinction coefficient (EmM) of 85.82, DeutP (λ392nm; 
EmM=170),  MesoP (λ394nm; EmM=170) and GaPP (λ413nm, EmM=249) (43). PP (λ408nm; 
EmM=297) concentration was determined in 1.5 M HCl (43), ZnPP (λ415nm; EmM=150) 
in ethanol (43); biliverdin (λ377nm; EmM=51.5) in methanol (44) and bilirubin (λ451nm, 
EmM=60) in chloroform (45). CoPP, SnPP, FeTPP and CoTPP concentrations were 
calculated gravimetrically according to their molecular weight (MW) =654.6, 750.26, 
679.99, 704.02 and 707.1, respectively.  
 
Generation of VL domain containing CDR3 sequence, i.e. CDR1-CDR3 
monomer – amino acid sequences of the sdAbs constructs, i.e. CDR1-CDR3 
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monomer were designed by Frederico Aires-da-Silva and Zélia Gouveia based on 
determined sequences of the sdAbs 1A6 and 2H7. Briefly, the sequence of the 
CDR1 of sdAbs 1A6 or 2H7 was inserted in the region of the CDR3 of the sdAbs 
1A6 or 2H7, generating the represented sdAbs constructs (Fig. 1). The gene 
sequence of these constructs was synthesized by the company NZYtech with a 
E.coli  codon usage optimized  and cloned into a pUC57 vector. The sequences of 
each construct were flanked by NheI and XhoI (New England Biolabs) sites. The 
DNA sequence of the constructs was digested in NheI and XhoI and cloned into a 
bacterial expression vector pET28a. The sdAbs used in this work were 
characterized in the Chapter 2. 
 
Generation of single chain variable fragments (scFv) with the format VL-VL 
containing CDR3, i.e. CDR1-CDR3 dimer 1A6-2H7 (Fig. 1) – The amino acid 
sequence of the these sdAbs constructs, i.e. CDR1-CDR3 monomer was designed 
by Frederico Aires-da-Silva and Zélia Gouveia based on determined sequences of 
the sdAbs 1A6 and 2H7. A linker encoding the 28 amino acid; G T E L E I L S G G 
G G S G G G G S G G G G S S G R L L was used to connect the two sdAbs CDR1-
CDR3 monomer 1A6-2H7, in which the CDR3 sequence of the sdAb 1A6 contains 
the sequence corresponding to the CDR1 sequence of sdAb 2H7 (Fig. 1). The 
gene sequences of these constructs were synthesized by the company NZYtech 
with an E.coli codon usage optimized and cloned into a pUC57 vector. The cloning 
into bacterial expression vector pET28a was performed as above. The sdAbs used 
in this work were characterized in the Chapter 2. 
 
Generation of single chain variable fragments (scFv) with the format VL- VL 
based on the original sequence of the sdAb 1A6 and 2H7, i.e  CDR1 Dimers 
(Fig. 1) –  For first sdAb, each sdAbs 1A6 and 2H7 DNA sequence was amplified 
by specific oligonucleotide primers covering all their sequence. The forward primer 
was preceded by a Nhe I site, while the reverse primer was followed by a linker 
encoding the 28 amino acid; G T E L E I L S G G G G S G G G G S G G G G S S G 
R L L and NotI and XhoI site. The amplified sequence was purified, digested and 
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cloned into the NheI/XhoI (New England Biolabs) sites of the bacterial expression 
vector pET28a. For DNA sequence amplification of the second sdAb, other specific 
oligonucleotide primers covering each of sdAbs 1A6 and 2H7 DNA sequences were 
used. These include, a forward primer preceded by a NotI site and a reverse primer 
followed by a stop codon and an XhoI site. These sequences were purified, 
digested and cloned into the NotI/XhoI sites of the pET28a containing the sequence 
of the first sdAb. The sdAbs used in this work were characterized in the Chapter 2. 
 
SdAb constructs expression and purification – The sdAbs constructs cloned in 
a pET28a expression vector were transformed in the strains E. coli BL21-
CodonPlus(DE3), Tuner and SHuffle T7 (NEB) cells and sequences were confirmed 
(Macrogen DNA Sequencing service), before expression and further purification. 
For protein expression in small scale, a 3 mL of Super Brown (SB) medium was 
inoculated with one colony of the transformed bacteria with pET28a -constructs 
plasmids with the appropriated antibiotic (Kan) grown to exponential phase 
(600nm=0.6-0.9) at 37ºC. Expression was induced by the addition of 1mM isopropyl 
β-ᴅ-1-thiogalactopyranoside (IPTG) and growth during overnight at 37ºC. Cells 
were harvested by centrifugation (2800g for 15 min at 4 ºC) and resuspended in 
500 µL of 20% BugBuster® Master Mix (Novagen) in PBS supplemented with 
protease inhibitors (Roche). The protein extract was collect from the supernatant by 
centrifugation (2800g, 15 min., 4ºC). The expression of the protein was evaluated 
by ELISA using anti-Human influenza hemagglutinin (HA) as the sdAbs contain a 
HA tag. For protein expression in large scale,  one liter of LB, containing 50 µg/mL 
carbenicillin was inoculated with 10 mL of overnight culture of SHuffle T7 bacteria 
cells transformed with pET28a -constructs plasmids and grown to exponential 
phase (600nm=0.6-0.9) at 37ºC. Expression was induced by the addition of 1mM 
IPTG and growth during 6 h at 37ºC. Cells were harvested by centrifugation (4000g 
for 15 min at 4 ºC) and resuspended in 50 mL equilibration buffer (50 mM HEPES, 
1 M NaCl, 5 mM CaCl2, 10 mM imidazole, pH 7.8) supplemented with protease 
inhibitors (Roche). Cells were lysed by sonication (20min., on ice) and the inclusion 
bodies containing the sdAbs were recovered by centrifugation (12096g, 30 min., 
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4ºC). Then, the pellet was washed (50mM HEPES, 1M NaCl,10mM imidazole, 5mM 
CaCl2, 2M urea, 1mM -mercaptoethanol (-ME) pH 7.8), sonicated (20 min., on 
ice) and collected by centrifugation (12096g, 30 min., 4ºC). The inclusion bodies 
were then re-suspended in a 6 M Urea buffer containing benzonase (>250U, 
Sigma)(50mM HEPES, 1M NaCl, 10mM Imidazole, 5mM CaCl2, 6M urea, 1mM -
ME, pH 8.0) and incubated overnight (4ºC, under agitation) for protein denaturation. 
Next day, the denatured sdAbs were purified under denaturing conditions using a 
His Trap Fast Flow (FF) column (GE Healthcare), and washed twice with 20 and 30 
mM of imidazole to remove contaminants (i.e. non specific proteins)(50 mM 
HEPES, 1M NaCl, 6M Urea, 1mM -ME, 5mM CaCl2, and 20 or 30 mM Imidazole 
pH 7.8). The sdAb were eluted in highly concentrated imidazole buffer (50 mM 
HEPES, 1M NaCl, 500 mM Imidazole, 6M urea, 1mM -ME, 5mM CaCl2, pH 7.8). 
Re-folding was done using a method for fast removal of the denaturing buffer to non 
denaturing (50 mM Tris-HCl, 200 mM NaCl, 0,1 mM EDTA, 10% Glycerol, pH 8.5), 
namely desalting PD10 desalting to promote protein folding. The refolded proteins 
were then centrifuged to remove protein precipitates (4000g, 4ºC, 10 min.), 
aliquoted and stored (-80ºC) until used. The purity of the sdAbs was assessed by 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel with 
15% acrylamide composition under denaturating conditions followed by based 
coomassie stain (Instant Blue, Gentaur, 30 min., RT) or by Western blotting using 
an Horseradish labeled anti-HA  (clone 3F10, Roche). 
 
Protein expression analysis by ELISA – SdAb constructs collected from the 
supernatant of small scale expression were incubated in a 96 well ELISA plates 
(Costar 3690) (2h, RT), washed (3x, PBS, 0.1% Tween 20) and blocked in protein 
free blocking buffer (Pierce; 1h, RT). The sdAbs constructs were detected using a 
rat anti-HA mAb (3F10; Roche; 0.1µg/mL in protein-free blocking buffer). Plates 
were washed (5x, PBS, 0.1% Tween 20) and the primary mAb was detected using 
an alkaline phosphatase labeled rabbit anti-whole rat IgG (Sigma) polyclonal Ab (1 
hour, RT) diluted (1/2000) in protein free blocking buffer. Alkaline phosphatase was 
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revealed with para-Nitrophenylphosphate (pNPP, 1mg/mL; Sigma). To evaluate the 
total amount of protein, sdAb were coated in 50 mM carbonate/bicarbonate, pH 9.6 
(1h; RT or 16; 4ºC) in 96 well ELISA plates (Costar 3690) and the rest of the 
procedure was performed as described above. Absorbance was measured in a 
microplate reader at 450nm (Vitor 3 luminometer; Perkin Elmer). 
 
ELISAs to screen sdAb constructs for heme recognition - 96 well ELISA plates 
(Costar 3690) were coated with hemin (100µM) in carbonate buffer (0.1M NaHCO3, 
pH 8.6)(1h, RT or overnight at 4ºC), washed (3x, PBS, 0.1% Tween 20) and 
blocked in protein free blocking buffer (Pierce; 1h, RT). Plates were washed (4x, 
PBS, 0.1% Tween 20) and purified sdAbs diluted in PBS were added (1h 30 min., 
RT). Plates were washed (5x PBS, 0.1% Tween 20) and heme-bound sdAbs were 
detected using a rat anti-HA mAb (3F10; Roche; 0.1µg/mL in protein-free blocking 
buffer). Plates were washed (5x PBS, 0.1% Tween 20) and the primary mAb was 
detected using an alkaline phosphatase labeled rabbit anti-whole rat IgG (Sigma) 
polyclonal Ab (1 hour, RT) diluted (1/2000) in protein free blocking buffer (Pierce). 
Alkaline phosphatase was revealed with para-Nitrophenylphosphate (pNPP, 
1mg/mL; Sigma). To evaluate the total amount of protein, sdAb were coated in 50 
mM carbonate/bicarbonate, pH 9.6 (1h; RT or 16; 4ºC) in 96 well ELISA plates 
(Costar 3690) and the rest of the procedure was performed as described above. 
Absorbance was measured in a microplate reader at 450nm (Vitor 3 luminometer; 
Perkins Elmer). 
 
Heme competition assays – SdAbs (2.5 µg/mL) constructs were pre-incubated 
(90 min., RT, mild agitation) with different tetrapyrroles or hemoproteins and ELISA 
was performed as described above. Concentrations of tetrapyrroles or 
hemoproteins used for pre-incubation are expressed as heme molar equivalents. 
 
Biacore – The affinities of sdAbs constructs towards heme were obtained using 
surface plasmon resonance (SPR)(BIAcore 2000, BIAcore Inc.). Briefly, sdAbs 
were captured on a CM5 chip using amine coupling at ~800 resonance units (RU). 
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Heme at 0-4000 nM was injected for 4 min and sdAb-bound heme was allowed to 
dissociate (10 min.) before matrix regeneration (10 mM Glycine, pH 2.5). The signal 
was subtracted from that of an immobilized cell to generate sensorgrams of the 
amount of bound heme as a function of time. The running buffer, HBS-P (0.01 M 
HEPES pH 7.4, 0.15 M NaCl, 0.005% v/v Surfactant P20; BIAcore) was used for all 
sample dilutions. BIAcore kinetic evaluation software (version 3.1) was used to 
determine dissociation constant (KD) from the association and dissociation rates 
using a one-to-one binding model. An irrelevant sdAb was used as negative control. 
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